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Summary 
 
 
Summary           
Liquid-core microcapsules can be described as miniature sized particles (< 1 mm in 
diameter) consisting of a liquid-(core) enveloped completely within a defined porous or 
impermeable membrane, and can be manufactured from a wide range of natural and/or 
synthetic materials. These structures usually take a spherical form and have been shown 
to have many exploitable characteristics in numerous processes. In this study, these 
particles were used as a tool for the recovery and/or purification of different molecules 
in their associated environments. 
The first section of this study was devoted to the characterization of a methodology to 
manufacture microspheres/microcapsules using an alginate hydrogel as the 
encapsulation matrix. Due to its many advantages, such as an easy operation and the 
ability to control droplet size, the vibrating nozzle (jet) technique was chosen as the 
manufacturing technique. Using the single nozzle system, and a pressurized flow 
control system to delivery the polymer, it was possible to produce 
microspheres/spheres, under reproducible conditions, in a size range of 100 μm to 2 mm 
in diameter, with the produced structures having a standard size deviation of between 1-
1.5%, for any size generated. Whilst the size was mainly dependant on nozzle diameter, 
it was identified that this feature could be altered further by increasing/decreasing the 
frequency of the vibration and/or the flow of the polymer.  
For the concentric system, similar reproducible results were obtained, but due to the 
more complicated system, brought about by the two-flow mechanism to the nozzle, the 
size deviation increased to around ± 2.5% in most cases. Due to the separate flows of 
the outer and inner phases, it was possible to control the core and membrane size of the 
microcapsules during production, with either being able to occupy between 10-90% of 
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total capsule volume. It was shown throughout this work that this trait can be a very 
important property, as it can affect the numerous characteristics of capsules, such as: 
mechanical strength, buoyancy and most importantly for this study, the mass transfer 
(permeability) of external and/or internal compounds to and from the core of the 
microcapsules. For both arrangements it is possible to produce > 1.2 l/hr of 
microspheres and > 2 l/hr of liquid-core microcapsules, and this can be easily and 
naturally elevated to higher volumes by increasing the number of nozzles on the 
encapsulator. 
Firstly the microcapsules were used as an innovative technique (known as capsular 
perstraction) to recover the commonly found pharmaceutically active compounds; 
sulfamethoxazole, metoprolol, furosemide, carbamazepine, clofibric acid, warfarin and 
diclofenac from water. The approach of preparing capsules with different solvents 
within their cores and combining them in water, contaminated with pharmaceuticals, 
enabled a rapid recovery of the drugs from this sphere. In addition the uptake of 
warfarin was examined to assess the conditions affecting mass transfer of the molecules 
into the capsules. It was subsequently determined that the stagnant organic layer was the 
main limiting factor. This part of the study emphasized how the characteristics (size and 
membrane thickness) of capsules can affect the removal rate of compounds into the 
liquid-core and also how the rate of extraction can be simply controlled by varying these 
parameters during the capsule manufacturing process. 
In a second application, the capsular extraction technology was further developed by 
adopting it as an aide for the recovery and purification of the antibiotic geldanamycin 
from Bennett’s medium. From this work it was shown how a small quantity of capsules 
was capable of rapidly extracting the molecule from the culture medium. Again the 
limitations to mass transfer were accessed, and it was discovered that the main rate-
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limiting step was the external resistance outside of the capsules, which can be governed 
by controlling the outer turbulence. In a further development the capsules showed their 
potential to be used as a mechanism for concentrating, purifying and enabling 
crystallization of the extractant, using a very simplistic and straightforward procedure, 
which was not destructive to the microcapsules, hence enabling their continuous re-use. 
Finally the capsules were applied to a real-time situation, in order to examine the 
feasibility of using the simple, non-toxic and sterile technology as a novel in-situ 
product recovery technique, to improve the production and recovery yield of 
geldanamycin in cultures containing the bacterium Streptomyces hygroscopicus. 
Implementation of this approach resulted in the rapid removal of the metabolite from an 
environment which was causing its break-down and seriously affecting recovery yields. 
Extraction enabled the molecule to be transferred into a stable and secure domain, 
where it was protected from external influences. This removal improved overall net 
production by 30% compared to fermentations containing no capsules. Most 
importantly however, the capsule-facilitated recovery process acted as a methodology, 
which enabled high recoveries (> 53%) of the fermented geldanamycin to be obtained 
as highly purified crystals (> 97%) using a facile, inexpensive and reproducible process, 
which should be easily implemented at a lab-scale or industrial-level.  
 
 
Keywords: Liquid-core microcapsules; Capsular perstraction; Alginate; Dibutyl 
sebacate; Oleic acid; Pharmaceutically active compounds; Geldanamycin; In-situ 
product recovery and Downstream processing. 
Table of Contents         
Summary          vii 
Table of contents         x  
 
 1.   Microencapsulation using vibrating technology    1 
1.1. Abstract         2 
1.2. Introduction         3 
1.3. Production of microspheres/microcapsules     10 
1.3.1. Factors governing selection of an encapsulation procedure   10 
1.3.1.1. Requirements of encapsulation techniques for  
  producing microspheres/ microcapsules for medical and  
  biotechnological applications     11 
1.3.2. Mechanical procedures       11 
1.3.2.1. Theoretical background behind the formation of droplets by  
  liquid extrusion through a nozzle      12 
1.3.2.2. Spray-drying      15 
1.3.2.3. Jet cutting technique      16 
1.3.2.4. Rotating (spinning) disk atomization    17 
1.3.2.5. Electrostatic extrusion      18 
1.3.2.6. Coaxial air-flow      19 
1.3.2.7. Vibrating-jet (nozzle) technique     20 
1.3.2.7.1. Production of droplets by Rayleigh’s jet instability (theoretical 
         aspects behind jet break-up)     22 
1.4. Membrane polymers        25 
1.4.1. Alginate        25 
 x
1.4.2. Chitosan        28 
1.4.3. Cellulose sulphate        29 
1.5. Production of microcapsules (type I, III and IV) using the vibrating-jet 
 technique         30 
1.5.1. General components of a vibrating nozzle encapsulator   31 
1.5.2. Monocentric nozzle system      32 
1.5.2.1. Production of type IV microspheres using the single-flow system 33 
1.5.2.2. Production of type I and III microcapsules using the single-flow 
  nozzle system       38 
1.5.3. Concentric nozzle system       41 
1.5.3.1. Production of type I microcapsules using the two-flow nozzle  
  system        42 
1.5.4. Challenges facing the vibrating nozzle system: Possible solutions  48 
1.5.4.1. Large scale production/scale-up     48 
1.5.4.2. Polymer choice      51 
1.6. Nomenclature        56 
1.7. References         57 
 
2. Removal of pharmaceuticals from water: Using liquid-core 
      microcapsules as a novel approach      75 
2.1. Abstract         76  
2.2. Introduction         77 
2.3. Materials and methods       79 
2.3.1. Chemicals        79 
2.3.2. Methods        81 
2.3.2.1. Glassware preparation      81 
 xi
2.3.2.2. Reverse phase high performance liquid chromatography  
  (RP-HPLC)       81 
2.3.2.3. Preparation of liquid-core microcapsules    82 
2.3.2.4. Measurement of microcapsules size    83 
2.3.2.5. Determination of mass transfer     84 
2.3.2.6. Capsular perstraction of pharmaceuticals from aqueous solutions 86 
2.4. Results and discussion       88 
2.4.1. Capsular perstraction       90 
2.4.2. Capsular perstraction of selected pharmaceuticals using dibutyl sebacate  
 liquid-core microcapsules       90 
2.4.3. Capsular perstraction of selected pharmaceuticals using oleic acid liquid- 
 core microcapsules       92 
2.4.4. Capsular perstraction of selected pharmaceuticals using dibutyl sebacate 
 and oleic acid liquid-core microcapsules simultaneously   94 
2.4.5. Effect of varying operating and microcapsule parameters on extraction 
  rate: Factors affecting mass transfer of pharmaceuticals into microcapsules 95 
2.4.5.1. Effect of agitation speed on the extraction rate of warfarin  96 
2.4.5.2. Effect of alginate membrane on the extraction rate of warfarin 97 
2.4.5.3. Effect of microcapsules size on the extraction rate of warfarin 99 
2.4.5.4. Volumetric mass transfer coefficient (kL)    101 
2.5. Conclusions         102 
2.6. Nomenclature        104 
2.7. Acknowledgments        105 
2.8. References         105 
 
 
 xii
3. Capsular perstraction as a novel methodology for the recovery 
      and purification of geldanamycin      113 
3.1. Abstract         114  
3.2. Introduction         115 
3.3. Materials and methods       117 
3.3.1. Chemicals        117 
3.3.2. Methods        118 
3.3.2.1. Quantitative determination of geldanamycin   118 
3.3.2.2. Preparation and characterization of liquid-core microcapsules 119 
3.3.2.3. Liquid-liquid extraction and capsular perstraction   119 
3.3.2.4. Determination of mass transfer     121 
3.3.2.5. Recovery of geldanamycin from microcapsules   122 
3.3.2.6. Re-crystallization of geldanamycin    123 
3.3.2.7. Purity of re-crystallized geldanamycin    124 
3.4. Results and discussion       124 
3.4.1. Solvent screening: Choice of solvent for liquid-core of microcapsules  124 
3.4.2. Capsular perstraction of geldanamycin: Factors affecting mass transfer 126 
3.4.3. Effect of agitation speed on the extraction rate of geldanamycin  126 
3.4.4. Effect of capsule size on the extraction rate of geldanamycin   127 
3.4.5. Effect of alginate membrane on the extraction rate of geldanamycin  129 
3.4.6. Volumetric mass transfer coefficient     130 
3.4.7. Recovery and purification of geldanamycin contained within liquid-core 
 microcapsules        132 
3.4.8. Recovery of geldanamycin from dibutyl sebacate liquid-core microcapsules 133 
3.4.9. Recovery of geldanamycin from oleic acid liquid-core microcapsules  135 
3.4.10. Purification of geldanamycin recovered from microcapsules   137 
 xiii
3.5. Conclusions         140 
3.6. Acknowledgements        142 
3.7. Nomenclature        142 
3.8. References         144 
 
4. Successful application of capsular perstraction as a novel in-situ 
      product recovery technique: Removal and purification of  
      geldanamycin from Streptomyces hygroscopicus cultures   150 
4.1.  Abstract         151 
4.2. Introduction         152 
4.3. Materials and methods       155 
4.3.1. Chemicals        155 
4.3.2. Methods        156 
4.3.2.1. Strain      156 
4.3.2.2. Spore production      156 
4.3.2.3. Antibiotic production      157 
4.3.2.4. Quantitative determination of geldanamycin   157 
4.3.2.5. Geldanamycin extraction from cultures    158 
4.3.2.6. Determination of biomass      158 
4.3.2.7. Geldanamycin stability      159 
4.3.2.8. Preparation and characterization of liquid-core microcapsules 159 
4.3.2.9. Addition and removal of capsules from cultures   160 
4.3.2.10. Recovery of geldanamycin from microcapsules   161 
4.3.2.11. Purification and crystallization of geldanamycin recovered from  
  capsules        162 
4.4. Results and discussion       163 
 xiv
 xv
4.4.1. Production of geldanamycin      163 
4.4.2. Geldanamycin stability       165 
4.4.3. In-situ product recovery using capsular perstraction    168 
4.4.4. Recovery and purification of geldanamycin from microcapsules  171 
4.5. Conclusions         176 
4.6. Acknowledgements        178 
4.7. Nomenclature        178 
4.8. References         179 
 
5. General discussion, conclusion and perspectives    184 
5.1. Vibrating-jet technique       185 
5.2. Removal of pharmaceutically active compounds from water  187 
5.2.1. Future perspectives: Treatment of the extracted pollutants   189 
5.3. In-situ product recovery of geldanamycin     193 
5.4. Nomenclature        196 
5.5. References         196  
6. Appendices         200 
6.1. Appendix A         201 
6.2. Appendix B         205 
 
 
        
Chapter 1: Microencapsulation using vibrating technology 
 
 
Chapter 1           
 
Microencapsulation using Vibrating Technology 
 
Micheal Whelehan and Ian W. Marison* 
 
Laboratory of Integrated Bioprocessing (LiB), School of Biotechnology, Dublin City 
University (DCU), Glasnevin, Dublin 9, Ireland. 
 
 
Keywords: Microencapsulation; Production of microspheres/microcapsules; Vibrating 
nozzle encapsulator; Rayleigh’s jet instability and break-up; Alginate; Monocentric and 
concentric nozzle; Multiple vibrating nozzle encapsulator and Heating nozzle/pulsating-
head device. 
 
 
Publication status: Chapter published under the above title in: Microspheres and 
Microcapsules by Mechanical Methods (Chapter 2). Kentus Books, London, MML 
Series. (2010) (in press).  
 
 
 
 
 
 1
Chapter 1: Microencapsulation using vibrating technology 
 
 
1.1. Abstract 
For well over a half a century now, microencapsulation and encapsulated products have 
played a very important role in numerous industries like agriculture, chemical, 
pharmaceutical, cosmetic and the food industry, whereby protection of the core material 
from its active environment, improved handling properties and controlled release of the 
encapsulant were the main reasons behind performing the process. In recent decades 
these particles have been applied to numerous biotechnology and medical processes, 
including cell encapsulation for the generation of artificial implants and the production 
of high density cell cultures. This has opened up a whole new exciting field for the 
technology and resulted in the development of new production procedures to help 
manufacture the desired microspheres/microcapsules. Whilst for industries like 
agricultural, food and cosmetic, the prerequisite for the successful employment of the 
technology is usually only limited to high production rates at low cost, for application in 
medical and biotechnological processes the criteria is somewhat more stringent. 
Successful application in these areas requires a technology, which has the capability to 
produce mono-dispersed, homogenous shaped capsules, with a narrow size distribution, 
using a short production time, under simple conditions, with high efficiency and high 
production rates using many different materials, including highly viscous solutions. It 
should also enable different production sizes and many different core materials to be 
encapsulated, and finally if required, can be performed under sterile conditions. To-date 
no established or newly developed encapsulation technique can fully adhere to the 
aforementioned criteria and the limitations possessed by all, have slowed down and/or 
prevented the use of encapsulation technology at an industrial level for biotechnological 
and medical applications.  
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Production of microcapsules by the controlled break-up of laminar liquid jets using 
vibrating technology has gained significant interest mainly due to its simplistic 
approach to produce homogenous microspheres/microcapsules of the desired size. 
Certain limitations still exist for this methodology, which have yet to be fully re-solved, 
such as an inability to manufacture large quantities and process highly viscous fluids. 
However, promising solutions have being suggested and developed, such as the multiple 
nozzle system, which can help overcome these shortfalls. 
This review initially discusses the importance of encapsulation and the reasons behind 
its implementation. The paper then sets out to discuss some of the mechanical 
techniques used to produce capsules for biotechnological and medical applications 
along with some of the more commonly used encapsulation matrices, discussing the 
pros and cons of each technique and material. A detailed description of the theoretical 
and practical know-how and aspects behind production of different capsules using 
vibrating technology is then given. Finally the challenges facing application of the 
technology at a large scale level are discussed. 
 
1.2. Introduction 
Microencapsulation can be defined as a process, which involves the complete 
envelopment of pre-selected core material(s) within a defined porous or impermeable 
membrane (shell) using various techniques, to give miniature sized particles ranging in 
size from 1-1000 μm1. Microcapsules can take many structural forms (Figure 1) and 
have proven to have many exploitable characteristics for application in many different 
processes (Table 1). They can be manufactured from a wide range of natural and/or 
 
1 Whilst no defined consensus exists, in general capsules < 1 μm in size are called nanocapsules, 1-1000 
μm are termed microcapsules and > 1000 μm are referred to as macrocapsules. 
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synthetic materials, but are also commonly found in nature i.e. plant seeds, bacterial 
spores, egg shells etc. 
The concept of encapsulating a material (also referred to as the encapsulant) within a 
defined membrane initially dates back to the 1930’s in the food industry [1], whereby 
the process was mainly referred to as ‘locking’ rather than encapsulation [2]. The first 
significant industrial use occurred in the 1950’s when microcapsules were incorporated 
into carbonless copy paper by the National Register Company [3], with the capsules 
produced by a complex coacervation process [4]. In this operation, capsules were filled 
with around 2-6% (v/v) of a leuco dye, which were coated on the underside of the top 
sheet of paper. Under compression the capsules burst, releasing the dye which is 
exposed to an acidic component that is coated on the lower sheet. The interaction of 
both of these components yields a dark dye (Sparks 1991). To date carbonless copy 
paper incorporating microcapsules is still employed commercially and is one of the 
most significant products utilizing microencapsulation technology with an annual 
worldwide consumption in the order of 10 million tons [5]. 
Early versions of microcapsules were impermeable and had to be broken apart, most 
often by mechanical means, for the inner ingredients to become active. Examples 
include controlled release of flavors, aromas, perfumes, drugs, detoxicants, fertilizers 
and precursors in textiles and printing [6]. In the following years and decades 
microencapsulation technology was applied successfully to the cosmetic, printing, 
chemical, pharmaceutical, agriculture and food industries where it has become well 
developed and accepted [7-9]. A large number of materials were encapsulated and 
modification of mass transfer characteristics and reduced interactions of the encapsulant 
with the environment were the main reasons for performing the process [10].  
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Encapsulation of flavor compounds by extrusion started in the 1950’s [11] and has 
become a major technique in the aroma industry [12]. In the 90’s a  wave of patents 
appeared relating to aroma encapsulation, in which most of the patents covered special 
aspects of the encapsulation of flavor oils within a gelatin wall by complex coacervation 
[10]. In the US alone there are several hundred types of capsules being used as food 
additives [13]. Microcapsules have also been used as extraction aides for various 
compounds, such as warfarin [14], hexavalent chromium ions [15] and propionic acid 
[16]. In these cases, encapsulation prevented the formation of stable emulsions which 
subsequently reduces the settling time of an extraction process [10].  
In recent times the technology has been applied to medical and biotechnological 
disciplines where the encapsulation of recombinant therapeutic proteins [17,18], cell 
implants [19-21] and mammalian cells [22,23] has taken place. They have also being 
applied to bioconversion [24,25] and fermentation processes [9,26,27] .  
Due to its many existing and potential applications in many diverse areas, 
microencapsulation has received much attention from both academic and commercial 
bodies [28], and its further development is of a major interest both from an economic 
and scientific point of view. The growing interest is demonstrated by the exponential 
increase in the number of publications (non-scientific and scientific articles and patents) 
reporting on the subject over the decades since the 1950’s. In the period between 1955-
59, less than hundred publications were available, but this number has increased to 
nearly ten thousand for the period 2000-05 alone [29].  
There are six main reasons for the encapsulation of a material within a membrane 
compared to its non-encapsulated species and these include: 
1) Protection (stabilization) of the encapsulant from interactions with reactive 
environments an/or future surroundings; 
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2) Sustained (continuous), controlled or timed release of the core material; 
3) Targeting of compounds to specific sites; 
4) Enabling usage as extraction aides for product removal including in-situ product 
recovery; 
5) Improved flow properties of the encapsulant for enhanced handling (inc. safety), 
usage and storage, and 
6) Improved organoleptic properties of the core material. 
Table 1 outlines some examples where the technology has been employed and also 
outlines the reasons for performing the process. 
 
Table 1: Examples of some encapsulated species and the basis for performing the 
procedure. 
Impetus 
(1-6) 
Examples References 
1 
 
 
 
 
 
 
 
 
 
 
Cells (Prevention) 
Mammalian (immuno-response and cell  
damage due to agitation and aeration) 
Yeast (ethanol toxicity) 
Enzymes 
Improved stability and reactivity 
Prevent denaturing 
Food additives and bioactives 
Off-setting loss and deterioration by 
High temperature food processing 
Passage through the gastrointestinal tract 
 
[20,30] 
[31,32] 
[33,34] 
 
[35,36] 
[37] 
 
 
[6] 
[38] 
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Oxidation  
Hygroscopicity 
Evaporation (aroma compounds) 
Recombinant Proteins  
Improved stability and protection 
[7,39] 
[6] 
[2,12] 
 
[18] 
2 Agrochemicals 
Bioactive ingredients 
Pharmaceuticals 
Vitamins  
Adhesives 
Flavors 
Fragrances 
[40] 
[41] 
[42,43] 
[44,45] 
[46] 
[12,47] 
[48,49] 
3 Antibodies  
Vitamin C 
Bioactive ingredients 
[50] 
[45] 
[51] 
4 Environmental pollutants 
Extraction of pharmaceutical and  
Herbicides/pesticides 
Heavy Metals 
In-situ product recovery 
Culture environments 
Primary and 
Secondary metabolites  
Bioconversion processes 
Lipase-catalyzed reactions 
 
[14] 
[52] 
[15] 
 
 
[26] 
[27,53] 
 
[25] 
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Hydrolysis of Penicillin G [24] 
5 Pesticides 
Biosorbents 
Food (natural colorings) 
[54,55] 
[56] 
[6] 
6 Taste (shark liver oil) 
Appearance (tea bags) 
[57] 
[58] 
 
Structurally, microcapsules can be classified as five different types [2,6,10,12,59], 
which are shown in Figure 1.  
Type I: Mononuclear: These are the simplest form of microcapsules, in which the core 
material (usually a liquid, in which case they can be referred to as liquid-core 
microcapsules [60]) is surrounded by a continuous defined membrane. The diameter of 
the core material and the membrane thickness can vary in size with either occupying 
between 10-90% of total capsule volume. These particles are also termed simple or 
single-core microcapsules. 
Type II: Double/multi-shells (walls): Usually mononuclear microcapsules in which a 
second or multiply shells are added to the original capsule. The extra shells are added to 
modify the original stability and/or permeability characteristics of the microcapsules 
[61,62]. 
Type III: Polynuclear (multi-core): Microcapsules containing two or more separate 
cores [63,64] and are usually formed from emulsions. 
Traditionally, microcapsules are seen as spherically shaped particles with a well defined 
shell and core structure (type’s I-III) but other forms do exist. 
Type IV: Microbeads/microspheres: Most common type of capsule and contain particles 
(including cells) entrapped within a solid matrix, which does not possess a distinctive 
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membrane [65]. Whilst these structures can be termed capsules they are usually referred 
to as microbeads [65] or microspheres [66,67]. In this review both terms are used 
interchangeably. They can be converted into type I by the addition of an outer shell and 
the subsequent liquefaction of the core, and is the basis for the production of the 
classical poly-L-lysine-alginate microcapsules as described in 1980 by Lim and Sun 
[68]. These particles can also be manufactured with no material trapped inside, and can 
be used as immobilization matrices. 
Type V: Irregular or non-spherical shaped capsules. These particles can be 
mononuclear, polynuclear or solid particle entrapment. These are the most common 
type of capsules used in industry, but will not be discussed in this review. 
 
 
   
 
 
 
 I. Single-core II. Multi-shell III. Multi-core 
  
 
 
IV. Entrapment V. Irregular  
Figure 1: The five main structural forms of microcapsules (adapted from 
[2,6,10,12,59]). Type III – V can also have multiply shells added to modify stability and 
permeability of the capsules.  
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1.3. Production of microspheres/microcapsules 
Many different techniques for the production of microsphers/microcapsules have been 
described [62,69]. For simplicity the methods can be categorized as chemical, 
physicochemical or mechanical processes [9] and include techniques such as: chemical; 
in-situ polymerization [70] and interfacial polymerization [71]; physiochemical; 
complex coacervation [72] and mechanical; spray-drying [59] and extrusion based 
methods [73].  
 
1.3.1. Factors governing selection of an encapsulation procedure 
The encapsulation process requires a technique for enveloping the desired product into 
capsules of the desired size and properties from the selected wall polymers. As 
suggested by Ubbink and Kruger [74] and Madene et al. [12], the technique selected for 
encapsulation should always depend on the end-use (which is governed mainly by the 
core material and to a smaller degree the shell material) of the encapsulated product. 
This is in contrast from normal practice, whereby the technique is usually chosen before 
the core and polymer materials (companies usually have set equipment already in 
place). Success (or failure) on adapting the core/polymer materials to the procedure, to 
enable production of the capsules, is then usually performed using an empirical (trial 
and error) approach. The major disadvantage of this approach is that from the outset it 
focuses on a specific technology to solve problems, which it may only be able to 
partially solve, or not at all [74]. This ultimately results in the production of an 
ineffective product. However, placing emphasis on final product application enables a 
clearer specification of the requirements to be fulfilled by a prospective technology 
before selection begins [74].  
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1.3.1.1. Requirements of encapsulation techniques for producing microspheres/ 
microcapsules for medical and biotechnological applications 
Successful application and performance of microcapsules in medical and 
biotechnological applications requires a methodology capable of producing small (< 
200 μm), mono-dispersed, homogenous and spherically shaped spheres/capsules, with a 
narrow size distribution, using a short production time, under mild and simple 
conditions and low costs, with high encapsulation efficiencies (% of product 
encapsulated) and production rates, from highly viscous solutions, allowing different 
production sizes and the ability to produce type I-IV microcapsules, which can all be 
performed under sterile conditions if required.  
 
1.3.2. Mechanical procedures 
This section describes some of the common mechanical procedures used for producing 
microspheres/microcapsules for medical and biotechnological applications. These 
operations use mechanical procedures rather than a well defined physical or chemical 
phenomenon to produce the desired particles [69]. They are based on the principle of 
generating a droplet(s) from a polymer extruded through a nozzle (orifice). They work 
using mechanical means (i.e. cutting or vibration forces) to increase the normal dripping 
process at the orifice, or they break-up an extruded liquid stream produced by the 
polymer when it is passed through the nozzle. After production, the droplets are 
immediately solidified to spheres/capsules by either physical e.g. cooling or heating, or 
chemical means e.g. gelation. Mechanical procedures are the major methodologies used 
for the production of microspheres for biotechnological and medical applications. 
Various coating and spray-drying methods are often used in industry, whereas the 
extrusion of a polymer through a nozzle(s) is used mainly at a lab scale [10,75]. Some 
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of the main mechanical technologies for fluid dispersion into droplets and subsequent 
conversion into capsules are: 1) spray-drying; 2) jet-cutting; 3) rotating disc; 4) 
electrostatic; 5) coaxial air-flow and 6) the vibrating nozzle. The principal of operation 
of these techniques will be discussed, along with their capabilities to match the criteria 
set out in section 1.3.1.1 and finally their ability to produce type I-IV microcapsules. 
Since these methods are primarily based on droplet formation at an orifice, an 
understanding of this process is required to enable an adequate understanding of each 
system, and this phenomenon will be discussed in the following section. 
 
1.3.2.1. Theoretical background behind the formation of droplets by liquid 
extrusion through a nozzle  
The extrusion of a liquid through an orifice results in one of five different droplet 
formation processes occurring at the discharge point of the nozzle (Figure 2), with the 
mechanism dependent on the velocity  of the extruded liquid [76]. The different 
mechanisms arise due to the interaction of gravitational, surface tension, impulse and 
frictional forces [77]. At very low velocities
v
( )Ivv < , the extruded liquid sticks to the 
edge of the nozzle until the gravitational force is high enough to overcome the surface 
tension, resulting in the release of a drop (mechanism 1). A small rise in the velocity 
increases the number of droplets formed, whilst further escalation amplifies droplet 
formation (mechanism 2), and can result in coalescence of the droplets occurring, 
reducing mono-dispersity. The diameter of the droplet formed (  during mechanism 
1 and 2 can be estimated from equation 1 [10,62,78,79], which approximates the 
balance between the two main forces present; gravitational force pulling the drop down 
and the force of surface tension holding the drop pendant to the tip at the instant of drop 
detachment [80], and is as follows; 
)dd
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3
6
ρ
σ
g
dd nd =        (1) 
 
where  is the diameter of the nozzle, Nd σ  is the surface tension of the extruded liquid, 
g is the acceleration due to gravity and ρ  is the density of the fluid. 
 
Mechanism 1 and 2 are commonly used at a lab scale where only small volumes of 
droplets are required and this process is commonly known as dripping [80,81]. As seen 
in equation 1 the size of the droplets produced here is mainly dependent on the nozzle 
diameter. 
However, for systems producing alginate drops which are subsequently gelified into 
spheres/beads by landing in a bath of CaCl2, it must be noted that; 
   
         (2) cabd dd ≠
 
in which  is the diameter of the produced Ca-alginate bead. cabd
   
Recently Chan et al. [82] extended equation 1 further by adding in an overall correction 
factor (  which enables a good approximation of   to be obtained. )K cabd
 
  K
g
dd nd ⋅= 3 6 ρ
σ
      (3) 
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In their study Chan et al. [82] calculated that the overall correction factor varies from 
0.73 to 0.85 under the conditions examined which correlated well with their 
experimental data, resulting in an average absolute size deviation of > 5%.  
Further increasing the velocity causes the formation of an uninterrupted laminar jet 
(continuous stream), which eventually breaks-up into droplets by axial symmetrical 
vibrations and surface tension (mechanism 3). An additional escalation of the jet 
velocity , leads to statistical distribution of the droplet size, which is caused by 
either spiral symmetrical vibrations (mechanism 4) or by the high frictional forces that 
are present, when the jet is sprayed (mechanism 5). As will be discussed in section 
1.3.2.7., applying an additional frequency force to the laminar jet (mechanism 3), will 
result in the controlled break-up of it into uniform, mono-dispersed droplets of equal 
size. The size of the droplets can be pre-selected within a certain size range and depends 
on, the frequency applied. Whilst mechanism 2 and 3 enable the formation of mono-
dispersed droplets of equal size only the latter is used at an industrial level, as it enables 
the production of high quantities of droplets (subsequently produced into 
spheres/capsules) when a vibrational frequency is applied to the extruded jet.  
IIvv >
 
Iv   IIv
 
 
 
 
 
 
 
Figure 2: Different mechanisms of droplet formation as a function of jet velocities [76]. 
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1.3.2.2. Spray-drying 
Spray-drying is a unit operation in which a liquid product (containing the encapsulant 
and the shell material) is atomized by a hot gas current in a drying chamber, allowing 
the evaporation of moisture and formation of microspheres [59]. A double sized nozzle 
is employed, allowing air (an inert gas liked nitrogen is rarely used) from an annular 
geometry to atomize the liquid stream, which forms fine particles containing the 
microencapsulated product in a dispersed state. These particles are then dried by flash 
evaporation and pass through a cyclone and are collected in a holding chamber [83]. 
Depending on the starting feed material (viscosity, density etc) and operating conditions 
(atomization pressure, nozzle type) a very fine powder of capsules (10-50 μm) or large 
size particles (2-3 mm) can be obtained [59]. Spray-drying is the most commonly used 
and oldest microencapsulation technology in the food industry [39,84], due to low cost 
and the readily available equipment [59] and has mainly been employed to encapsulate 
flavors using gum acacia as the shell material [1]. 
The main advantages of spray-drying, is the ability to obtain large scale production with 
high encapsulation efficiencies, in continuous mode, at relatively low costs. The set-up 
is straightforward and is adaptable to commonly used processing equipment [83,84], 
and if required, can be performed under sterile conditions. The main disadvantages are 
that the produced capsules have an irregular shape and a large size distribution, whilst 
they also tend to form aggregates. Polar active agents with low boiling points such as 
ethyl acetate are also difficult to encapsulate. In the food industry a major limitation is 
the restricted number of materials available to be used as the shell of the particles [29].   
The technique is mainly used to produce type IV capsules by spraying the encapsulant 
dispersed in the polymer matrix but can also produce type I and III by spraying 
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emulsions and coacervates [10]. In general the process is used for producing dry 
particles [9].   
 
1.3.2.3. Jet cutting technique 
The jet cutting technique is a relatively new process, which was developed by Vorlop 
and Breford in 1994 and is based on the mechanical impact of a cutting wire on a solid 
liquid jet [85]. When a polymer is forced through a special nozzle at high velocity, a 
solid liquid jet is formed within a very short distance of the nozzle. This jet can then be 
broken-up into equal cylindrical segments when passed through a cutting tool, which 
consists of several wires fixed onto a holder [85]. Due to surface tension, these 
cylindrical segments form spherical droplets/beads when passing through the air, the 
former forming spheres when dropped into hardening/polymerization solutions. The 
diameter of the resulting particles is dependent on: (1) the number of cutting wires; (2) 
the number of rotations of the cutting tool; (3) the mass flow rate through the nozzle and 
(4) the mass flow depending both on the nozzle diameter and the velocity of the fluid 
[86]. This simple and effective method enables the production of small mono-dispersed 
homogenous shaped beads, > 200 μm to several millimeters in diameter, with a narrow 
standard size deviation using viscous fluids at high production rates [85,87].  
The main disadvantage of this method is the loss of material incurred during each cut of 
the liquid jet. This is known as the cutting loss and can be decreased by re-cycling or 
applying proper inclination of the cutting tool or nozzle and by also using smaller 
cutting wires [85]. Whilst these losses can be reduced to negligible amounts for the 
production of small beads, they do however increase with the increasing size of the 
produced particles (due to use of thicker cutting wires) and cannot be ignored if this 
method is to be applied at an industrial level. Other disadvantages include the inability 
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to produce beads < 200 μm in size, and to be performed under sterile conditions for 
large scale production. Although Schwinger at al. did encapsulate murine fibroblasts 
aseptically [88], it was achieved by placing the machine under a laminar flow safety 
bench, which would not be feasible for large scale production. The affect of this 
invasive technique on cells or other encapsulants within the polymer during the cutting 
process is yet unknown (i.e. within the cutting loss and their ability to be fully re-cycled 
for future encapsulation without any damage been caused). The jet velocities applied 
also have the potential to deform the spheres upon impact in the hardening/collection 
solution but this can be overcome using a soft landing method [89] or a pre-gelling step 
[85] instantaneously after jet cutting and before impact in the collection bath. However 
these add further complexity to the process. At present the technique is used mainly to 
produce Type IV capsules but has shown the capability to produce Type I 
microcapsules [85]. 
 
1.3.2.4. Rotating (spinning) disk atomization 
Spinning disk atomization is a technique which is based on the disintegrating of a feed 
liquid performed on disc(s) to produce droplets [90]. When a liquid is dropped onto the 
surface of a rotating disk it is centrifugally accelerated to a high velocity and distributes 
as a thin film on the disc. Depending on the flow rate of the feed, droplets/microspheres 
are then released due to the centrifugal forces at the tip (teeth) of the rotating disk or 
from ligamentry streams released from the edge of the disk [91]. The size of the droplets 
produced is determined mainly by the rotation speed of the disk. This simplistic 
technique has shown the capability to produce microspheres ≥ 200 μm in diameter [91], 
with a narrow size distribution and is easily scalable, with possible production 
capacities of tons/day using a multi-disk system [28]. 
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The main disadvantages of this system are the large surface area or volume required to 
collect the produced beads [90] and problems in ensuring sterility of this area during 
cell encapsulation. Other disadvantages include deformation of beads due to the high 
impact speed into the solution and the production of satellite beads which can affect the 
standard size deviation [91]. At present this systems seems capable of only making type 
IV microcapsules.  
  
1.3.2.5. Electrostatic extrusion 
The basis of electrostatic droplet generation is the acceleration of the normal droplet 
formation process using electrostatic forces to pull the droplets off the orifice (needle) at 
a considerably faster rate compared to the normal dripping process, whereby removal is 
based solely on gravitational force. The electrical potential, which can be static or 
pulsed [92] is applied to the extruded polymer solution by passing it through a charged 
needle, with the produced droplets subsequently falling into a collecting/hardening 
solution, which has being earthed or holds an opposite charge [93,94]. If the electrodes 
are parallel plates, a uniform electric field is generated with respect to direction and 
strength, thus a uniform force is applied to the droplets at the tip of the nozzle [95]. It 
has been reported that the strong electric fields do not cause cells to lose viability and 
activity during the producing (encapsulation) process [96]. This technique is capable of 
producing smaller microbeads compared to normal dripping (≥ 50 μm in diameter), of 
uniform size and shape under reproducible conditions and can also be performed under 
sterile conditions [96]. The main disadvantages include low production rates due to the 
low polymer flow rate through the needle, although this can be improved by increasing 
the number of needles. However a study undertaken by Bugarski and coworkers showed 
that even when scaled-up to a system of  20 needles, it was still only possible to obtain a 
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low flow rate of 0.7 l/h (36 ml/h per needle) [94]. Furthermore, increasing cell and 
alginate concentrations hugely increase the size and size distribution of microbeads 
produced by this system [96]. At present this system has only shown the capability to 
produce type IV microcapsules. 
 
1.3.2.6. Coaxial air-flow 
The coaxial air-flow technique (also known as the concentric air-jet technique), like the 
electrostatic extrusion method, is also based on the acceleration of the normal dripping 
process at an orifice. However, instead of electrostatic forces, the technique uses a 
stream of compressed air to pull the liquid droplets from the nozzle at a faster rate 
compared to the normal gravitational force [89,97]. The coaxial concentric nozzle 
consists of an inner orifice, in which the polymer material is extruded and an outer 
orifice, through which the compressed air flows and strips the droplets formed at the tip 
of the internal nozzle [89]. The process is capable of producing capsules with diameters 
> 200 μm, of uniform size and shape, under reproducible and mild conditions and can 
be performed under sterile conditions [62,97-99]. The main disadvantage of the system, 
like electrostatic extrusion, is the low production rates due to the low flow rate of the 
polymer solution extruded through the needle. This can be overcome to some degree by 
increasing the air flow rate, but this can increase the trajectories of the produced drops 
resulting in a larger surface area being required, which could increase the complexity of 
the process. Even with these increases, significantly smaller throughputs are achieved in 
comparison to the other methods such as jet cutting and vibrating techniques [62]. This 
technique is also only able to produce Type IV microcapsules.  
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1.3.2.7. Vibrating-jet (nozzle) technique 
The vibrating-jet technique, which is more commonly known as the vibrating nozzle 
technique or prilling [10,100,101], is one of the most widely used methods for the 
production of microspheres and microcapsules [28]. The technique is based on the 
principal of laminar jet break-up by the application of a vibrational frequency with 
defined amplitude to an extruded jet. As discussed in section 1.3.2.1., when a liquid is 
extruded through a nozzle at certain flow rates, it produces a laminar liquid jet which 
can break-up freely into short lengths by natural irregular disturbances (provided these 
perturbations reach a threshold, otherwise little or no break-up occurs). These segments 
then form spherical droplets in the air due to the surface tension of the extruded liquid. 
However, natural break-up can be irregular and is not possible to fully control and 
hence results in the formation of droplets which are not of equal size and shape [102].  
Lord Rayleigh demonstrated that controlled break-up of laminar jets into small uniform 
droplets of equal size can be achieved, simply by applying a permanent sinusoidal force, 
at defined frequencies to the jet, resulting in the formation of one droplet per hertz of 
frequency applied (Figure 3). This highly regular and reproducible break-up occurs only 
at vibrational frequencies that are near the natural frequency for the break-up of the jet 
itself [102]. The characteristics of the drops formed are dependant on the nozzle 
diameter, the flow rate of the laminar jet, the size of the frequency at defined amplitude, 
and the viscosity of the extruded liquid [73] and will be discussed in the next section.  
The sinusoidal force can be applied by either vibrating the nozzle (vibrating nozzle 
technique), pulsating the polymer in a chamber before passing through the nozzle 
(vibrating chamber technique), or periodic changes of the nozzle/orifice diameter during 
extrusion [61,62,75]. Whilst no set agreement exists, the authors suggest that 
collectively these different methods of applying the sinusoidal force to the laminar jet, 
 20
Chapter 1: Microencapsulation using vibrating technology 
 
 
be termed the vibrating-jet technique. The choice of method used to apply the 
vibrational force is dependent on the system to which it is being applied to. For 
example, in liquid-liquid systems, it has being proven that the pulsation of the liquid is 
the optimal method, whilst for microsphere formation in a gas phase, all three 
techniques can be applied successfully [62].  
The rest of this review will focus solely on the vibrating-jet technique, in which 
emphasis will be given on theoretical background, choice of membrane polymers for the 
procedure and the capability to produce type I-IV microcapsules. During the 
explanation of the production process, the ability of the methodology to match criteria 
set out in section 1.3.1.1. will be discussed and examined and where problems exist for 
meeting the criteria, solutions will be suggested, explained and their possible 
incorporation into the process, will be described. 
Continuous laminar jet 
of liquid 
Formation of spherical drops 
due to surface tension  
Applies a superimposed  
force resulting in the 
controlled break-up of the 
laminar jet 
Mechanical vibrating 
of the nozzle at set 
frequencies 
  dn 
 vj 
λ 
  dd 
 Droplet formation 
dd = equal size  
Figure 3: Controlled break-up of a laminar liquid jet into droplets of equal size. This is 
achieved by applying a sinusoidal force to the extruded jet, by mechanical vibrating the 
nozzle at a set frequency with defined amplitude.  
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1.3.2.7.1. Production of droplets by Raleigh’s jet instability (theoretical aspects 
behind jet break-up) 
At the end of the 19th century Lord Raleigh analyzed theoretically the aspects behind the 
instability of liquid jets and their ability to break-up into droplets due to axial symmetric 
disturbances [103]. Using a linearized stability analysis, Rayleigh showed that for 
wavelengths smaller than the circumference of the jet no break-up occurred [104]. For 
longer wavelengths the disturbances grow exponentially andl result in break-up. He 
proposed a mathematical description (equation 4) for inviscid and Newtonian fluids 
relating the optimal wavelength of the disturbance as a function of the jet diameter. 
 
jopt d⋅= 2πλ        (4) 
 
where optλ  represents the optimum wavelength for break-up of a jet of diameter . jd
 
The frequency is related to the wavelength and the jet velocity by the following 
equation; 
 
  
f
v j=λ         (5) 
in which  represents jet velocity and the frequency vibration. jv f
 
In 1931, Weber extended the equation further and included the effects of the physico-
chemical properties of the fluid on determining the optimal wavelength for jet break-up 
and proposed the following equation [105]; 
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where η  is fluid viscosity. The size determination of the jet diameter has being based 
on different assumptions such as;  
 
nj dd =           (7) 
 
as proposed by Schneider and Hendricks  [106]. nd
 
However, Brandenberger and Widmer [107] showed that for nozzles using a precision-
drilled sapphire stone as an orifice the relationship between both  and  is a 
function of Weber’s number of the nozzle  and is given by the following 
equation; 
jd nd
)( nWe
 
  337.033.4 −⋅= n
n
j We
d
d
        (8) 
where 
  σ
ρ nn
n
dvWe ⋅⋅=
2
       (9) 
in which  is the velocity of the liquid in the nozzle.      nv
 
Since one droplet is generated by each hertz of vibration, the drop diameter , can be 
calculated by the following simple mass balance equation [73]; 
dd
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Fdd ⋅= π        (10) 
 
where is the flow rate of the extruded liquid. F
 
The vibrational frequency is itself linked to the wavelength by the following equation  
 
πλ ⋅⋅= 2
4
jd
Ff        (11) 
 
This implies that the droplet diameter, as a function of wavelength and the jet diameter, 
is given by the following equation;  
 
3 2
2
3
optjd dd λ=        (12) 
 
Equations 4-12 imply, that for a given nozzle diameter, there are two main parameters 
to be determined to achieve optimal droplet formation: vibrational frequency and jet 
velocity. These two parameters trigger the production conditions and they have to be 
optimized within a certain range [62]. The equations also suggest that a range of 
frequencies exist around  , whereby uniform sized droplets can be obtained, and is 
dependent on the nozzle diameter, rheology of the fluid and the surface tension [10]. 
Whilst this vibration system is theoretically based on liquids with Newtonian fluid 
dynamics it is also applied to non-Newtonian liquids such as alginate [73], to make 
uniform drops, which can be produced into microspheres by methods such as ionotropic 
gelation. The equations can be used to give an approximation of the frequency and flow 
optf
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rates needed to break-up the polymers into the desired particles [62]. However, in most 
cases the required values for a given nozzle diameter, are obtained and determined 
experimentally using an empirical approach for each system, in which the calculated 
value is employed as a reference (starting) point [61,62,73]. For most polymers it must 
be again noted, as in equation 2, that the size of the droplet does not necessarily equal 
the size of the fabricated sphere/bead.  
 
1.4. Membrane polymers  
Whilst a limited number of encapsulation methods seem to exist to produce the desired 
capsules, there is however an enormous range of polymer materials available to produce 
microspheres/microcapsules. These include natural materials such as proteins (whey 
proteins), carbohydrates (starch and maltodextrin), lipids (hydrogenated fat), acacia 
(Arabic) gums, cellulose and synthetic polymers  [6,12,108]. The description and 
assessment (to perform as an encapsulation matrix), of some of the most commonly 
used polymers to produce capsules using the vibrating-jet technique for 
biotechnological and medical applications will be discussed in this section. 
 
1.4.1. Alginate 
Alginate is a general term referring to a group of naturally occurring hydrophilic 
polysaccharides found abundantly in nature [109,110], and was first discovered in the 
late 19th century by Edward Stanford [43,111]. Commercial alginates (in which 
production began in the 1920s) are usually derived from the cell wall of various species 
of Marine brown algae found in coastal regions and includes extracting species such as 
Macrocystis pyrifera (also known as giant kelp), Ascophyllum nodosum, and Laminaria 
hyperborean [112]. Alginate-like polymers can also be extracted from two bacterial 
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genera (Pseudomonas and Azotobacter) which produce the alginate as an exopolymeric 
polysaccharide during their vegetative growth [111,113].  
In structural terms (Figure 4), nearly all alginates are composed of un-branched 
homopolymeric regions of two sugars: D-mannuronate (donated as M-blocks) and L-
guluronate (donated as G-blocks) separated by regions of alternating M- and G-blocks, 
the exception being alginates synthesized by Pseudomonas, which lack G-blocks [114]. 
The M to G ratio in alginate and their distribution throughout the polymer dictates the 
gelling and the mechanical properties of the gel produced during the gelation process 
[115,116]. 
The addition of an alginate droplet to a solution of divalent cations results in a mild 
ionotropic gelation reaction which produces a spherical porous hydrogel network 
(Figure 9 and 10) and is the most common methods to produce spheres/beads. For 
decades now, alginate gels have been used commercially in a variety of industrial 
processes, such as textiles, paper, water treatment, plastics, ceramics, pharmaceutical 
and the food industry [117] and in recent times it has being applied to medical and 
biotechnological processes mainly in the area of cell and tissue encapsulation. The vast 
amounts of literature available in the last two-three decades show how significantly 
important this compound has become in these research areas.  
Since the pioneering study by Chang in 1964 [118], which suggested the idea of 
encapsulation for the immunoprotection of transplanted cells, and was followed by the 
ground breaking work of Lim and Sun in 1980 [68], alginate has become the basic 
matrix material for cell, tissue and macromolecules encapsulation for research into the 
treatment of many different diseases, which are caused by the bodies inability to 
produce critical molecules such as growth factors, hormones and enzymes [110]. 
Indeed, it has been estimated that > 85% of all articles published since Lim and Sun’s 
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work, which deal with cell encapsulation involve modifications of their poly-L-lysine-
alginate system [65]. This interest has mainly come about due to alginates ability to 
form heat stable gels using a simple, rapid, gentle and non-toxic gelation technique 
using divalent cations and relatively cheap and available materials2. Alginate is also 
biocompatible with most cells and does not have a detrimental affect on many different 
types of compounds.  
Calcium and barium are mostly used as the complexation ions to produce the gelled 
structure because of their selectivity and co-operative binding to the G-Blocks [119]. 
Calcium is non-toxic and has been the most used ion for cell immobilization purposes. 
Whilst barium does form a stronger gel compared to calcium, use of high concentrations 
in the gelling process may lead to leakage of toxic ions. However, this can be overcome 
or reduced to a minimum amount, by using low concentrations of the ion and by also 
applying extensive washing after gelification [120].  
The main limitations of using alginate as an encapsulation matrix is essentially due to 
the poor mechanical stability of the hydrogel in the presence of mono and divalent 
cations which can have an adverse affect on the structure by destabilizing the 
polyelectrolyte interactions involved in gel integrity. These ions are commonly found in 
cell culture media or the physiological environment surrounding the applied 
microcapsules [22] and this area will be discussed in greater detail in section 1.5.4.2. 
 
Figure 4: Molecular structure of alginate. 
                                                 
2 Indeed, the successful production of alginate gels, only requires some alginate and calcium chloride 
solution, a syringe and a needle. 
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1.4.2. Chitosan  
Chitin is a natural polymer extracted from crab shells, shrimps and other crustaceans by 
alkaline hydroylsis and can also be derived from the cell walls of fungi and the cuticle 
of insects [35,57,121]. Chitosan (Figure 5) is a biocompatible, biodegradable and non-
toxic cationic linear polysaccharide which is rarely found freely in nature. It is 
composed of β-(1-4)-linked D-glucosamine and N-acetyl-D-glucosamine units and is 
obtained by the extensive deacetylation of chitin by hydrolyzing the amino-acetyl 
groups using NaOH [57,75]. It can form hydrogels by ionic [122] or chemical cross-
linking [123] with the bi-functional agent glutaraldehyde and degrades via enzymatic 
hydrolysis [124]. Due to its weak mechanical properties and lack of bioactivity, 
chitosan is often combined with other materials to achieve more desirable mechanical 
properties for encapsulation. Chitosan has also being used to coat capsules to enhance 
stability and modify permeability instead of poly-L-lysine, due to it being regarded as 
more biocompatible [125,126]. It has also shown the ability to significantly exceed the 
stability of the poly-L-lysine-alginate complex in the pH range of 2-5 and also in the 
presence of salt [127]. Solubility is attained in aqueous solutions via protonation of its 
amine groups in acidic environments. Once, dissolved, chitosan can remain in solution 
up to a pH in the vicinity of 6.2. [122].  
  
 
 
 
 
 
Figure 5: Molecular structure of chitosan. 
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1.4.3. Cellulose sulphate 
Cellulose sulphate (Figure 6) is a biocompatible ester and is prepared in the laboratory 
by heterogeneous sulphation of cotton cellulose [128,129]. Linters (also known as 
cotton wool), which are a product of cotton processing is used as the cellulose raw 
material, and a mixture of sulphuric acid and n-propanol are used as the reaction 
solutions. As linters have a large ratio of volume to weight, substantially more reaction 
solution compared to cellulose is required during the sulphation reaction (in a standard 
reaction 1 kg of cellulose will require 20 kg of reaction solution to perform the process). 
This means that a large quantity of reaction solution is exhausted as waste after 
sulphation, which leads to high costs of production and a heavy payload for the 
environment [130]. However, improvements of the standard cellulose sulphate 
production process have being developed, in which the reaction solutions are 
regenerated and used repeatedly [130]. This method has the potential to reduce the cost 
of production and the corrosive environmental waste which is generated, thus enabling 
the polymer to compete with other cheaper materials.  
Microcapsules are obtained from electrostatic interactions by dripping solutions of the 
polymer into the synthetic polycation poly(diallydimethylammonium chloride) 
[PDADMAC] (Figure 7). This results in a rapid reaction at the interface between the 
polymer and the polycation, cumulating in the formation of a mechanically stable 
membrane around the capsule core, which consists of un-reacted cellulose sulphate 
[129]. Materials to be encapsulated e.g. cells or enzymes or various compounds can be 
dissolved in the non-denaturing cellulose sulphate under relevant physiological 
conditions. During capsule formation, these materials get trapped within the core of un-
reacted polymer, where they are protected from the PDADMAC [129]. Cellulose 
sulphate-PDADMAC microcapsules containing a liquid core have many advantages 
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over other polymers such as the ability to be manufactured by a simple single step 
process [50,129], which enables easy scale-up, they have excellent mechanical 
properties due to strongly interacting sulphate groups [50,128] and the membranes have 
a narrow pore size and a homogenous structure [129].   
 
 
 
 
 
 
 
 
Figure 6: Molecular structure of sodium   Figure 7: Molecular structure of   
cellulose sulphate [129].   PDADMAC [129]. 
  
1.5. Production of microcapsules (type I, III and IV) using the 
vibrating-jet technique 
This section will discuss how type I, III and IV microcapsules are produced from a 
device based on the vibrating-jet technique, and emphasis will be based on the ability of 
the process to meet the criteria set out in Section 1.3.1.1. All experiments, unless 
specified, were performed on a lab-scale Encapsulator Model IE-50R from Inotech 
Biotechnologies, Basel, Switzerland (now EncapBioSystem, Greifensee, Switzerland) 
using sodium-alginate (Keltone LV and was obtained from Inotech) as the shell 
(polymer) material at concentrations of 2% (w/v) and a gelling (hardening) bath 
consisting of calcium chloride. All images of microcapsules were taking using a camera 
attached to a light microscope, interface to a PC and were taking at a magnification of 
40X, unless stated differently. The aforementioned encapsulator enabled the production 
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of mono-dispersed and homogenous microspheres/microcapsules with a standard size 
deviation of ± 2.5% at alginate concentrations of between 1.5-2.5% (w/v) [results will 
not be discussed or shown]. This system is based on laminar jet break-up, induced by 
applying a sinusoidal frequency with defined amplitude to the liquid jet extruded 
through a nozzle. This encapsulator is designed to work with either a monocentric 
[single-flow] (Figure 8e) or concentric nozzle [two-flow] (Figure 12a-b) system. The 
chosen nozzle system depends on the type of microcapsules required [62].  
 
1.5.1. General components of a vibrating nozzle encapsulator  
Whilst different encapsulation devices, based on vibrating technology are available on 
the market e.g. Nisco Engineering AG, Inotech Biotechnologies AG and Brace 
Technologies, most consist of several central elements and can be assembled simply to 
make a lab scale encapsulator. These elements include: 
• Pump mechanisms to feed the polymer(s) and/or core material to the nozzle(s).  
• Nozzle(s) to create laminar liquid jet. 
• Vibrating device and control system using signal frequency and amplitude to 
enable controlled break-up of liquid jet. 
• Stroboscopic light to allow visualization of droplet chain and tuning of 
frequency. 
• Agitated gelling bath to enable controlled gelification/polymerization of droplets 
to form microspheres/microcapsules and 
• Collection device to enable easy recovery of produced particles. 
In order to obtain the desired capsules at the required volumes, additional parts can be 
added to improve the process i.e. multiply the number of nozzles (section 1.5.4.1.) or 
high a frequency generator (section 1.5.2.1.) Figure 8 shows a schematic representation 
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of a lab-scale encapsulator with additional equipment and is based on the Inotech 
Encapsulator IE-50R. This system can be used to produce Type I, III and IV 
microcapsules using a single-flow or a concentric nozzle system.  
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Figure 8: Schematic representation of an encapsulation device based on the principle of 
laminar jet break-up by vibrational frequencies. The schematic represents the Inotech 
encapsulator IE-50R and has a single-flow nozzle system (e) in place. 
 
1.5.2. Monocentric nozzle system 
The single-flow nozzle system can be used to directly produce type III and IV 
microcapsule/microspheres, but is mainly used to produce the latter in which cells or 
other solid particles are encapsulated within a polymer matrix. It consists of a single 
orifice (Figure 8e) in which the extruded polymer material passes through. The Inotech 
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encapsulator IE-50R uses a precision-drilled sapphire stone as the orifice on the tip of a 
stainless steel cone [107], although other materials have been used to create the 
precision orifice, but they usually suffer from limitations caused by imperfections in the 
nozzle geometry [107]. Nozzle diameters of between 50-1000 μm are available, which 
enable the production of particles in the size range of 100 μm to 2 mm in diameter.  
 
1.5.2.1. Production of Type IV Microspheres using the Single-Flow Nozzle System 
The product to be encapsulated is mixed with the polymer matrix before being placed in 
the delivery apparatus (Figure 8: a.1 and a.2). A very steady flow of the polymer 
through the nozzle at controllable rates is required to obtain the optimal break-up of the 
extruded liquid jet into droplets, which will enable the production of mono-dispersed 
microspheres with a very narrow size distribution. The flow of alginate to the nozzle 
can be achieved by one of two different systems3, the selected one usually being 
dependent on the quantity of microspheres required. For the first mechanism, a 
pulsation free high precision syringe pump (a.1) is used for the extrusion of volumes of 
between 1-60 ml of polymer through the nozzle. For the second, an air pressure 
regulation system (a.2) is used. In this system compressed air is supplied to a vessel 
(which can be agitated if required) containing the polymer at a head pressure of between 
0.1-2 bar and the desired flow rate is set using a pressure reduction valve. This system 
enables very large volumes to be delivered through the nozzle in a single process, and 
also produces more uniform and steadier flow rate of the alginate solution compared to 
the syringe pump method. This enables a narrower size distribution to be obtained for 
the produced particles compared to microspheres produced using the syringe pump 
 
3 Other pumping systems do exist for example Nisco Engineering uses a LineaseptaTM pumping bag 
system to delivery the polymer.  
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delivery mechanism. For the air pressure system, standard size deviations of 1-1.5% 
have been achieved compared to 1.5-3.0% for the syringe pump system. 
The alginate, pumped through the nozzle, must be at a flow rate that is high enough to 
overcome the viscosity and/or the surface tension of the polymer solution, so that it can 
be extruded through the nozzle to form a continuous stable laminar liquid jet 
(mechanism 3 section 1.3.2.1.). However, the flow rate must not be too high, which 
could prevent jet break-up in a controllable manner and/or could result in the formation 
of a spray (mechanism 5 section 1.3.2.1.). High jet velocities will also increase the 
impact forces on the droplets when entering the gelification/collecting bath, resulting in 
deformation of the drops [62,89] whilst also increasing the occurrence of coalescence 
[102]. The size of this impact force on the droplets can be limited by reducing the 
distance between the nozzle and the impact site, or decreasing the jet velocity, but this 
leads to reduced production volumes. A simpler method is to add a surfactant such as 
Tween 80, which does not affect the sphere/capsule formation process [14] and can 
significantly reduce surface tension [91], preventing or reducing the occurrence of 
deformation and/or coalescence. 
The extruded liquid jet is broken-up into droplets of equal size by the application of a 
vibrational frequency with defined amplitude to the laminar jet [73].  For the Inotech 
Encapsulator, the sinusoidal force is applied by passing the polymer through a pulsation 
chamber (Figure 8c) just before reaching the nozzle. This method enables more 
reproducible results to be achieved compared to vibrating the nozzle itself (vibrating 
nozzle experiments have been performed on an Inotech Encapsulator IEM, results are 
not shown). The size of the applied frequency to obtain optimal break-up of the jet can 
be estimated using equations 5 and 6, for a given nozzle diameter and flow rate [62]. 
The calculated frequency can be ± 20-40% of the required frequency for optimal jet 
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break-up, which is determined using an empirical approach as discussed in section 
1.3.2.7.1. The value estimated using equations 5 and 6 acts as a starting point and as 
mentioned previously a range of frequencies exist (around ) whereby uniform sized 
droplets can be produced. As seen in equation 12 the droplet diameter formed here is 
mainly dependent on the jet diameter, which is directly related to nozzle diameter 
(equation 8 and 9). A general rule of thumb for producing alginate microspheres 
(alginate concentration 1.5-2.0%) using the Inotech Encapsulator (IE-50R and IEM) is 
that the final bead diameter is approximately twice that of the nozzle diameter. 
Nevertheless, this size can be varied within a certain range by increasing/decreasing the 
frequency of the vibration and/or the flow rate of the polymer with higher frequencies 
and lower jet velocities enabling the generation of smaller droplets (equation 10). 
Application of higher/lower frequencies to the jet might not only decrease/increase 
droplet size but could also result in the coalescence of droplets [61,73] (higher 
frequencies) or the formation of one or more small droplets between the main ones 
called satellites
optf
4 [61,62,73], which will again affect the overall standard size deviation. 
Satellites are usually formed at frequencies below the optimal frequency for jet break-up 
[62]. 
Optimal break-up of the jet results in the formation of a single bead chain (Figure 8f) 
which can be monitored using a stroboscopic lamp (Figure 8g) placed directly behind 
the chain. The frequency of the lamp is directly related to the frequency applied to the 
nozzle and this enables individual drops to be observed during break-up. The formation 
of droplets from a laminar liquid jet by vibrational frequencies can be so regular that 
they may appear to be slowed down, completely stopped or in reverse motion whilst 
 
4 Yuen  could explain the formation of satellites by extending Rayleigh’s linerized theory to a third order  
131. Yuen MC: Nonlinear Capillary Instability of a Liquid Jet. Journal of Fluid Mechanics 1968, 
33:131-163. 
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being viewed through the lamp [102]. A video camera may also be installed to observe 
the drops and enables the direct measurement of their diameters.  
A by-pass system (Figure 8h) is used to prevent polymer droplets, which may not be the 
required size or shape from entering the gelling bath, and also enables the retrieval of 
this polymer, which can be then re-used for future experiments. The apparatus consists 
of an electronically or manually controlled cup, which can be positioned directly 
underneath the nozzle when required. The by-pass system is usually operated during 
initial priming (setting optimal flow rate and frequency) of the nozzle with the polymer 
solution.  
To prevent coalescence of the droplets from occurring, which results in loss of mono-
dispersity and an increase in the standard size deviation [104], a strong negative charge 
is induced onto their surface during break-up using an electrostatic voltage system 
(Figure 8d). Coalescence in the air, can lead to the formation of particles with at least 
double the volume of other beads present (Figure 9a), or upon impact during entry into 
the hardening solution resulting in the production of irregular shaped particles known as 
doublets (Figure 9b). The voltage system applies an electric potential between the 
nozzle and an electrode (Figure 8i) placed directly beneath the nozzle. As droplets fall 
through the electrode, the induced charge on their surface causes the droplets to repel 
one another, resulting in dispersal of the chain into a cone like shape (Figure 8k) due to 
Coulomb forces [104]. Deflection of the droplets during break-up from their vertical 
position prevents them impacting one another in the air and results in entrance into the 
hardening solution occurring over a larger area. The size of the charge required for 
adequate separation of the jet in mainly dependent on, jet velocity, droplet diameter, 
concentration of the polyelectrolyte used, with higher values required for larger jet 
velocities and low polymer concentrations. The IE-50R is capable of applying an 
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electrical potential of 0-2.15 kV between the nozzle and the electrode. The main 
advantages of the system is that it enables higher frequencies to be used to produce 
smaller mono-dispersed beads for a given nozzle size [104] as well as allowing higher 
jet velocities for increased production capacity. The addition of a higher potential (> 
2.15 kV) is not advised and can result in unstable droplets which can deform and/or 
burst [104,132].  
Upon landing in the agitated bath containing calcium chloride, the alginate droplets are 
hardened by ionotropic gelation to form microspheres. A very critical point for the 
droplet is entry into the gelling solution. When a solution with a high surface tension is 
used such as calcium chloride [91], the polymer droplets can be held back partially at 
the surface of the hardening solution, during entrance, resulting in the formation of non-
spherical droplets which are gelified before regaining there original shape (Figure 16a 
shows the outcome of this processes for the production of Type I microcapsules). As 
mentioned previously the problem of the surface tension can be overcome by the 
addition of a surfactant, which enables the formation of spherical microspheres (Figure 
16b).  
The Encapsulator may also be used for the continuous production of microspheres. In 
this system peristaltic pumps are used to control the movement of the hardening 
solution (Figure 8m) and newly formed microspheres from the reaction vessel to a 
collecting device (Figure 8o) and also add fresh solution to the vessel of the 
encapsulator. This keeps the volume at a constant level to ensure the impact height for 
all droplets is equal. After being given sufficient time to harden, microbeads are 
removed, and used immediately or modified further to produce the desired particles.   
Once the optimal parameters have being obtained for particle production, a standard 
operating procedure should be defined on the parameters used, with slight tuning if 
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necessary, to enable the repeated production of the required microspheres on the 
Encapsulator IE-50R. Provided all other parameters are kept constant (i.e. alginate 
concentration, impact height etc), the size of the particles produced in each run will be 
in general ± 2.0 % of the original size, with a small amount of tuning of the frequency 
and/or flow rate enabling this to be reduced even further.  
 
1.5.2.2. Production of type I and III microcapsules using the single-flow nozzle 
system 
After production, Type IV microspheres can be converted into Type I microcapsules by 
addition of a further membrane followed by subsequent liquefaction of the now inner 
matrix incorporating the encapsulated product, to produce Type I microcapsules [22]. A 
well known example of this encapsulation technique is the production of alginate-poly-
L-lysine microcapsules for the immobilization of mammalian cells and has being used 
since the 1960’s [22,118,133]. Capsules produced using this approach can be seen in 
Figure 11a. 
Type III microcapsules (Figure 11b) can be produced on the Inotech Encapsulator IE-
50R by gently mixing the alginate with a hydrophobic substance such as oleic acid. For 
the capsules in Figure 11b, 1ml of oleic acid was mixed with 49 ml of alginate 
(although much higher amounts of oil can be used).  The mixture is then produced into 
microcapsules using the same procedure for the production of type IV microcapsules. 
The main problem with this method is the difficulty in obtaining equal amounts of oil 
within each capsule. This predicament can be reduced by mixing at higher speeds for 
longer periods and extruding the liquid through the nozzle immediately after mixing. 
Figure 11b shows an example of type IV microcapsules produced by the 
aforementioned method.  
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 (a) (b) 
Figure 9:  Light microscope images displaying droplet coalescence after jet break-up: 
(a) in the air, prior to reaching the hardening bath, resulting in double volume calcium-
alginate microbeads and (b) during entry into the gelling bath resulting in the formation 
of doublets. 
 
 
 
 
 
 
 
 
Figure 10: Light microscope image showing microspheres produced after the 
application of an electrostatic charge to prevent coalescence. Charge induction enabled 
the production of mono-dispersed, homogenous, spherical microspheres of equal size 
and shape. calcium-alginate microbeads where produced under the same conditions as 
spheres in Figure 9 and have a diameter of 763.02 μm ± 1.89%. 
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 (a) (b) 
 
 
 
 
 
 
  
(c) (d) 
 
Figure 11: Light microscope images of microcapsules type I, III and IV produced by 
using a single-flow nozzle system on an Inotech encapsulator IE-50R or directly 
produced from these microcapsules: (a) Type I microcapsules produced from type III 
microcapsules as outlined in section 1.5.2.2. The capsules contain CHO cells and are 
enveloped in a poly-L-lysine-alginate membrane and have a diameter of around 500 
μm; (b) Type III microcapsules, with a diameter of 953.81 μm ± 1.96%, containing 
multi-cores of oleic acid; (c) Type IV microspheres containing cells of Streptomyces 
hydroscopicus var. geldanus, which can also be produced into type I if required. 
Displayed microspheres had a diameter of 681.25 μm ± 2.51% and (d) Type IV 
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macrospheres with a diameter of 2.5 mm ± 2.01% and containing the anti-inflammatory 
drug diclofenac. This picture was taken to scale using a digital camera. 
 
1.5.3. Concentric nozzle system  
The Inotech Encapsulator IE-50R employing the concentric nozzle system is of similar 
set-up to the single-flow nozzle system as seen in Figure 8, the main difference involves 
the replacing of the single-flow nozzle with a concentric system (Figure 12a), which 
itself requires two feeds, one for the outer shell and the other for the inner core. The 
concentric nozzle system consists of two single nozzles termed an internal and an 
external nozzle, in which the inner nozzle is placed directly into the outer one (Figure 
12b). Both nozzles can also be used on the Encapsulator as a single-flow system. The 
encapsulant is usually in the form of a liquid but if the encapsulation of a solid is 
required, this can be achieved by suspending the solid in a liquid, which is then 
extruded through the central orifice. For the Inotech system, diameters of 100-1000 μm 
are available for the outer nozzle and 50-900 μm for the inner one. Conventional 
wisdom tells us that the external orifice aperture must always be larger than the internal 
one to obtain the desired encapsulation of the core material within the chosen 
membrane. The external nozzle can be anywhere between 50-900 μm wider compared 
to the internal nozzle orifice diameter, which enables control of membrane size 
(membrane size can also be determined by varying the volume of the shell/core material 
and will be discussed in the next section). Type I microcapsules can be described as 
having an average diameter ( )md  , which is the sum of the core and the shell material 
diameters5 and an average internal diameter ( )cd  which consists solely of the 
                                                 
5 For Type III and IV microcapsules dm, is also taken as the diameter of the whole capsule.  
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)
measurement of the core diameter. The average size (thickness) of the microcapsule 
membrane (  can then be obtained from the following equation  mM
 
  
2
cm
m
dd −=M        (13) 
 
The concentric system is used mainly to produce type I microcapsules. 
 
1.5.3.1. Production of type I microcapsules using the two-flow nozzle system 
For the concentric system the two liquids required for production of the microcapsules 
can also be supplied to the nozzle using either a syringe pump or a pressure regulation 
system or a combination of both. The simultaneous supply of the two feeds to the 
concentric nozzle results in the formation of a co-extruded laminar liquid jet, which is 
subsequently broken-up into mononuclear drops, by the application of a vibrational 
frequency (Figure 12b and 12c). The produced droplets are then gelled into the desired 
mononuclear microcapsules. The effect of the two liquid-flows on producing liquid-core 
microcapsules using the Inotech Encapsulator IE-50R in comparison to producing 
microspheres will be discussed in this section. 
The capsule diameter is mainly dependent on the diameter of the outer nozzle and like 
the single nozzle system; the size can be varied within a certain range by 
increasing/decreasing the applied flow rate and vibrational frequency. The diameter of 
the internal nozzle and the flow rate of the material will also affect the final capsule size 
with increasing diameters and volumes resulting in larger core volumes, hence bigger 
sized capsules. A general rule of thumb for the production of type I microcapsules is 
that the final  can vary between 1.5-2.5 times the size of the external nozzle diameter md
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with decreasing sizes resulting from higher frequencies and lower flow rates of the shell 
and core material. The diameter of  can vary between 1.0-2.5 times the diameter of 
the inner nozzle with increasing flow rates resulting in larger diameters. This implies 
that the thickness of the membrane material can be predetermined and controlled within 
a certain range
cd
6 for a given concentric nozzle system by varying the ratio of the flow 
rate (volume) of the shell material to the volume of the core material in the extruded 
concentric liquid jet, during the microcapsule production process (Figure 13). The 
membrane thickness can be a very important characteristic of microcapsules as it has 
the ability to significantly affect the egress/ingress of compounds from microcapsules 
[14,27,52]. 
Unlike the monocentric nozzle system, no equations presently exist to help determine 
close values and/or an approximation of the optimal flow rates and vibrational 
frequency for the system and the values must be determined using an empirical 
approach. Similar to the single-flow nozzle system a range of frequencies around the 
 value exist for the break-up of the jet into uniform droplets. In general, to obtain 
good production conditions the flow rate of the shell material is usually at least twice 
that of the core liquid; however this value can be reduced to obtain thin-membrane 
microcapsules as mentioned previously. Depending on the diameters of the internal and 
external nozzles and the flow rates of the two materials it is possible to obtain 
mononuclear capsules with a membrane diameter smaller than 50 μm and greater than 
500 μm.  
optf
 
6 For example, an external nozzle with a diameter which is 100 μm greater than the internal nozzle will 
general produces capsules with a membrane thickness size of around 100 μm. However, by increasing 
/decreasing the core/shell material volumes, the membrane thickness can be considerably reduced to < or 
> 100 μm in diameter (Figure 13). 
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The application of frequencies below the  can again lead to the production of 
miniature sized satellites (Figure 14a and b). For the concentric nozzle system, these 
structures can have the following effects on the production processes: (1) they can form 
smaller mononuclear capsules during gelification, which are completely separate and 
independent of the larger desired microcapsules (Figure 14a), which will significantly 
increase the overall standard size deviation and (2) the small independent particles may 
become incorporated into the membrane of the large capsules. This may occur when 
small satellites collide with the larger droplets either during jet break-up and/or when 
entering the gelling bath. This results in the formation of a smaller independent core 
adjacent to the larger liquid-core and/or in some cases it joins onto the core material 
itself (Figure 14b).  
optf
A charge can also be applied to the mononuclear droplets to enable their dispersion and 
prevent coalescence occurring in the air and/or upon impact resulting in the formation 
of duplets and/or larger microcapsules (Figure 15). This charge must be applied at 
higher values compared to the monocentric nozzle system to enable similar droplet 
dispersion to be achieved. This is due to the smaller percentage of polyelectrolyte 
present in the droplet because of the core material7. Upon landing in the gelling bath 
drops can be again held back momentarily due to the high surface tension, which can 
again result in the formation of oval shaped capsules (Figure 16a). In some instances 
this delay can cause the droplet to burst, releasing the core material before gelification 
takes place (Figure 17). It is hypothesized that this bursting is caused by the movement 
of the core liquid out through the pre-hardened membrane material when capsules are 
been held back briefly at the surface of the hardening solution and hence results in 
release (bursting) of the core liquid. Bursting of the droplet can also be caused by high 
 
7 This problem can be overcome by increasing the alginate concentration, however as mentioned 
previously this will increase viscosity, which can prevent extrusion and/or jet break-up. 
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impact forces when the pre-gelified droplet hits the hardening solution. As mentioned 
previously surface tension can be reduced by the addition of a surfactant and/or by 
slightly heating (50-60 °C) the gelification solution. This will enable quicker entry of 
the drop into the solution preventing its deformation and resulting in an instantaneous 
gelification. Under ideal conditions a standard size deviation of  < 2.5% and an 
encapsulation yield > 90% for the encapsulant can be obtained for capsules produced by 
this process, and depending on several variables, 200-2000 capsules per second can be 
produced. Most solvents can be encapsulated using the co-extrusion laminar jet break-
up technique, provided a difference exists between the viscosity/surface tension of the 
membrane polymer and the liquid-core material [14].  
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 (a)   (b) (c) 
Figure 12: Images displaying the two-flow nozzle system used to directly produce type 
I microcapsules on the Inotech Encapsulator IE-50R: (a) Concentric nozzle with an 
internal diameter of 400 μm and an external diameter of 600 μm; (b) Schematic 
representation of the internal structure of the two-flow nozzle system and (c) Real-time 
image showing the laminar jet break-up of a co-extruded jet into mononuclear droplets. 
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Figure 13: Light microscope image of mono-dispersed and uniform mononuclear 
microcapsules (type I) produced using the concentric nozzle system. The capsules 
displayed contain dibutyl sebacate as the liquid-core material and have a  of 616.92 
μm ± 1.52%, a  of 551.81 μm ± 1.23% and a  of 32.55 μm ± 5.88%.   
md
cd mM
Small independent 
microcapsules 
(satellites) 
Satellite incorporation into 
the membrane of capsules, 
where they can migrate to 
the core 
 
 
 
(a) (b) 
Figure 14: Light microscope images displaying the different types of satellites formed 
during the production of Type I microcapsules using the concentric nozzle system: (a) 
small independent microcapsules with a  of 123 μm ± 19.78% and a  of  85.38 μm 
± 22.6%. The larger microcapsules have a  of 751.12 μm ± 4.29% and a  of 
567.94 μm ± 2.7% and (b) satellite incorporation into the capsule membrane and/or the 
core material. 
md cd
md cd
 46
Chapter 1: Microencapsulation using vibrating technology 
 
 
 
 
 47
 
 
 
 
 
Doublets 
Larger 
capsule 
Figure 15: Light microscope image shown the affects of droplet coalescence after jet 
break-up and during entry into the hardening bath when using the concentric nozzle 
system. This can result in the formation of doublets and larger-sized capsules. 
 
 
 
 
 
 
 
 
 
 
 
 (a) (b) 
 
Figure 16: Light microscope image of: (a) Non-spherical capsules formed due to the 
high surface tension of the gelling bath and (b) Improved structure and spherical shape 
as a result of heating the hardening solution which also contained the surfactant Tween 
80. 
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Figure 17: Light microscope image showing the release of the core liquid from type I 
microcapsules due to bursting of the capsules when entering (impacting) the gelling 
bath.  
 
1.5.4. Challenges facing the vibrating nozzle system: possible solutions 
As discussed and shown in the previous section, the jet break-up technique based on 
vibration technology has shown the capability to match most of the criteria set-out in 
section 1.3.1.1. However, it is still susceptible to two commonly known problems, 
which need to be addressed and overcome to enable further development of the process, 
and which will help facilitate its application towards a relevant industrial process. This 
section discusses the two main challenges and describes possible solutions to these 
problems. 
 
1.5.4.1. Large scale production/scale-up 
The vibrating technique using a monocentric or concentric nozzle system is usually 
limited to relatively small production yields of microspheres/microcapsules, as it only 
produces single droplets, one after another at any given time. The production flow rate 
is mainly dependent on the nozzle diameter with increasing diameters resulting in 
higher production volumes. However even for the largest orifice diameters, very low 
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production volumes are still achieved. For example, using the single-flow nozzle system 
on an Inotech Encapsulator IE-50R with an orifice diameter of 500 μm, only yields a 
maximum flow rate of 1.25-1.35 l/hr. For the concentric system (external nozzle of 600 
μm and internal of 400 μm), a maximum flow rate of only around 2.1-2.7 l/hr can be 
achieved. It must also be noted that these flow rates do not equal production volumes, as 
losses will be incurred during initial priming of the system. Whilst these volumes are 
sufficient for lab-scale research and application, they fall well short of quantities (tons 
or cubic metres per day) required at an industrial level.  
Brandenberger and Widmer [107] showed that the monocentric nozzle system can be 
scaled-up to achieve increased production quantities by simply adding more nozzles 
(from one to thirteen) for polymer extrusion. This enabled the simultaneous production 
of thirteen homogenize liquid jets which were broken-up and produced into microbeads 
of equal size and shape by the application of an equal vibrational frequency to all the 
extruded liquids. The flow rate of the jets was kept equal by using a concentric split, 
which enabled a relative flow difference between all nozzles of < ± 2.0%. Before 
extrusion through the nozzles the polymer solution passes through a vibrating chamber 
which transmits an equal disturbance to the solution hence resulting in the break-up of 
all jets into droplets of equal size (difference of droplet size of < 0.7% and was mainly 
attributed to small differences in the diameters of the nozzles). This is another reason 
for using a pulsating chamber to exert the perturbation onto the extruded jet instead of 
vibrating the nozzle, as to subject all liquid jets with the same sinusoidal force using the 
latter would pose a difficult engineering challenge.   
By using the multi-nozzle system with a nozzle diameter of 200 μm, Brandenberger and 
Widmer [107] obtained a semi-continuous production capacity of up to 5 l/hr (0.385 l/hr 
per nozzle). This low production level was achieved due to the 1 litre capacity of the 
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polymer delivery apparatus. This can easily be overcome by increasing the volume of 
the delivery mechanism by using large pressurized vessels to control the flow. Due to 
the stop-start production initiated by the low delivery volumes, a clean-in-place (CIP) 
process using steam and filtered water was applied to the multi-nozzle system to prevent 
clogging of the nozzles by gelled alginate. The use of larger polymer volumes would 
reduce the need for this procedure, hence reducing the number of steps which would 
otherwise add cost and complexity to the process. 
Using this system as an example, and the previously mentioned flow rates and nozzles 
diameters, it is estimated that a system (monocentric) incorporating a nozzle diameter of 
500 μm, should be capable of reaching a production capacity of around 17 l/hr for the 
monocentric system, and for the concentric set-up a capacity of around 27-35 l/hr could 
be obtained. These quantities are still below what would be required for industrial 
applications, but as discussed previously by Heinzen et al. [62], provided the vibrational 
frequency, amplitude and flow rate are kept constant across all nozzles, larger quantities 
can be obtained simply by further increasing the number of nozzles which should still 
enable the production of spherical and equal-sized capsules. At present the authors are 
not aware of any research which has being published which discusses the maximum 
number of nozzles which can be placed on the same machine (nozzle plate) for optimal 
production. 
The multi-nozzle system developed by Brandenberger and Widmer [107] did not 
employ an electrostatic voltage system to separate the droplets during jet break-up and 
this resulted in coalescence of the droplets, which increased the overall standard size 
deviation. It should be possible to apply a charge to the individual chains to enable 
separation. This could be applied using individual electrodes placed directly underneath 
each nozzle. Unlike other parameters, the charge applied to the each jet does not have to 
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be the equal, and needs only be applied at a minimum value which adequately separates 
the chain (higher values,  [≤ 2.15 kV] would also not affect the production process and 
would just result in greater dispersions of the droplets).  The multi-nozzle system has 
also shown the capability to be operated under sterile conditions [62,107]. It is 
envisaged that in the future, encapsulating devices (based on the vibrating-jet 
technology) applied at an industrial level could possibly contain several hundred 
nozzles which would enable the required quantities of tons/day to be produced.   
 
1.5.4.2. Polymer Choice  
Whilst encapsulation can take place using a large number of materials as the shell, the 
jet break-up technique, due to vibrational frequencies, has mainly focused on using 
alginate as the encapsulation matrix. Indeed the other mechanical processes described in 
this review also use the polymer as their number one choice. The use as an 
encapsulation material of non-Newtonian polyelectrolytes such as alginate, which 
exhibit pseudoplastic behavior [101], is limited in biotechnological and medical 
applications. This is on account of their naturally low mechanical stability (which will 
be discussed first) and their sensitivity towards chelating compounds such as such as 
phosphate, citrate, EDTA and lactate, or other anti-gelling cations like Na+ or Mg2+ 
[134]. These can reduce the mechanical stability of the hydrogel and in some cases 
cause complete dissolution of the gel network structure, releasing the encapsulant itself. 
These compounds are commonly found in biological and bioprocessing environments 
[135] and the sensitivity of alginates towards them is the main reason behind its limited 
success toward industrial and medical applications [136].  
As shown in numerous studies increased alginate concentrations can result in 
microspheres with considerably improved mechanical properties. However, exponential 
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increases in viscosity are obtained with accumulating concentrations of alginate [101]. 
In some cases, depending on the source and purification procedure used, doubling the 
concentration will cause a 10-fold increase in the viscosity of the alginate solution 
[10,101]. As mentioned in section 1.5.2.1. very high viscosities can prevent extrusion of 
the alginate through the nozzle, especially when syringe pumps are being used, on 
account of their limited power. This problem can be resolved by pumping the solution 
under high pressure through the nozzle but the high jet velocities and/or viscosities can 
again prevent the break-up of the jet [135]. Using the Inotech encapsulator it was 
possible to extrude and break-up alginate solutions between concentrations of 2.5-3% 
(w/v). However concentrations ≥ 3% (w/v) could not be extruded and/or caused 
unstable jet break-up, leading to the production of hetero-disperse beads [136]. These 
results are somewhat in contradiction to results obtained by Prusse et al. [89], in which 
it was observed that microspheres could not be produced at alginate concentrations, in 
some situations at, and above 2% (w/v). This study also claimed then when production 
did occur at 2%, large standard size deviation was obtained and the spherical structure 
of the particles was compromised. This is again in contradiction to results obtained by 
our research group and is probably due to the use of different alginate solutions having 
higher viscosity/molecular weight range.  
This problem of only being able to use solutions, containing low concentrations of 
alginate, which only allows the production of particles with limited mechanical strength, 
can be resolved by reducing the viscosity of the alginate solution. This can be achieved 
by increasing its temperature during extrusion through the nozzle(s). Recently an 
apparatus has being developed (by EnCapBioSystems), for heating and/or maintaining 
polymers solutions at controllable temperatures as they pass through the pulsation 
chamber, before extrusion and break-up. This apparatus, termed a heating 
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nozzle/pulsating-head device (Figure 18), consists of a temperature control unit 
connected to a heating element placed adjacent to a circular aluminum casing, which 
conducts the heat from the element. The pulsating chamber (monocentric/concentric) 
with the nozzle holder attached sits within the heating device and is completely 
enveloped. The casing itself can be fastened tightly to the nozzle housing to improve 
heat transfer and enables a more precise temperature control. The heating apparatus can 
supply a controllable temperature of up to 60 °C ± 1 °C to the chamber which 
subsequently heats and/or maintains the temperature of the polymer during extrusion 
and jet break-up. The shell and/or core liquid can be heated in their reservoirs to the 
desired temperature using standard water baths before being pumped along insulted 
tubing to the pulsating chamber.  At present only preliminary experiments have being 
preformed in regard to using this device and as of yet, no concrete conclusions can be 
made. However initial experiments have being performed and have shown the device to 
enable concentrations of alginate of ≥ 4% (w/v) to be successfully produced into 
microspheres which showed considerably improvements in mechanical strength 
compared to lower concentrations of alginates. 
Whilst increasing alginate concentration can significantly improve mechanical strength, 
it does not however overcome its sensitivity towards chelating agents and other anti-
gelling cations. In response to this predicament, numerous attempts have been made to 
help stabilize alginate gels using various hardening techniques. These include 
complexation with ions other than calcium i.e. barium [137] or additional complexation 
with other polymers [138]. Other methods include covalent cross-linking of alginate and 
a alginate-polyethyleneimine mixtures with glutaraldehyde [139,140], acrylamide [135] 
and epichlorohydrin [141]. Glycol alginate has itself been cross-linked with proteins 
[142]. Whilst the stability and strength of the gel structure improved significantly in 
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some instances, the gels did however still show sensitivity towards chelating agents, or 
in some cases the hardening step was not suitable for the encapsulated particles (i.e. 
cells) or the cross-linking component was itself affected when applied to the new 
environment i.e. hydrolytic enzymes [142]. Long term stability is still a major problem 
and most be overcome to enable use of alginate for encapsulation of artificial organs 
and for incorporation in biotechnological processes [143].  
Another sizable problem with using alginate relates to structural differences. The overall 
composition and the sequence of the D and G regions of the polymer (Figure 4) can 
vary extensively between different batches of alginate and is mainly dependant on the 
species of origin, location of alginate in the plant and the time of year in which 
harvesting was performed. This variable composition has many negative affects on 
reproducibility of experiments (especially for cell encapsulation) and is still one of the 
limiting factors for large scale use of alginate at an industrial level [144]. However, 
certain bacterial strains do produce alginate homogenously. Bacterial alginate 
fermentations mainly use A. vinelandii as the producing organism but are not usually 
available commercially due to low production volumes (around 4 g/l), which make the 
product commercially non-viable [111,112]. However research has being undertaken to 
control and increase the production of alginate by certain bacteria [112]. Provided high 
enough concentrations can be manufactured, this type of research could enable the 
continuous production of alginates with a constant structure, which could potentially 
solve the consistency problems plaguing applicability in biotechnological and medical 
applications.  
At present very few polymers seem to be available to produce the desired capsules 
according to the criteria in section 1.3.1.1. However the heating device previously 
mentioned has the potential to increase this number of polymers by enabling very 
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viscous polymers and gums, which only form liquids above room temperature to be 
extruded (i.e. gelatin) to produce microspheres/microcapsules. However, subjecting the 
polymer to high temperatures (up to 60 °) has the potential to adversely affect the 
encapsulant which could be counterproductive to the processes itself. This certainly 
would be the case for the encapsulation of most animal cell lines, probiotic bacteria as 
well as the entrapment of heat sensitive pharmaceuticals. Most aroma compounds are 
themselves very volatile and the process could result in evaporation of large amounts 
during the capsules production process.  
Whilst alginate has proven to be a very versatile and interesting compound to work with 
and has provided the encapsulation community with a vast amount of interesting results 
and ideas for nearly 50 years, the authors feel that in the coming decades, for 
encapsulation technology to reach its full potential in biotechnological and medical 
processes, a shift from the extensive research on alginate is required toward other 
polymers.  
 
 
 
 
 
 
 
Pulsating chamber 
Inlet for polymer 
solution  
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Nozzle 
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Figure 18: Image of the heating nozzle/pulsating-head device for the Inotech 
Encapsulator IE-50R. The nozzle holder displayed belongs to a monocentric system.  
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1.6. Nomenclature 
Table 2: List of abbreviations and symbols, which are listed according to their 
appearance in the text. 
Abbreviation/Symbol Definition Unit 
v Liquid velocity m/s 
dd Droplet diameter μm 
dn Nozzle diameter μm 
σ Surface tension N/m 
g Acceleration due to gravity m/s2 
ρ Fluid density kg/m3 
dcab Diameter of Ca-alginate bead μm 
K Overall correction factor - 
λopt Optimal wavelength μm 
dj Jet diameter μm 
λ Wavelength of perturbation μm 
vj Jet velocity m/s 
f Vibrational frequency 1/s 
η Fluid viscosity kg/ms 
Wen Weber’s number - 
F Liquid flow rate m3/s 
vn Liquid velocity through the nozzle m/s 
dm Diameter of microcapsule μm 
dc Diameter of core of microcapsule μm 
Mm Size of microcapsule membrane μm 
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M-block (region) D-mannuronate - 
G-block (region) L-guluronate - 
PDADMAC poly(diallydimethylammonium chloride) - 
CIP Clean in place - 
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2.1. Abstract 
In recent years ever-increasing amounts of pharmaceuticals are being detected in the 
aquatic environment and in some cases, they have even been discovered in drinking 
water. Their presence is attributed mainly to the inability of sewage treatment plants to 
adequately remove these compounds from the sewage influent. The aim of this study 
was to investigate the feasibility, kinetics and efficiency of using liquid-core 
microcapsules as a novel methodology, termed capsular perstraction, to remove seven 
pharmaceuticals commonly found in the environment, from water. The process involves 
the envelopment of pre-selected organic solvents within a porous hydrogel membrane to 
form liquid-core microcapsules, which can be used to extract a large range of 
compounds. Results indicate that this novel approach is capable of extracting the seven 
chosen compounds rapidly and with a variable efficiency. The simultaneous use of both 
dibutyl sebacate and oleic acid liquid-core microcapsules at a liquid volume ratio of 
only 4% (v/v) resulted in the following extractions within 50 min of capsule addition to 
contaminated water: furosemide 15%; clofibric acid 19%; sulfamethoxazole 22%; 
carbamazepine 54%; warfarin 80%; metoprolol 90% and diclofenac 100%.  
The effects of different agitation rates, microcapsule size and membrane thickness on 
the rate of mass transfer of warfarin into the liquid-core (dibutyl sebacate) of 
microcapsules was also examined. Results showed that the main rate-limiting step to 
mass transfer was due to the stagnant organic film (microcapsule size) within the core of 
the microcapsules. A volumetric mass transfer coefficient of 2.28 x 10-6 m/s was 
obtained for the smallest microcapsules, which was nearly 4-fold higher compared to 
the value (0.6 x 10-6 m/s) obtained for the largest microcapsules used in this study. Even 
with this resistance liquid-core microcapsules are still capable of the rapid extraction of 
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the tested compounds and may provide a platform for the safe disposal of the 
pharmaceuticals after removal.  
 
2.2. Introduction 
The presence and fate of pharmaceutically active compounds (PhACs) in ground, 
surface and drinking waters is now recognized as an emerging environmental issue [1]. 
This topic has been frequently reported in the last decade with a plethora of studies 
showing the widespread detection of these compounds in the aquatic environment at 
significant concentrations [1-4].  
Several studies carried-out globally have concluded that treated wastewater from 
conventional sewage treatment plants (STPs) is one of the main point sources for entry 
of pharmaceuticals into environmental waters [5-12]. This ingress occurs mainly via 
human excreta (urine or stool), as either parent molecules or subsequent metabolites 
[13]. STPs were not designed to specifically remove pharmaceuticals from sewage 
influent [6] and their elimination in these plants can sometimes depend only on their 
ability to adsorb to solid particles (activated sludge) or to biodegrade naturally [14]. 
Pharmaceuticals not readily degraded in STPs are being discharged into receiving 
waters as changed or unchanged forms, usually forming complex mixtures of many 
compounds in treated effluents. This results in the contamination of rivers, lakes, 
estuaries and in some instances ground and drinking water [2]. 
The ecotoxicological implications of chronic exposure to sub-therapeutic levels of 
PhACs in the aquatic environment on humans and wildlife to date is yet largely 
unknown and is the focus of much on-going debate [15]. Pomati et al. (2006) showed 
how a mixture of thirteen drugs commonly found in the environment at sub-therapeutic 
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levels inhibited the growth of human embryonic kidney 293 cells (HEK293) by as much 
as 30% compared to controls [16]. It was concluded that the mixture of drugs at 
environmental exposure levels inhibited cell proliferation by affecting the physiology 
and morphology of the HEK293 cells [16].  
The inability of primary and secondary methodologies in STPs to remove adequately 
some or all PhACs present in STPs effluents, has lead to extensive research into 
developing tertiary methods to remove these compounds. Tertiary methods used to 
remove pharmaceuticals from water include photocatalysis [17], flocculation [18], 
ozonation [19], advanced oxidation [20] membrane filtration processes [21] and 
adsorption by activated carbon [22]. Unfortunately, these methods are used rarely, 
mainly due to high costs [6] and in most cases are only financially viable when very 
dilute streams have been pre-concentrated. Processes used to pre-concentrate dilute 
streams are themselves very expensive, labour intensive and require large amounts of 
energy [23].  
Liquid-liquid extraction is a relatively cheap and robust method which has been used for 
over a century in the chemical industry for the separation and pre-concentration of 
compounds and has also been used as an important separation process in water 
treatment [24,25]. Unfortunately this process is susceptible to several problems, 
including being unfeasible for large volumes of dilute streams due to the need for an 
extremely high contact area. However, these obstacles can be overcome by increasing 
agitation speed and/or the volume of the solvent used, but this can lead to elevated costs 
and/or the formation of stable emulsions, which are difficult to remove and prevent the 
re-cycling of the solvent for future use. The extraction solvent may also contaminate the 
water being treated due to direct contact of the two phases. 
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As discussed previously these limitations may be overcome by encapsulation of the 
solvent within a hydrogel membrane [26,27]. This membrane prevents direct contact 
between the two phases, which stops the formation of stable emulsions and also enables 
rapid extraction of compounds due to the large interfacial contact area provided by 
microcapsules. This enables a reduction in solvent volume and agitation speed 
compared to solvent extraction processes. This novel methodology (termed capsular 
perstraction) of encapsulating a hydrophobic organic solvent within a hydrogel has been 
successfully and efficiently demonstrated for the extraction of a range of pesticides and 
herbicides from aqueous solutions [27]. In this work, the extraction efficiency of the 
process improved with increasing hydrophobicity of the compounds recovered. Similar 
results were also observed by Boucher et al. (2008), who showed that the partition 
coefficient of five compounds between water and the oil-core of naturally occurring 
microcapsules from rapeseed was linearly correlated with their hydrophobicity [28]. It 
was also shown that microcapsules not only recover pollutants but also provided a 
mechanism, which enabled the subsequent bio-degradation of the recovered compounds 
[29].  
In this study, the feasibility, kinetics and efficiency of using liquid-core microcapsules 
as a novel methodology for the recovery of seven PhACs from aqueous solutions were 
investigated 
 
2.3. Materials and methods 
2.3.1. Chemicals 
Methanol, water, ammonium acetate, dichloromethane and dichlorodimethylsilane were 
of high performance liquid chromatography grade and were all obtained from Sigma-
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Aldrich (Dublin, Ireland). Formic acid, calcium chloride, 3-(N-Morpholino) 
propanesulfonic acid (MOPS), sodium chloride (NaCl) and Tween 80 were obtained 
from Fluka (Buchs, Switzerland) and were of at least analytical grade. Clofibric acid, 
sulfamethoxazole, furosemide, warfarin, carbamazepine and metoprolol tartrate salt 
were all obtained from Sigma-Aldrich (Dublin, Ireland) and were of a purity > 95%. 
Sodium alginate was purchased from Inotech Biotechnologies (Basel, Switzerland). 
Dibutyl sebacate (Sebacic acid dibutyl ester, CAS No. 109-43-3) was of analytical grade 
and obtained from Fluka (Buchs, Switzerland). Oleic acid (cis-9-Octadecenoic acid, 
CAS No. 112-80-1) was of analytical grade and was obtained from Sigma-Aldrich 
(Dublin, Ireland).  
Stock solutions of the pharmaceuticals were prepared in water using methanol as a co-
solvent [30] to facilitate the solubility of each drug in the aqueous (water) phase. 
Initially the drugs were dissolved in methanol and were then added to the water, with a 
final methanol concentration of 5% (v/v), to obtain the desired concentration of the 
pharmaceuticals. The compounds were present in the aqueous phase at a concentration 
of 20 mg/l for all experiments, except diclofenac, which was used at a concentration of 
8 mg/l. The presence of methanol at the employed concentration had a negligible affect 
on the mass transfer. Stocks were filtered under vacuum using 0.2 μm nylon membranes 
(Sigma, Dublin, Ireland). When salts were used, stocks were prepared in terms of the 
parent analyte. Standard solutions for calibrations were prepared in methanol.  
Alginate stock solutions [2% (w/v)] were prepared by dissolving alginate powder in 
MOPs buffer [10 mM MOPs, 0.85% (w/v) NaCl pH 7.0] and mixing overnight on a 
magnetic stirrer at 4 ºC. After solubilisation the alginate solution was filtered using a 
0.45 and 0.22 µm cellulose acetate filter membrane (Whatman, Dassel, Germany) under 
a pressure of 2 bar.  
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2.3.2. Methods 
2.3.2.1. Glassware preparation 
Prior to use, all glassware was silanised by rinsing thoroughly with a 10% (v/v) solution 
of dichlorodimethylsilane in dichloromethane, followed by rinsing twice with 
dichloromethane and twice with methanol. 
 
2.3.2.2. Reverse phase high performance liquid chromatography (RP-HPLC) 
RP-HPLC was used throughout this work using an Agilent 1100 series unit (Agilent 
Technologies, USA). The analytes were separated on a reversed-phase C18 Luna (2) 
column, dimensions 150 mm X 4.60 mm X 5 μm with an associated security guard 
cartridge system (Phenomenex, Cheshire, UK). The mobile phase was a binary gradient 
mixture of 0.1% (v/v) ammonium acetate, adjusted to pH 5.5 by the addition of formic 
acid and methanol. The gradient started at 10% (v/v) methanol, maintained isocratically 
for the first 5 min, thereafter the methanol content was raised linearly to 90% (v/v) 
within 13 min and was maintained isocratically for 20 min. This enabled complete and 
separate elution of all pharmaceuticals. The total run time was 30 min and retention 
time was used for peak identification. Samples (20 μl) were injected onto the column, 
which was maintained at 25 ºC, using a mobile phase flow rate of 0.8 ml/min and all 
pharmaceuticals were detected at a fixed wavelength of 270 nm. All samples were 
diluted in methanol and filtered using 0.20 μm nylon filters (Sigma, Dublin, Ireland) 
before analysis. Internal and external standards were run to ensure accurate results. The 
quantification of compounds was based on the external standard method using 
chromatogram peak areas. For standard calibrations a linear regression (r2) value of at 
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least 0.998 was obtained for all pharmaceuticals and a limit of detection of > 0.1 mg/l 
was achieved for each drug. 
 
2.3.2.3. Preparation of liquid-core microcapsules 
Mono-disperse and mono-nuclear microcapsules of different sizes were prepared using 
the co-extrusion laminar jet break-up technique (Inotech encapsulator IE-50-R, Basel, 
Switzerland). The encapsulator was fitted with one of two different sized concentric 
nozzles. The nozzles consisted either of an internal diameter of 200 µm and external 
diameter of 300 µm or an internal diameter of 400 µm and external diameter of 600 µm. 
Alginate was supplied to the external nozzle using an air pressure regulation system 
which enabled flow rates of 10-30 ml/min to be generated using a maximum head 
pressure of 0.5 bar. The desired flow rate was set using a pressure reduction valve. The 
organic phase was supplied using a precision syringe pump connected to the inner 
nozzle to supply the organic phase at flow rates of between 5 and 15 ml/min. Spherical 
microcapsules were obtained by the application of a set vibrational frequency, with 
defined amplitude, to the co-extruded liquid jet consisting of alginate and the core 
solvent. The resulting concentric jet broke up into microcapsules which fell into a 
magnetically stirred gelling bath 15 cm below the nozzle. The gelling bath consisted of 
32 g/l CaCl2, 10 mM MOPS pH 7.0 and 0.1-0.2% (v/v) Tween 80, which was added to 
reduce the surface tension of the gelation solution. To prevent coalescence of the 
microcapsules during jet break-up and/or when entering the gelling bath, a high 
negative charge was induced onto their surface using an electrostatic voltage system 
which applied an electrical potential of 0-2.15 kV between the nozzle and an electrode, 
placed directly underneath the nozzle. As microcapsules fell through the electrode, they 
were deflected from their vertical position resulting in their impact occurring over a 
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larger area in the gelation solution. This enabled mono-disperse microcapsules with a 
standard size deviation of less than ± 2.5% to be manufactured. Microcapsules were 
allowed to harden for at least 30 min to ensure complete gelation and were then washed 
and filtered using a porous mesh to remove any un-reacted components.  
Microcapsules can be described as having an average outer diameter (dm) consisting of 
the alginate shell and liquid-core and an average internal diameter (dlc) consisting solely 
of the liquid-core (Figure 1). Five different sized liquid-core microcapsules containing 
either dibutyl sebacate or oleic acid were used in this study and are described as follows. 
Dibutyl sebacate liquid-core microcapsules: (1) dm 621.01 µm ± 1.53%, dlc 546.4 µm ± 
1.07%; (2) dm 737.36 µm ± 2.39%, dlc 569.91 µm ± 2.45%; (3) dm 1106.04 µm ± 
1.97%, dlc 765.21 µm ± 1.23%; (4) dm 1535.77 µm ± 2.32%, dlc 1065.08 µm ± 1.99%. 
Oleic acid liquid-core microcapsules: (5) dm 682.61 µm ± 1.75%, dlc 502.57 µm ± 
1.86%. 
 
2.3.2.4. Measurement of microcapsule size 
The size and size distribution of microcapsules were determined using a camera (model 
DP30BW, Olympus, Japan) attached to a light microscope (model, BX-51, Olympus, 
Japan) interfaced to a PC operating with CellF image analysis software (Olympus, 
Japan). Up to 100 microcapsules where measured for each batch manufactured using a 
magnification of 40X and the mean size and standard deviation were determined. 
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Alginate 
Liquid-core 
shell 
 dm  dlc 
Figure 1: Light microscope image of mono-disperse and mono-nuclear dibutyl sebacate 
liquid-core microcapsules used in section 2.4.5.1. and 2.4.5.2. to extract all seven 
pharmaceuticals from water. Capsules displayed have a dm of 621.01 μm ± 1.53 % and a 
dlc of 546.4 μm ± 1.07%. 
 
2.3.2.5. Determination of mass transfer 
Mass transfer of the pharmaceuticals into the microcapsules and their resistance to mass 
transfer was calculated using the following simple global mass transfer equation:  
 
( eaqaqLaq CCakdtdC −=− )      (1) 
 
In this equation,  is the drug concentration in the aqueous phase at time   is the 
overall mass transfer coefficient, which can be estimated from kinetic measurements. 
 is the concentration of the pharmaceutical in the aqueous phase when equilibrium 
has been reached and can be determined from the following equation: 
aqC .t akL
e
aqC
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K
C
C meaq =         (2) 
 
where  is the drug concentration in the microcapsules. The partition coefficient mC K  
defined as the ratio of the pharmaceutical in the microcapsule to the concentration in the 
aqueous phase at equilibrium and was obtained from equation (3). 
 
   e
aq
e
m
C
CK =        (3) 
 
where  is the drug concentration in the microcapsules when equilibrium has been 
obtained. The concentration of the drug inside the microcapsule at t  was obtained from 
the following mass balance; 
e
mC
 
   ( ) ( )00 mmmaqaqaq CCVCCV −=−     (4) 
 
where  is the volume of the aqueous phase (bulk liquid) and is calculated by taking 
into account its dilution by water contained within the membrane of the microcapsules. 
 is the volume of the added microcapsules. 
aqV
mV
 
Substituting equations (2) and (4) into (1) results in 
 
   ( aqaq
m
aqL
aqL
aq CC
V
V
K
akCak
dt
dC −⋅−⋅=− 0 ) .   (5) 
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Integration of equation (5) yields the following equation; 
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01
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The volumetric mass transfer coefficient  was determined from the graph of equation 
6 in which  is the specific interfacial mass transfer area per unit volume between the 
two phases. 
Lk
a
 
2.3.2.6. Capsular perstraction of pharmaceuticals from aqueous solutions 
All capsular perstraction experiments were performed at 25 ºC in 100 ml Duran bottles, 
containing a constant volume of the aqueous phase [100 ml water with dissolved 
pharmaceutical(s)] and the organic phase (2 ml) within the microcapsules. This enabled 
a direct comparison of results obtained. Since experiments required five differently 
sized microcapsules to be added to the aqueous phase during experiments, the volume 
of the organic solvent was kept constant by adding different amounts of microcapsules 
using graduated tubes. Microcapsules were added to 100 ml of water containing PhACs 
and placed in a thermostatted rotary water-bath shaker (Infors AG, Bottmingen, 
Switzerland), after a sample was taken from the aqueous phase to determine the initial 
concentration ( ) of the pharmaceutical(s). Samples (0.1 ml) were drawn using a 
graduated 1 ml syringe (Sigma, Dublin, Ireland) and bevelled 23G needle (Microlance, 
Fraga, Spain) to prevent removal of microcapsules. Sampling from the aqueous phase 
0
aqC
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was preformed at defined intervals and the samples were analyzed using RP-HPLC to 
determine the extraction kinetics of the pharmaceuticals into the microcapsules. For all 
experiments the pharmaceuticals concentration removed due to sampling had a 
negligible affect on mass transfer. Control experiments containing only aqueous phase 
and the pharmaceutical(s) were ran for all extraction experiments to ensure that any 
decline in pharmaceutical concentration was due only to removal by microcapsules and 
not by degradation. 
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2.4. Results and discussion 
 
Table 1: Characteristics of PhACs, which were used to help chose the compounds for the work undertaken in this 
study. Drugs are listed according to increasing hydrophobicity (LogPoct). 
Compound 
(CAS No.) 
Therapeutic  
Class 
Chemical Structure LogPoct Position in 
sales listo 
% 
Removal in 
STPs 
Conc. in 
environmental 
waters (ng/l) 
Sphere 
 
Sulfamethoxazole 
(723-46-6) 
 
 
Antibiotic 
(bacteriostatic) 
  
0.89a 
 
N.P. 
 
17-71k 
 
410f 
1000m 
13-45p 
 
Ground water 
Surface water 
Drinking water 
Metoprolol 
(37350-58-6) 
 
Beta-blocker 
(receptor) 
 
1.9b 66 0-83n 2200j Surface water 
Furosemide 
(54-31-9) 
 
Loop diuretic 
 
2.03c 8 and 32 8-54k 1.72-255q Surface water 
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Carbamazepine 
(298-46-4) 
 
Anticonvulsant 
(antiepileptic) 
 
2.45b 77 0k-7h 1100f 
1100h 
30f 
Ground water 
Surface water 
Drinking water 
 
Clofibric acid 
(-) 
 
Metabolite of 
three lipid 
regulatorsd 
 
 
 
2.57b 
 
N.P. 
 
34-51k 
50g 
0-91n 
 
4000f 
175-185b, 1075f 
270f 
 
Ground water 
Surface water 
Drinking water 
Warfarin 
(81-81-2) 
Anticoagulant 
 
3.0e 9 - 1.0l Surface water 
 
 
Diclofenac 
(15307-86-5) 
Analgesic/Anti-
inflammatory 
 
4.50b 21 and 56 0-75n 15-489m Surface water 
 
 
a[31]; b[32]; c[30]; d[33]; e[34]; f[1]; g[35]; h[8]; i[36];  j[37]; k[6]; l[38]; m[3]; n[2]; o(HSE 2004); p[39] and q[40]. N.P., 
Not present. – Not available. 
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2.4.1. Capsular perstraction 
To examine the capability of capsular perstraction to recover pharmaceuticals in this study, 
seven different compounds (Table 1) were chosen for extraction and selection was based on 
their varying LogPoct values. Drugs were also pre-selected on their ability to match the 
following criteria: (1) presence in the top 100 most commonly prescribed medicinal 
products in Ireland [53]; (2) specific mode of action (different therapeutic classes); (3) 
inability to be adequately/fully removed by STPs and (4) presence in the aquatic 
environment. Table 1 highlights the values for the pre-selection criteria. 
Dibutyl sebacate and oleic acid were the solvents chosen for individual encapsulation 
within an alginate hydrogel for extraction experiments. This selection was based on: (1) 
their very high hydrophobicity (LogPoct = 6.2 and 7.7, respectively), which ensures a 
negligible diffusion of both solvents through the microcapsule wall; (2) their ability to 
extract a range of hydrophobic compounds from aqueous environments [26,27,41,42] and 
(3) their high affinity for some of the drugs (results not shown).  
 
2.4.2. Capsular perstraction of selected pharmaceuticals using dibutyl sebacate liquid-
core microcapsules 
To assess the efficiency of capsular perstraction using dibutyl sebacate as the core 
extractant to recover pharmaceuticals from aqueous solutions, microcapsules with a dm of 
737.36 μm and a dlc of 569.91 μm were incubated in water containing all seven 
pharmaceuticals and agitated at 300 rpm. From Figure 2 it can be seen that both warfarin 
and diclofenac are rapidly extracted from the aqueous phase, with both reaching an 
equilibrium concentration after 90 min with over 80% of the original drug extracted. The 
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higher concentration of each drug extracted compared to the other compounds could be 
attributed to the higher LogPoct values of these two compounds (3.0 and 4.5, respectively) 
in comparison to the other five drugs. Their very hydrophobic nature and limited solubility 
in water, makes the hydrophobic liquid-core of microcapsules a more suitable environment 
for these compounds [25,43]. Rapid extraction of all other pharmaceuticals was also 
obtained with equilibrium reached after 10 min for all compounds with 10-20% of initial 
concentration removed. There is no direct correlation between the amount of these 
compounds extracted into the organic phase with their LogPoct [44]. This is evident as both 
sulfamethoxazole and metoprolol have the lowest LogPoct values yet greater quantities are 
extracted compared to the other three compounds (furosemide, clofibric acid and 
carbamazepine) in this group. This implies that the partitioning of these drugs is not only 
based on their hydrophobicity, but might also depend on other factors, such as charged 
functional groups, steric effects and size. [25,45]. Higher levels of extraction of these 
compounds can be simply achieved by increasing the number of microcapsules used. 
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Figure 2: Capsular perstraction of all seven pharmaceuticals from water using dibutyl 
sebacate liquid-core microcapsules. Symbols: Sulfamethoxazole (open diamonds), 
metoprolol (open squares), furosemide (open triangles), clofibric acid (open circles), 
carbamazepine (closed diamonds), warfarin (closed squares) and diclofenac (closed 
triangle). C(t)/C(0) represents the ratio of the concentration at time t to the initial 
concentration C(0). 
 
2.4.3. Capsular perstraction of selected pharmaceuticals using oleic acid liquid-core 
microcapsules 
Oleic acid containing liquid-core microcapsules with a dm of 682.61 μm and a dlc of 502.57 
μm were examined for their ability to extract all seven pharmaceuticals from water. The 
extraction conditions were the same as those for the dibutyl sebacate liquid-core 
microcapsules, such that results could be compared directly. From Figure 3 it can be seen 
that metoprolol is rapidly extracted with less than 50% remaining after just 10 min and 
equilibrium reached after 40 min with only 30% of the initial concentration remaining. 
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High quantities of diclofenac and carbamazepine are also extracted, 35% and 40% 
respectively, with equilibrium times of 30 and 50 min. Warfarin is not extracted using these 
microcapsules, which is in complete contrast to the results obtained with dibutyl sebacate 
liquid-core microcapsules, where over 80% was extracted (Figure 2). These results 
highlight the fact that extraction efficiency is not solely based on the hydrophobic 
characteristics of the compound that is extracted, but may also be dependent on the 
properties of the extractant, such as functional group, solubility etc. Of the remaining three 
compounds tested, all are extracted rapidly (equilibrium obtained after 10 min) but only 
low amounts were removed (between 5 and 10%). 
 
 
 
 
 
 
 
 
 
 
Figure 3: Capsular perstraction of all seven pharmaceuticals from water using oleic acid 
liquid-core microcapsules. Symbols: Sulfamethoxazole (open diamonds), metoprolol (open 
squares), furosemide (open triangles), clofibric acid (open circles), carbamazepine (closed 
diamonds), warfarin (closed squares) and diclofenac (closed triangle). C(t)/C(0) represents 
the ratio of the concentration at time t to the initial concentration C(0). 
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2.4.4. Capsular perstraction of selected pharmaceuticals using dibutyl sebacate and 
oleic acid liquid-core microcapsules simultaneously 
There are numerous reports which state that water effluents from STPs can contain a large 
collection of different PhACs at varying concentrations [8,13,38]. It is envisaged that to be 
viable, any methodology used to treat waters containing PhACs, must be able to remove 
high levels of many different types of pharmaceuticals simultaneously. Since oleic acid and 
dibutyl sebacate liquid-core microcapsules showed different selectivities, it was decided to 
use both types of microcapsules concurrently in order to establish if effective recovery of 
all seven pharmaceuticals from water could be achieved. Extraction experiments were 
performed under the same conditions as those with the individual microcapsules and with a 
total solvent concentration of 4 ml (2 ml each for both dibutyl sebacate and oleic acid). 
From Figure 4 it can be seen that diclofenac, metoprolol, warfarin and carbamazepine are 
rapidly and effectively extracted with respectively around 100, 90, 80 and 50% of the drugs 
removed at equilibrium, all obtained within 40-50 min. The remaining three drugs, 
furosemide, clofibric acid and sulfamethoxazole, were rapidly extracted (equilibrium time 
of 10 min) with between 15 and 22% removed at equilibrium. In many cases the percentage 
of the pharmaceutical(s) removed using this novel approach is higher compared to recovery 
of the same drug(s) by conventional STPs, with increases in some instances of 50-100% 
being obtained (Table 1, data was unavailable for the removal of warfarin). 
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Figure 4: Capsular perstraction of all seven pharmaceuticals from water using a 
combination of dibutyl sebacate and oleic acid liquid-core microcapsules. Symbols: 
Sulfamethoxazole (open diamonds), metoprolol (open squares), furosemide (open 
triangles), clofibric acid (open circles), carbamazepine (closed diamonds), warfarin (closed 
squares) and diclofenac (closed triangle). C(t)/C(0) represents the ratio of the concentration 
at time t to the initial concentration C(0). 
 
2.4.5. Effect of varying operating and microcapsule parameters on extraction rate: 
Factors affecting mass transfer of pharmaceuticals into microcapsules 
Microcapsules can display three main resistances to mass transfer (Figure 5) when 
extracting compounds into the liquid-core [26,27,46]. To determine the dominating mass 
transfer resistance(s), the following parameters were varied: (1) agitation speed (stagnant 
aqueous film); (2) membrane thickness (alginate membrane) and (3) size of microcapsule 
(stagnant organic core). Warfarin was chosen as the test compound and extracted using 
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microcapsules containing a liquid-core of dibutyl sebacate. The effects of varying 
parameters on the extraction of warfarin were measured by removing samples from the 
aqueous phase at defined time intervals, and the effects were calculated using equations 1-
6.  
 
 
 
 
 
 
 
Stagnant aqueous 
film around the 
microcapsule 
Stagnant organic core 
Alginate membrane 
 
Figure 5: Light microscope image of a single dibutyl sebacate liquid-core microcapsule 
(dm of 1106.04 µm and a dlc of 765.21 µm), displaying the three main resistances to mass 
transfer. 
 
2.4.5.1. Effect of agitation speed on the extraction rate of warfarin 
Initially mass transfer takes place through a laminar sub-layer or stagnant aqueous film, 
which is located immediately adjacent to the interface between the two different phases. It 
is anticipated that high stirring speeds (which initiate an elevated degree of turbulence), will 
increase the mass transfer, since eddies will penetrate into the stagnant aqueous film and 
reduce the width.  To show the effects of agitation speed on the extraction of warfarin into 
the liquid-core of microcapsules, experiments were conducted where equal volumes of 
capsules with a dm of 621.01 µm and a dlc of 546.4 µm were placed into aqueous solutions 
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of warfarin and the bulk liquid mixed at different agitation rates. From Figure 6 it can be 
seen that for agitation rates at and above 150 rpm, the diffusion rate of warfarin into the 
liquid-core of microcapsules was constant. It can be deduced that the external (bulk liquid) 
mass transfer resistance is not the rate-controlling phenomenon provided agitation speeds 
of ≥ 150 rpm are applied. Similar observations have been reported in [46] and [27]. 
 
 
 
 
 
 
 
 
 
 
Figure 6: Effect of agitation speed on the extraction rate of warfarin from water into the 
dibutyl sebacate liquid-core of microcapsules. Symbols: 0 rpm (circles), 150 rpm 
(triangles), 300 rpm (diamonds) and 400 rpm (squares). C(t)/C(0) represents the ratio of the 
concentration of warfarin at time t to the initial concentration C(0). 
 
2.4.5.2. Effect of alginate membrane on the extraction rate of warfarin 
The hydrogel membrane of the microcapsules used in this study is mainly composed of 
water and alginate complexed with calcium ions. Due to its hydrophilic nature, negative 
charge and occurring regions of polymer chains, it was anticipated that these characteristics 
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might have an affect on the mass transfer of the hydrophobic warfarin into the liquid-core. 
Previously, numerous authors established that alginate hydrogels can hinder the diffusion 
of compounds [47-49]. Resistance to mass transfer due to the calcium-alginate in the 
membrane was observed by Wyss et al. (2004) when hydrophobic methylparathion was 
extracted from water using a similar type of microcapsule [27]. To test this hypothesis 
microcapsules with two different membrane thicknesses of 83.72 μm (dm 737.3578 µm, dlc 
569.913 µm) and 37.3 μm (dm 621.01 µm, dlc 546.4 µm) were manufactured and incubated 
in aqueous solutions of warfarin, with a constant agitation speed of 150 rpm. As can be 
seen in Figure 7, the membrane thickness did not appear to affect significantly the transfer 
of warfarin into the organic phase of microcapsules since warfarin reached an equilibrium 
concentration after 90-100 min for both types of microcapsule. A similar outcome was 
reported by Stark (2001) for the extraction of phenylethanol into dibutyl sebacate liquid-
core microcapsules, whereby reducing the membrane thickness resulted in a small increase 
in the extraction rate [46]. It can be therefore concluded that the rate-limiting step for mass 
transfer is not due to the alginate membrane. Due to the very high structural porosity of 
calcium alginate gels [50], which possess a large pore size distribution, ranging in size from 
5 to 200 nm [51], the diffusion of low molecular weight molecules through this structure is 
unlikely to be limiting, providing there is no chemical and/or physical interaction with the 
alginate. Thus, it has been reported that low molecular weight compounds such as glucose, 
can diffuse relatively unhindered through the gels when low concentrations of alginate are 
used [52]. Whilst the extraction of warfarin through the thicker membrane was slightly 
reduced (Table 2), the very porous shell of alginate gels means that it is still possible to 
extract hydrophobic compounds at a rapid rate. 
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Figure 7: Effect of the alginate membrane on the extraction rate of warfarin from water at 
an agitation speed of 150 rpm using dibutyl sebacate liquid-core microcapsules. Symbols: 
membrane thickness 83.72 μm (diamonds) and membrane thickness 37.3 μm (squares). 
C(t)/C(0) represents the ratio of the concentration of warfarin at time t to the initial 
concentration C(0).  
 
2.4.5.3. Effect of microcapsule size on the extraction rate of warfarin 
Due to the relatively high viscosity of dibutyl sebacate (10 times higher than water) and the 
absence of turbulence within the microcapsules, diffusion within the liquid-core is assumed 
to occur mainly by convection. To establish this effect on the mass transfer of warfarin into 
the liquid-core, microcapsules with different sizes were incubated into aqueous solutions of 
warfarin and agitated at a constant rate of 150 rpm. The capsules used had a dm of 737.36 
μm, 1106.04 μm and 1535.77 μm and were termed small, medium and large, respectively. 
From Figure 8 it can be seen that for small microcapsules, equilibrium was reached after 90 
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min compared to 150-200 min for medium sized microcapsules and greater than 200 min 
for large microcapsules. These results clearly indicate that the main resistance to mass 
transfer is located within the stagnant core of dibutyl sebacate. These results are further 
emphasized by the kL values obtained for each microcapsule size (Table 2). 
 
 
 
 
 
 
 
 
 
 
Figure 8: Effect of microcapsule size on the extraction rate of warfarin from water at an 
agitation speed of 150 rpm. Symbols: large microcapsules (diamonds), medium sized 
microcapsules (triangles) and small microcapsules (squares). C(t)/C(0) represents the ratio 
of the concentration of warfarin at time t to the initial concentration C(0).   
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2.4.5.4. Volumetric mass transfer coefficient (kL) 
Table 2: The kL values for the extraction of warfarin into the dibutyl sebacate liquid-core 
of microcapsules. During experiments either agitation speed of the bulk liquid, the 
membrane thickness or size of microcapsules were varied, whilst all other parameters were 
kept constant. Values were obtained experimentally (Figures 6-8) and using equations 1-6.  
Varied parameter Value of varied parameter kL (10-6 m/s) 
Agitation speed (rpm) 150 2.281 
 300 2.261 
 400 2.31 
Membrane thickness (µm) 83.722 2.05 
 37.3 2.27 
Microcapsule size (rc µm) 737.3578 2.04 
 1106.043 1.2 
 1535.777 0.6 
All agitation speeds were at 150 rpm, except where specified otherwise. 
1Microcapsule size: dm 621.01 µm and dlc 546.4 µm. 
 
Table 2 highlights the kL values calculated for each parameter varied during capsular 
perstraction experiments for warfarin removal. As seen in Figure 8, these values 
demonstrate how the dominant resistance to mass transfer is the stagnant organic core 
within microcapsules. A kL value for the smallest microcapsules used (dm 621.01 µm) of 
2.28 x 10-6 m/s was determined, which is nearly 4-fold higher compared to that of the 
largest microcapsules (dm 1535.77 µm), in which a value of 0.6 x 10-6 m/s was obtained. A 
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graph of microcapsule size versus kL shows a linear correlation between the two parameters 
at the values examined in this experimental work (Figure not shown). When extracting 
phenylethanol, Stark (2001) also observed that the limiting resistance to mass transfer was 
due to the stagnant organic film within microcapsules [46]. The kL values obtained in this 
study are of a similar order of magnitude to the values obtained by [46] and [27]. The 
slightly reduced mass transfer of warfarin into the microcapsules, due the stagnant organic 
core did not significantly limit the extraction process. The results obtained show that very 
high extraction rates can be obtained due to the large interfacial contact area between the 
microcapsules and the aqueous phase containing the warfarin. This internal mass transfer 
resistance cannot be overcome, but can be lowered significantly by reducing the size of the 
capsules as much as possible.  In summary, microcapsules with a porous hydrogel 
shell/membrane material, such as alginate, are capable of the rapid extraction of small 
molecules even if they possess significant hydrophobic characteristics. 
 
2.5. Conclusions 
Adequate treatment of water contaminated with PhACs requires a methodology which has 
the ability to remove a large amount of different pharmaceuticals, preferably in one single 
step. In this study this objective was achieved using capsular perstraction as a novel 
approach and involved using microcapsules consisting of either a liquid-core of dibutyl 
sebacate or oleic acid. The simultaneous use of these two types of microcapsules resulted in 
between 15 and 100% of the seven compounds been extracted rapidly (within 50 min of 
capsule addition) from the aqueous phase. Higher amounts of the drugs can be extracted by 
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simply increasing the amount of the organic solvent by the addition of more microcapsules 
to the water, which would also result in an increased rate of extraction.  
Capsular perstraction has many advantages over the more traditionally used methods such 
as liquid-liquid extraction which includes (but not confined to): (1) the ability to perform 
rapid extractions at low agitation rates; (2) the avoidance of direct contact between the 
aqueous and organic phases during extractions; (3) simple recovery of microcapsules 
(solvent) from the water by sedimentation or flotation. The buoyancy of the microcapsules 
can be predetermined by varying the ratio of the alginate volume, to the volume of the core 
material in the extruded concentric liquid jet, during the microcapsule production process; 
(4) as previously shown, the stable microcapsules could be re-cycled for continuous use 
after the removal of the recovered compound by back-extraction into a separate phase; (5) 
the ability to control the selectivity of the extracted compounds by incorporating different 
liquids within the core during the manufacturing process. Most solvents can be 
encapsulated using the co-extrusion laminar jet break-up technique, provided a difference 
exists between the surface tension of the membrane polymer and the liquid-core material 
and (6) the prevention of membrane fouling by the envelopment of liquid-cores with 
membranes which are not prone to fouling. These advantages will result in more efficient 
extractions by increasing extraction speeds, reducing the volume of solvent required, 
preventing stable emulsion formation and contamination of the water being treated by the 
extraction solvent. Liquid-core microcapsules have also shown the capability to be used as 
a platform for the safe disposal of the recovered pollutants. These advantages all have a 
positive affect on the economic viability of the process. 
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Finally this work also emphasized how the characteristics (capsule size and membrane 
thickness) of capsules can affect the extraction rate of compounds into the liquid-core, and 
how the rate of extraction can be controlled by varying these characteristics. 
 
2.6. Nomenclature 
Table 3: List of abbreviations and symbols 
Abbreviation/Symbol Definition     Unit 
PhACs Pharmaceutically active compounds     - 
STPs Sewage treatment plants     - 
dm Outer diameter of microcapsules     µm 
dlc Diameter of liquid-core of microcapsules     µm 
Caq Pharmaceutical conc. in aqueous phase     mg/l 
kL Volumetric mass transfer coefficient     m/s 
kLa Overall mass transfer coefficient     1/s 
a Specific interfacial mass transfer area per unit 
volume 
    1/m 
aqC  Pharmaceutical conc. in aqueous phase     mg/l 
e
aqC  Equilibrium conc. of pharmaceutical in aqueous 
phase 
    - 
Cm Pharmaceutical conc. in microcapsules     mg/l 
K Partition coefficient of pharmaceutical between 
microcapsules and aqueous phase 
    - 
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e
mC  Equilibrium conc. of pharmaceutical in 
microcapsules 
    - 
Vaq Volume of aqueous phase     l 
0
aqC  Initial conc. of pharmaceutical in aqueous phase     mg/l 
Vm Volume of microcapsules     l 
0
mC  Initial conc. of pharmaceutical in microcapsules     mg/l 
C(t) Conc. of pharmaceutical at time t     mg/l 
C(0) Initial conc. of pharmaceutical     mg/l 
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3.1. Abstract 
The molecular complex ‘Heat shock protein 90’ has become a novel target for anti-
cancer drugs in recent times on account of its ability to perform as a chaperone towards 
proteins involved in cancer progression. The ansamycin geldanamycin binds to this 
complex with high affinity and prevents it from performing correctly, which results in 
tumor destruction. 
The aim of this study was to investigate the feasibility of applying liquid-core 
microcapsules as a novel technique (termed ‘capsular perstraction’), for the recovery 
and purification of geldanamycin from culture media. Results demonstrated how this 
procedure was capable of rapidly extracting > 70% of geldanamycin from culture media 
using a liquid-core volume to medium ratio of only 1%. Optimum conditions for 
removal, including agitation speed, microcapsule size and membrane thickness were 
examined and it was shown how the stagnant aqueous film around the microcapsules 
was the main resistance to mass transfer. A volumetric mass transfer coefficient of 5.66 
x 10-6 m/s was obtained for the highest agitation speed (400 rpm), which was 
considerable greater compared to the value of 0.88 x 10-6 m/s achieved for the lowest 
speed of 100 rpm. 
Removal of geldanamycin from microcapsules was also examined to fully investigate 
the potential of such particles for in-situ product recovery, and it was demonstrated how 
the methodology can be used as a simple mechanism for purifying the compound (> 
99%) through solvent extraction and crystallization.  
The results of this work demonstrate the novel use of capsular perstraction as a 
methodology for the recovery and purification of geldanamycin from culture 
environments.  
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3.2. Introduction 
The benzoquinone ansamycin geldanamycin is a naturally occurring antibiotic produced 
as a secondary metabolite by the actinomycete Streptomyces (S.) hygroscopicus var. 
geldanus [1].  It was discovered in the culture filtrates of a submerged fermentation in 
1970 [2] and has a broad spectrum, exhibiting activity against Gram positive and 
negative bacteria [3], protozoa and fungi [2]. Interest in the molecule was stimulated as 
a result of the discovery of its antitumor properties [4]. Whitesell and coworkers 
showed in 1994 that one of the principal cellular targets for geldanamycin is the Heat 
shock protein 90 (Hsp90) [5], an ATP-dependent chaperone complex found in 
eukaryotes [6-9], which is expressed at elevated levels (2-10 fold higher) in tumor cells 
compared to normal tissue [10,11]. This chaperone is necessary for the folding, 
assembly and activity of multiple mutated and over expressed signaling proteins, which 
initiate and promote growth and/or survival of tumor cells [12]. Geldanamycin binds 
with high affinity to the N-terminal domain ATP binding site of Hsp90 [13], causing the 
loss of its chaperone capabilities towards client proteins [14], subsequently leaving 
them malformed, unstable and readily degradable by the cells proteosome, which results 
in tumor destruction [13]. 
Unfortunately, geldanamycin cannot be used clinically for targeted cell-therapy as it has 
shown significant hepatotoxicity in animal models during clinical trials [15]. However, 
semi-synthetic derivates of the antibiotic such as, 17-allyamino-17-
demethoxygeldanamycin (17-AAG) and 17-dimethylaminoethylamino-17-demethoxy-
geldanamycin (17-DMAG) were found to be less potent and toxic compared to the 
parent molecule whilst retaining similar molecular activities [14,16,17]. These novel 
antitumor agents are presently in clinical trials with 17-AAG being tested on patients 
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with advanced-stage cancer [12]. At present, the future clinical success of geldanamycin 
as a novel chemotherapeutic agent will be dependent on chemically altered derivates of 
the drug [18] with large quantities of natural geldanamycin required for synthesis to 
take place. 
To date, only limited research has been published on the fate and behavior of 
geldanamycin during production in submerged fermentations [18-21]. Recently it was 
shown how the in-situ removal of the compound from cultures of S. hygroscopicus 
cultivated in Bennett’s media, resulted in a 3-fold increase in production titers [19]. It 
has been suggested that this increased quantity was due to removal of the antibiotic 
from a hostile fermentation environment which caused product degradation [19]. 
Indeed, geldanamycin concentrations rapidly declined to negligible amounts in cultures, 
and it has been postulated that this is due to either chemical and/or enzymatic 
mechanisms [22]. While neither study discovered the defining reasons behind the 
breakdown during fermentations, they did clearly emphasis the importance of in-situ 
recovery of the compound from the culture environment. 
In recent years a novel and very effective process termed ‘capsular perstraction’ has 
been developed and has shown the ability to recover successfully, a large range of 
compounds from a diverse range of aqueous environments, whilst also being able to 
provide a protective environment for the extracted component. The procedure involves 
the envelopment of organic solvents within a porous hydrogel membrane to form liquid-
core microcapsules [23]. This novel technique has being applied to a number of areas, 
including: water treatment [23-25], enzyme technology [26,27], Bioprocessing [28] and 
cell culture [29,30]. Capsular perstraction has shown many advantages over 
traditionally used recovery methods, such as liquid-liquid extraction, including the 
ability to perform rapid extractions at low agitation rates due to the large interfacial 
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contact area provided by the capsules themselves. This requires the use of less solvent 
and energy, which is not only environmentally beneficial but also improves the overall 
economic prospects of the process. Another benefit is the avoidance of direct contact 
between the aqueous and organic phase, which prevents contamination, as well as 
averting the formation of stable emulsions, which present a difficult downstream 
processing challenge [31].  
The aim of this study was to examine the possibility of employing liquid-core 
microcapsules as a novel technique for the recovery and purification of geldanamycin 
from culture media. Initial experiments involved the selection of a suitable solvent to 
recover the antibiotic; followed by encapsulation within a porous hydrogel membrane. 
Capsular perstraction experiments were then undertaken to examine the factors affecting 
the uptake of geldanamycin into the liquid-core. Finally the recovery and purification 
(crystallization) of the compound from the microcapsules was investigated.  
 
3.3. Materials and Methods 
3.3.1. Chemicals 
Geldanamycin microcrystalline powder (> 99% purity) was obtained from LC 
Laboratories (Massachusetts, USA). Water, methanol, acetonitrile and dichloromethane 
were of high performance liquid chromatography grade and were all obtained from 
Sigma-Aldrich (Dublin, Ireland). Dibutyl sebacate, oleic acid, calcium chloride, 3-(N-
Morpholino)propanesulfonic acid (MOPS), Tween 80, 1-octanol, hexane, N-Z amine A 
from bovine milk and glucose monohydrate were all obtained from Sigma-Aldrich 
(Dublin, Ireland) and were of at least analytical grade. Yeast extract and beef extract 
were obtained from Oxoid (Basingstoke, UK). Sodium alginate (Keltone LV) was 
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obtained from Inotech Biotechnologies (Basel, Switzerland). Miglyol 812 N was a kind 
gift from Sasol (Witten, Germany). 
Two previous studies[20,32] had successfully used the following liquid medium 
composition (termed Bennett’s medium) to produce and recover geldanamycin from 
cultures using the organism S. hygroscopicus var. geldanus: 1 g/l yeast extract, 1g/l beef 
extract, 2 g/l N-Z-amine A and 50 g/l glucose monohydrate which was autoclaved 
separately from the other components. The media had a pre-sterilization pH of 7.0 and 
was used throughout this study as the aqueous phase to closely mimic the fermentation 
conditions. 
Stock solutions of geldanamycin in Bennett’s media and water were prepared using 
acetonitrile as a co-solvent to facilitate the solubilisation of 10 mg/l of geldanamycin in 
the aqueous phase. Firstly geldanamycin was dissolved in acetonitrile by agitation on a 
magnetic stirrer, and added to the media to a final acetonitrile concentration of 5% (v/v) 
in order to obtain the desired concentration of the compound. Standard solutions of 
geldanamycin for calibrations were prepared in 100% acetonitrile. Due to the reported 
photolytic nature of geldanamycin, all solutions and experiments were stored and 
performed in the dark to maintain maximum stability.  
 
3.3.2. Methods 
3.3.2.1. Quantitative determination of geldanamycin 
Reverse phase high performance liquid chromatography (RP-HPLC) was employed 
throughout this work using an Agilent 1100 HPLC series (Agilent Technologies, USA) 
consisting of a quaternary pump with online degasser, thermostatted auto-sampler, 
diode array detector (DAD) and thermostatted column compartment. All modules were 
interfaced to a PC operating with ChemStation software, systems version A.08.03. The 
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analytes were separated on a reversed-phase C18 Luna (2) column, dimensions 150 mm 
x 4.60 mm x 5 µm, with associated security guard cartridge system (Phenomenex 
Cheshire, UK). Column temperature was maintained at 25 oC. Isocratic elution was 
employed using a mobile phase flow rate of 1 ml/min. For the detection of 
geldanamycin in dibutyl sebacate, oleic acid and methanol, a mobile phase of 80% 
methanol:20% water (v/v) was applied. For it’s detection in Bennett’s medium, water 
and acetonitrile, a mobile phase of 50% acetonitrile:50% water (v/v) was used. All 
samples were filtered with a 0.20 µm nylon filter (Sigma, Dublin, Ireland) and degassed 
prior to HPLC separation and detection. Samples (50 µl) were then injected onto the 
column after dilution with their respective mobile phase and detected at a fixed 
wavelength of 308 nm. Internal and external standards were used to ensure accurate 
results were obtained. The quantification of geldanamycin was based on the ratio of the 
chromatogram peak areas. 
 
3.3.2.2. Preparation and characterization of liquid-core microcapsules 
The full details of the procedure to manufacture and measure the size of the 
microcapsules used in this study have been described previously [23]. All capsules used 
in this work were manufactured from solutions contain 2% (w/v) alginate, and these 
particles can be described as having an average diameter (dm) consisting of the alginate 
shell and liquid-core, and an average internal diameter (dlc) consisting solely of the 
liquid-core (Figure 4a).  
 
3.3.2.3. Liquid-liquid extraction and capsular perstraction 
All liquid-liquid extraction and capsular perstraction experiments were carried out in 
100 ml Duran bottles containing a constant volume of aqueous phase (100 ml Bennett’s 
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medium containing solubilized geldanamycin) and one of the organic solvents (1 ml), to 
allow experiments to be compared. The organic solvents were either added directly to 
the aqueous phase (liquid-liquid extraction) or enclosed within the microcapsules 
(capsular perstraction). Since capsular perstraction experiments required a number of 
different sized microcapsules to be added during experiments, the 1 ml volume of 
organic solvent was kept constant by adding different amounts of capsules using 
graduated tubes. Before addition, microcapsules were filtered through a porous mesh 
(pore size 100-200 µm) to remove any water present. Duran bottles were then placed 
into a thermostatted incubator shaker (Innova 43, Brunswick Scientific, New Jersey, 
USA) at 25 ºC and a sample taken immediately from the aqueous phase to determine the 
initial concentration ( )oaqC  of the antibiotic. Geldanamycin extraction was determined 
by removal of samples from the medium at defined intervals using a syringe and 22 G 
needles with non-coring deflected tip (Foss, Dublin, Ireland). Such a procedure avoided 
the removal of organic solvent and/or microcapsules. For liquid-liquid extraction 
experiments, samples were centrifuged at 25 ºC before sample removal to ensure 
complete separation of the phases. Quantification of the antibiotic was performed using 
RP-HPLC. Control experiments were carried out to ensure that any decline in 
concentration was due to removal by the organic solvent and not by degradation.  
 
For liquid-liquid extraction experiments, the partition coefficients ( )aqorgK /  for the 
distribution of geldanamycin between one of the organic solvents and the aqueous phase 
(Bennett’s medium) was calculated using equation 1.   
Chapter 3: Capsular perstraction as a novel methodology for the recovery and 
purification of geldanamycin 
 
 
 121
e
aq
e
org
aqorg C
C
K =/      (1) 
where, eorgC  is the concentration of geldanamycin in the organic phase and 
e
aqC  is the 
concentration in the aqueous phase at equilibrium. 
 
3.3.2.4. Determination of mass transfer 
Mass transfer of geldanamycin into the microcapsules and their resistance to mass 
transfer was calculated using a simple global mass transfer equation (equation 2) as 
previously described [23]. 
 
( )eaqaqLaq CCakdt
dC
−=      (2)           
  
In this equation aqC  is the geldanamycin concentration in the aqueous phase at time t , 
Lk  is the volumetric mass transfer coefficient, which is calculated by taking into 
account a , the specific interfacial mass transfer area per unit volume between the two 
phases.  
The concentration of the antibiotic inside the microcapsules at time t  was obtained from 
the following mass balance: 
 
( ) ( )00 mmmaqaqaq CCVCCV −=−     (3) 
 
in which aqV is the volume of the aqueous phase (bulk liquid) and is calculated by taking 
into account its dilution with water contained within the membrane of capsules. 0aqC  is 
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the initial concentration of geldanamycin in the aqueous phase, mV  is the volume of 
microcapsules, mC  is the concentration of geldanamycin in the microcapsules at time t , 
whilst 0
mC  is the initial concentration in the capsules.  
 
3.3.2.5. Recovery of geldanamycin from microcapsules 
Geldanamycin extracted into dibutyl sebacate or oleic acid liquid-core of microcapsules 
was recovered (back-extracted) by washing the capsules with acetonitrile, methanol or 
acetonitrile saturated with oleic acid (back-extraction solutions) at 25 ºC. Saturation of 
acetonitrile with oleic acid was performed by mixing both liquids together for 24 hr in a 
thermostatted shaker. After agitation, both phases were allowed to settle for at least 24 
hr before use. Firstly capsules were removed from Bennett’s media using a porous mesh 
and washed three times in ultra pure water to remove any remaining media components. 
Capsules containing the organic solvent and geldanamycin within their core were then 
added to acetonitrile, methanol or acetonitrile saturated with oleic acid. Solutions were 
agitated at 300 rpm for 30 min to reach equilibrium. To ensure complete recovery of the 
compound, additional washing steps were performed until no more geldanamycin could 
be detected. When back-extracting the antibiotic from the oleic acid liquid-core using 
acetonitrile saturated with oleic acid, equation 4 was employed to calculate the partition 
coefficient oaacnK /  for the distribution of geldanamycin between the two phases.  
 
  
e
oa
e
acn
oaacn C
C
K =/       (4) 
where, e
acnC  is the concentration of geldanamycin in acetonitrile saturated with oleic  
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acid at equilibrium and e
oaC  is the concentration of geldanamycin in the oleic acid phase  
when equilibrium was obtained.  
To examine the effect of back-extraction on capsules, photographs of the particles 
before and after the washing steps were taken on a camera (model DP30BW, Olympus, 
Japan) attached to a light microscope (model BX-51, Olympus, Japan) interfaced to a 
PC operating with CellF image analysis software (Olympus, Japan). 
 
3.3.2.6. Re-crystallization of geldanamycin  
Geldanamycin contained within the oleic acid saturated acetonitrile was re-crystallized 
using the following procedure. The back-extraction solution was separated from the 
capsules by passing through a porous mesh and the fatty acid was removed by adding 
equal volumes of water to the solution. This addition caused the precipitation of oleic 
acid, which formed an emulsion and was separated by centrifugation at 4000 rpm for 30 
min at 25 ºC. The water addition and centrifugation steps were repeated twice, prior to 
filtration through a 0.20 µm nylon filter to ensure all oleic acid had been removed, as 
determined by RP-HPLC analysis. The solution was placed in a graduated glass beaker 
in a water bath set at 82.5 ºC ± 2.5 ºC to enable evaporation of acetonitrile. During 
evaporation, the solution was agitated slowly to facilitate nucleation and subsequent 
crystal growth. When no visible change in volume was observed, the temperature was 
increased to 100 ºC ± 2.5 ºC and evaporation continued until approximately 10% of the 
original volume was left. After boiling, the solution was immediately cooled to 4 ºC, 
which further reduced the solubility of geldanamycin in the suspension. Crystals were 
collected by filtrating under vacuum using 0.2 µm nylon filters and drying overnight at 
30 ºC.  
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3.3.2.7. Purity of re-crystallized geldanamycin 
The purity of the crystals was determined using either RP-HPLC or by measuring their 
melting point and comparing the results to those obtained for high purity commercial 
geldanamycin. For RP-HPLC, crystals were tested by re-dissolving in acetonitrile. Re-
crystallization did not affect the retention time of the antibiotic during the HPLC 
analysis. The melting point of re-crystallized and pure geldanamycin was established 
using a procedure outlined by the OECD guidelines for the testing of chemicals [37]. 
The melting point of the drug was determined by placing the samples in a Gallenkamp 
melting point apparatus (in capillary tubes) and measuring their melting temperature 
with a thermocouple thermometer 2022T  (Digitron, UK).   
 
3.4. Results and Discussion 
3.4.1. Solvent Screening: Choice of solvent for liquid-core of microcapsules 
Liquid-liquid extraction was carried out to determine the optimal solvent for the liquid-
core of microcapsules. For extractions, six different organic solvents were added 
individually to the media containing the geldanamycin and the two phases were agitated 
at 25 ºC for 24 hr at a speed of 150 rpm, which ensured equilibrium was obtained and 
the partition coefficients were determined. A high partition coefficient for geldanamycin 
extraction between the phases is significant for the success of an extractive fermentation 
[33], as it results in reduced solvent usage, whilst also enabling high concentrations of 
the product to accumulate within the organic phase. The solvents chosen were oleic 
acid, dibutyl sebacate, miglyol, dichloromethane, octanol and hexane. Selection was 
based on their capabilities to match the following criteria: (1) A relatively high LogPoct 
value (Table 1). This ensures a negligible diffusion of the solvent through the capsule 
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wall into the aqueous media phase when equilibrium is obtained. (2) The ability to be 
encapsulated within an alginate hydrogel membrane using the co-extrusion jet breakup 
technique. (3) To be stable under fermentation conditions, and (4) the ability to detect 
geldanamycin in the solvents using RP-HPLC. All solvents had also previously shown 
the ability to extract compounds with similar LogPoct to geldanamycin (LogPoct of 
geldanamycin = 2.54[34]). Table 1 displays the aqorgK /  values for geldanamycin 
between the media phase and the six pre-selected solvents. From the results it can be 
seen that both dibutyl sebacate and oleic acid extract the largest amounts of 
geldanamycin compared to the other solvents under examination, with values of 192.20 
± 2.03% and 212.33 ± 7.08% obtained respectively. This higher amount extracted could 
be due to the considerably higher LogPoct values possessed by these liquids compared to 
the other solvents. 
 
Table 1: The partition coefficient values of geldanamycin between Bennett’s medium 
and one of six pre-selected organic solvents.  
Organic solvent LogPoct of solvent aqorgK /  
Miglyol N.A. 54.88 ± 0.911% 
Dichloromethane 1.2535 179 ± 1.56% 
Octanol 3.0735 51 ± 5.68% 
Hexane 3.9035 15.85 ± 1.95% 
Dibutyl sebacate 6.233 192.20 ± 2.03% 
Oleic acid 7.733 212.33 ± 7.08% 
Solvents are listed according to increasing hydrophobicity (LogPoct). 
N.A., not available.  
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3.4.2. Capsular perstraction of geldanamycin: Factors affecting mass transfer 
Both dibutyl sebacate and oleic acid liquid-core microcapsules have been previously 
used for the successful removal of hydrophobic compounds from aqueous environments 
[23,24,26,28]. Although both solvents showed similar affinities for the antibiotic, 
dibutyl sebacate was firstly encapsulated within an alginate membrane for capsular 
perstraction experiments. This selection was based on the higher encapsulation affinity 
obtained when dibutyl sebacate was used during the encapsulation process in 
comparison to oleic acid (results not shown). This is attributed to the higher viscosity of 
the fatty acid, which makes incorporation within a hydrogel membrane more 
challenging [27].  
As discussed previously [23,24,33], the mass transfer of compounds into the liquid-core 
of microcapsules can be a function of different mass transfer resistances exhibited by 
the capsules, and these resistances are described as follows: (1) The stagnant aqueous 
film around the microcapsules. (2) The resistance due to the charged hydrophilic 
membrane, and (3) the stagnant organic layer within the capsules. In order to establish 
the effect of these impediments on geldanamycin diffusion, experiments were 
undertaken in which agitation speed of the bulk liquid, membrane thickness and the size 
of the microcapsules were varied. The effects on mass transfer were measured by 
removing samples from the aqueous phase at defined time intervals and calculating the 
Lk  for each varied parameter using equations 2 and 3. 
 
3.4.3. Effect of agitation speed on the extraction rate of geldanamycin 
The effect of agitation speed on the extraction rate of geldanamycin into the dibutyl 
sebacate liquid-core was examined by performing experiments which involved adding 
equal volumes of capsules with a dm of 616.92 µm and a dlc of 551.81 into solutions of 
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Bennett’s media containing the antibiotic. The bulk liquid was mixed at agitation rates 
of 100, 200, 300 and 400 rpm at 25 oC and the rate of extraction measured. From Figure 
1 it is apparent that increased agitation speeds result in higher removal speeds of 
geldanamycin. Equilibrium between the two phases was reached after 30, 40 and 50 min 
for speeds of 400, 300 and 200 rpm respectively, compared to > 100 min for an 
agitation speed of 100 rpm.  
 
Figure 1: Effect of different agitation speeds on the extraction of geldanamycin from 
Bennett’s media into dibutyl sebacate liquid-core of microcapsules. Symbols: 100 rpm 
(stars), 200 rpm (diamonds), 300 rpm (squares) and 400 rpm (triangles). C(t)/C(0) 
represents the ratio of the concentration of geldanamycin at time t to the initial 
concentration C(0). 
 
3.4.4. Effect of capsule size on the extraction rate of geldanamycin 
Previously it has been shown that the diffusion of hydrophobic warfarin [23], 
phenylethanol [33] and methylparathion [24] into the core was dependent on the size of 
the microcapsules used in the respective studies. Due to the relatively high viscosity of 
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dibutyl sebacate and the absence of turbulence within the microcapsules, it can be 
assumed that movement in the core occurs mainly through convection. To determine the 
resistance exhibited by the stagnant organic film, equal volumes of capsules with 
different sizes and a similar membrane thickness were placed into solutions of Bennett’s 
media containing geldanamycin and the bulk liquid agitated at a rate of 300 rpm. The 
capsules used had a dm of 484.81 µm, 598.28 µm and 751.125 µm and were termed 
small, medium and large respectively. Figure 2 shows how equilibrium concentration 
for all sizes is reached within 50 min of agitation commencing. It can be concluded that 
the size of the capsules had little or no affect on the extraction rate of the compound into 
the liquid-core, at least for the range of sizes studied in this work.  
 
Figure 2: Effect of capsule size on the extraction of geldanamycin from Bennett’s 
media into the dibutyl sebacate liquid-core of microcapsules at an agitation speed of 300 
rpm. Symbols: small microcapsules (diamonds); medium sized microcapsules (squares) 
and large microcapsules (triangles). C(t)/C(0) represents the ratio of the concentration of 
geldanamycin at time t to the initial concentration C(0). 
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3.4.5. Effect of alginate membrane on the extraction rate of geldanamycin 
To determine the resistance to mass transfer exhibited by the alginate membrane of 
microcapsules, experiments were performed in which capsules of a similar liquid-core 
diameter but with varying membrane sizes were placed into the media containing 
geldanamycin and the bulk liquid agitated at 300 rpm. The capsules tested had three 
different membrane sizes of 32.55 µm (dm 616.92 µm, dlc 551.81 µm), 49.143 µm (dm 
648.39 µm, dlc 550.104 µm), and 91.25 µm (dm 688.88 µm, dlc 506.38 µm) respectively. 
As seen in Figure 3 the increasing thickness of the membrane appears to only slightly 
limit the diffusion of the antibiotic into the core. Equilibrium times of around 40, 50 and 
60 min were obtained for membrane thickness of 32.55, 49.14 and 91.25 µm 
respectively. Similar results were observed in two previous studies, which also showed 
how the hydrophilic membrane had a negligible effect on the diffusion of small 
hydrophobic compounds into the liquid-core [23,33]. Although the movement of 
geldanamycin is slightly reduced when moving through thicker membranes, it is still 
possible to obtain rapid extraction of the compound. 
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Figure 3: Effect of alginate membrane on the extraction of geldanamycin from 
Bennett’s media into the dibutyl sebacate liquid-core of microcapsules at an agitation 
speed of 300 rpm. Symbols: membrane thickness 32.55 µm (squares), membrane 
thickness 49.14 µm (diamonds) and membrane thickness 91.25 µm (triangles). 
C(t)/C(0) represents the ratio of the concentration of geldanamycin at time t to the initial 
concentration C(0). 
 
3.4.6. Volumetric mass transfer coefficient 
The Lk  for the diffusion of geldanamycin into the dibutyl sebacate liquid-core of 
microcapsules was calculated for each parameter varied during this study and the values 
obtained are presented in Table 2. As seen in Figure 1, these values demonstrate that the 
main rate limitation to mass transfer is the resistance within the external bulk liquid 
phase (agitation speed). There is over a 6-fold difference between the values obtained 
for the lowest (100 rpm) and highest (400 rpm) agitation speeds, with values for kL of 
0.88 and 5.66 10-6 m/s respectively. This reduction could be due to the fact that 
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diffusion of hydrophobic geldanamycin in the media originally takes place through a 
stagnant aqueous film, which is found adjacent to the interface between the two 
different phases. Higher stirring speeds (high turbulence) increase the mass transfer, 
since eddies will penetrate into the film and reduce its width, hence increasing the 
extraction rate. Results of agitation speed versus Lk  show that both parameters are 
linearly correlated for the values examined within this work (Figure not shown). It is 
apparent that the movement of the antibiotic into the liquid-core is also slightly hindered 
by increases in the thickness of the capsular membrane and decrease in capsule size. 
Wyss et al. (2004) showed how the alginate membrane can affect the diffusion of 
hydrophobic compounds into microcapsules when the transfer of methylparathion was 
examined using a similar type of capsule, and was attributed to the hydrophilic nature of 
the hydrogel itself. Whilst the membrane can have an impact on the overall mass 
transfer of geldanamycin, it is nevertheless possible to control this resistance by 
reducing the membrane size during the microcapsule production process [23]. 
The results indicate that the external resistance controls the rate of geldanamycin 
diffusion through the bulk liquid. However, provided this is agitated at sufficiently high 
rates ≥ 200 rpm (turbulent conditions); rapid extraction rates can still be achieved for 
geldanamycin recovery from fermentation environments. 
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Table 2: The kL values determined for the extraction of geldanamycin from Bennett’s 
media into the dibutyl sebacate liquid-core of microcapsules.  
 
Varied parameter Value of varied parameter kL (10-6 m/s) 
Agitation speed (rpm) 100 0.88a 
 200 1.77a 
 300 4.33a 
 400 5.66 
Membrane thickness (µm) 32.55 4.33 
 49.144 4.26 
 91.25 3.33 
Microcapsule size (dm µm) 484.815 3.033 
 598.279 4.14 
 751.25 5.14 
Agitation was carried out at 300 rpm, unless specified otherwise. 
aSize of microcapsules: dm 616.92 µm and dlc 551.81 µm. 
 
3.4.7. Recovery and purification of geldanamycin contained within liquid-core 
microcapsules  
The successful application of capsular perstraction as a method for the recovery of 
geldanamycin from culture environments depends not only on the rapid and efficient 
extraction of the drug, but also on the feasibility to recover large amounts of the 
compound in a purified stated from the capsules, once extraction is complete. Ideally 
this technique should be a simple and rapid process, which is not detrimental to the 
recovered product, and which can be readily integrated into the downstream processing 
procedure for the compound of interest. 
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Due to its simplicity, the recovery of geldanamycin from dibutyl sebacate liquid-core 
microcapsules using solvent extraction was studied. The solvents acetonitrile and 
methanol were selected based on the following criteria: (1) Both were constituent 
solvents of the mobile phase used in RP-HPLC for the detection of geldanamycin. This 
enables the direct quantification of geldanamycin removed from the capsules without 
the need for a pre-treatment step (i.e. solvent evaporation), which prevents the loss of 
the product and also reduces process time. (2) Geldanamycin is soluble in both 
acetonitrile and methanol. (3) The compound is stable when stored in both solvents ≥ -
20 oC for long periods of time (> 1 year). (4) Both solvents are relatively volatile 
(boiling point of 82 and 64.5 oC for acetonitrile and methanol respectively), which 
allows evaporation (distillation) of the solvents to be carried out at low temperatures for 
final product purification, and (5) the calcium-alginate membrane of the microcapsules 
is stable when immersed in both liquids. These hydrogels have proven to be very 
durable in the presence of a range of organic solvents by comparison to other commonly 
used hydrogels [36]. 
 
3.4.8. Recovery of geldanamycin from dibutyl sebacate liquid-core microcapsules 
Dibutyl sebacate liquid-core microcapsules with a dm of 502.63 µm and a dlc of 327.48 
µm (Figure 4a) were used to extract geldanamycin from Bennett’s medium. Following 
capsular perstraction, the capsules were removed from the media and washed in 
acetonitrile or methanol to recover the antibiotic. In both cases, use of this procedure 
facilitated the retrieval of > 95% of the geldanamycin contained within the capsules. 
However, due to the core material being very soluble in both solvents, the complete loss 
of this material from the capsules occurred (Figure 4b and 4c). Whilst this method 
enabled the recovery of large amounts of antibiotic, the continuous loss of the core 
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material meant only single usage of capsules was possible. Similar results were 
observed by Stark et al. (2003) when ethanol was used to recover the aroma compound 
2-phenylethanol contained within dibutyl sebacate liquid-core microcapsules.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Light microscope image of: (a) Dibutyl sebacate liquid-core microcapsules 
with a dm of 502.63 µm and a dlc of 327.48 µm which were used to extract 
geldanamycin from Bennett’s media. (b) Microcapsules after washing with acetonitrile, 
and (c) after washing with methanol.  
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b 
 
c 
 
Alginate 
shell 
dlc 
dm 
Liquid-core of 
dibutyl sebacate 
Chapter 3: Capsular perstraction as a novel methodology for the recovery and 
purification of geldanamycin 
 
 
 135
3.4.9. Recovery of geldanamycin from oleic acid liquid-core microcapsules 
Although large quantities of geldanamycin were recovered from the dibutyl sebacate 
containing microcapsules, the continuous loss of the core material prevented the 
recycling of the particles for repetitive use. This implies that a new batch must be 
manufactured for each extraction and can significantly increase the overall cost of any 
recovery process. Due to the very low solubility of oleic acid in acetonitrile (result not 
shown), it was decided to examine the possibility of back-extracting geldanamycin from 
oleic acid liquid-core microcapsules using this solvent. It was anticipated that close 
examination of this system could result in the recovery of high concentrations of the 
drug, whilst maintaining the integrity of the capsule structure.  
To begin with, geldanamycin was recovered from Bennett’s medium using oleic acid 
containing microcapsules, which had a dm of 926.86 µm and a dlc of 734.12 µm (Figure 
5a). Capsules were then washed with equal volumes of acetonitrile, which resulted in 
little or no removal of liquid from the core; however > 25% of the geldanamycin 
remained inside after one wash. Repeated rinsing and/or increasing volumes of solvent 
enabled larger quantities of antibiotic to be retrieved, but unfortunately also resulted in 
the loss of some (Figure 5b) or all the core material (as seen in Figure 4b and c). To 
prevent this from occurring, the capsules were washed with acetonitrile saturated in 
oleic acid and the outcome displayed in Figure 5c. The saturation of acetonitrile with 
oleic acid prevented the loss of the core material, even when large volumes were used, 
due to the equilibrium concentration of the fatty acid being present in the back-
extracting solvent. The oaacnK /  for geldanamycin between the two different phases was 
calculated using equation 4 and equaled 3.3 ± 1.89%. Owing to its higher affinity for 
geldanamycin compared to oleic acid, the use of acetonitrile reduces the amount of 
solvent required to recover large amounts of the antibiotic. Also, due to the intact oil-
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core and the saturated acetonitrile not affecting the mechanical structure of the capsules 
(results not shown), it can be foreseen that these could be re-used for many future 
capsular perstraction applications.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Light microscope image of: (a) Oleic acid liquid-core microcapsules with a 
dm of 926.86 µm and a dlc of 734.12 µm, which were used to extract geldanamycin from 
Bennett’s media. (b) Capsules showing the loss of some of the oleic acid liquid-core 
after three individual acetonitrile washes, and (c) capsules shown no loss of the core 
material after three separate washes with acetonitrile saturated with oleic acid.  
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3.4.10. Purification of geldanamycin recovered from microcapsules 
Crystallization is one of the oldest and most effective processes for the preparation of 
solid products and is widely used for the manufacturing of specific active ingredients 
during final and intermediate stages of purification and separation, as it enables very 
high product purities and stabilities to be obtained. Its successful attainment is governed 
by many factors, two of the most important being solubility and purity of the product in 
the crystallization solution. The back-extraction process resulted in a very pure solution 
of geldanamycin dissolved in acetonitrile saturated with oleic acid (Figure 6c), with 
most of the media components removed after extraction (Figure 6b). Due to this high 
level of purity, it was decided to examine the possibility of recovering the antibiotic in a 
solid state using crystallization. The presence of oleic acid in the back-extraction 
solution (Figure 6c) initially prevented crystallization, and to obtain a successful 
method the fatty acid had to be removed. The addition of water to this solution resulted 
in the precipitation of oleic acid from the mixture in the form of an emulsion, which was 
completely removed by centrifugation and filtration. The geldanamycin which remained 
in the displaced oleic acid was recovered by repeating the back-extraction process. The 
removal resulted in a very pure solution of acetonitrile and water containing 
geldanamycin (Figure 6d) and resembled the chromatogram obtained for pure 
geldanamycin in water (Figure 6a). Heating of the solution resulted in the evaporation 
of acetonitrile from the solution, and due to the low solubility of the antibiotic in water 
(< 15 mg/l), the removal of acetonitrile quickly gave rise to the formation of a 
supersaturated solution. Continuous removal of the acetonitrile initiated nucleation 
followed by crystal growth, which was aided by the agitation of the liquid. Table 3 and 
Figure 6a and 6e display the results for the purity of the re-crystallized geldanamycin 
compared to the pure commercialized geldanamycin. In both cases, the re-crystallized 
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antibiotic had the same HPLC retention time and melting point as the market product. 
This proves that the crystals were indeed geldanamycin and that the purity of the 
recovered compound was not lower than that of the commercial product (the purity of 
this geldanamycin is > 99% dried material as claimed by LC Labs). This low 
temperature distillation resulted in the degradation of only 1.3% of the geldanamycin 
present in the mixture after oleic acid removal. 
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Figure 6: Chromatograms of geldanamycin at different stages of the purification 
procedure: (a) Commercial geldanamycin in water. (b) Commercial geldanamycin in 
Bennett’s media (c) Geldanamycin in oleic acid saturated acetonitrile (recovered from 
oleic acid liquid-core microcapsules). (d) Geldanamycin before crystallization in 
acetonitrile/water mixture (after precipitation and removal of oleic acid), and (e) re-
crystallized geldanamycin re-suspended in water. Note: All RP-HPLC runs were 
performed at a fixed wavelength of 308 nm. 
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Table 3: Values for the retention time and melting point, determined by RP-HPLC, for 
commercial and re-crystallized geldanamycin. 
 Commercial 
Geldanamycin 
Re-crystallized   
Geldanamycin 
Retention time  
(min) 
 10.159 ± 1.5% 9.826 ± 1.3% 
Boiling point  
(ºC) 
252~254 252~254 
 
3.5. Conclusions 
The primary goal of this study was to perform a detailed investigation into the 
feasibility of using capsular perstraction as a novel methodology to recover and purify 
geldanamycin from Bennett’s media. These results would then be used to determine if 
the extraction procedure could be feasible for future work involving the recovery of 
geldanamycin in-situ from cultures. 
The results obtained demonstrated how liquid-core microcapsules can be used as a 
simple methodology to recover large amounts of geldanamycin rapidly from an aqueous 
environment, whilst also successively providing a platform for the purification 
(crystallization) of the drug using a very simple procedure. It is envisaged that the 
application of these particles as a methodology for in-situ product recovery in 
fermentations producing geldanamycin, will not only increase the overall production 
titres by stabilizing the product after removal from the detrimental fermentation 
environment, but most importantly it will lead to significantly increased recovery yields 
of the antibiotic, mainly due to the successful and simple downstream processing 
approach offered by the technique. This has the potential to significantly reduce the 
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overall cost, as downstream processing can account for up to 70-80% of production 
costs for the manufacturing of pharmaceuticals. 
Since many bioprocesses can encounter problems such as product 
inhibition/degradation and/or low yields of recovery, it seems likely that this novel and 
simple technique may be readily adapted for use in many such operations. Experiments 
would simply involve the screening and selection of a solvent, which has a high affinity 
and selectivity for the target product to be encapsulated within a hydrogel. Most organic 
solvents can be encapsulated provided a difference exists between the surface tension of 
the solvent and the polymer. 
The results also highlight how different mass transfer resistances can control the rate of 
geldanamycin diffusion into the microcapsules. Whilst in some instances, these factors 
can have a significant impact on transfer rates; it is however possible to control the 
resistances by varying such parameters as, agitation speed or membrane size during 
capsule production, without affecting critical properties of the microcapsules.  
The study has shown the principle and efficiency of capsular perstraction for the 
recovery of a hydrophobic product from an aqueous environment, by demonstrating 
how microcapsules can be used as a simple methodology to remove large amounts of 
geldanamycin rapidly from Bennett’s media, whilst also showing the potential of this 
procedure as a mechanism for the subsequent purification (crystallization) of the 
antibiotic, using a very simple and straightforward procedure, in which a highly purified 
product (> 99%) can be obtained.  
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3.7. Nomenclature 
Table 4: List of abbreviations and symbols. 
Abbreviation/Symbol Definition Unit 
Hsp90 Heat shock protein 90 - 
17-AAG 17-allylamino-17-
demethoxygeldanamycin 
- 
17-DMAG 17-dimethylaminoethylamino-17-
demethoxygeldanamycin 
- 
RP-HPLC Reverse phase high performance liquid 
chromatography 
- 
dm Diameter of microcapsule µm 
dlc Diameter of liquid-core of microcapsules µm 
aqorgK /  Partition coefficient of geldanamycin 
between an organic solvent and an 
aqueous phase 
- 
e
orgC  Equilibrium conc. of geldanamycin in an 
organic solvent 
mg/l 
e
aqC  Equilibrium conc. of geldanamycin in the 
aqueous phase 
mg/l 
Caq Geldanamycin conc. in the aqueous phase mg/l 
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kL Volumetric mass transfer coefficient m/s 
a Total interfacial mass transfer area per 
unit volume 
mg/l 
Vaq Volume of the aqueous phase l 
0
aqC  Initial conc. of geldanamycin in aqueous 
phase 
mg/l 
Vm Volume of microcapsules l 
Cm Geldanamycin conc. in microcapsules mg/l 
0
mC  Initial conc. of geldanamycin in 
microcapsules 
mg/l 
oaacnK /  Partition coefficient of geldanamycin 
between acetonitrile saturated with oleic 
acid and oleic acid 
- 
e
acnC  Equilibrium conc. of geldanamycin in 
acetonitrile saturated with oleic acid  
mg/l 
e
oaC  Equilibrium conc. of geldanamycin in 
oleic acid 
mg/l 
C(t) Conc. of geldanamycin at time t mg/l 
C(0) Initial conc. of pharmaceutical mg/l 
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4.1. Abstract 
The goal of this study was to increase production, recovery and purification titres of the 
antibiotic geldanamycin during its synthesis in submerged fermentations, using capsular 
perstraction as a novel in-situ product recovery (ISPR) methodology. This ISPR-
technique involves employing porous particles, known as liquid-core microcapsules, as 
extraction aides for the recovery of compounds from different environments. Liquid-
core microcapsules can be described as miniature sized spherical structures, ranging in 
size from 1-1000 μm. They consist of a pre-selected liquid-(core) enveloped within a 
defined membrane of a chosen material. These structures can be manufactured to 
specific criteria and size distribution using the vibrating nozzle (jet) technique. 
The benzoquinone ansamycin geldanamycin is a naturally occurring antibiotic produced 
as a secondary metabolite by Streptomyces hygroscopicus var. geldanus in submerged 
fermentations, and has shown the capability to be very effective in eradicating tumor 
cells. However, some studies have shown that this compound may be very labile in the 
culture environment, resulting in low production titres and recovery yields, which have 
the potential to affect the overall economic viability of the bioprocess. 
In this study microcapsules with an outer diameter of 770.86 μm and containing a 
liquid-core of oleic acid, were added to geldanamycin producing cultures to recover the 
antibiotic from its detrimental fermentation environment, also to stabilize the compound 
and to facilitate the subsequent purification. The results showed a rapid and efficient 
removal of the antibiotic, which enabled an increase in production of 30% compared to 
control fermentations. It was shown that this immediate and selective in-situ extraction 
of the product prevented geldanamycin from being degraded (presumably 
enzymatically) in the culture environment. In addition to increased production levels, 
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the microcapsules served as a platform for the subsequent purification of the compound. 
This was achieved through back-extraction and crystallization of the antibiotic using a 
very simple procedure. This significantly reduced the complexity and number of 
downstream processing steps required to obtain large quantities of a highly purified 
product. Application of this innovative procedure allowed the recovery of > 53% of the 
antibiotic extracted from the fermentation, whilst obtaining a purity > 97%. It is 
envisaged that this procedure could be applicable as an ISPR-methodology and/or 
downstream processing procedure to many bioprocesses, which are limited due to 
product degradation, low recovery yields and/or overly complex purification operations. 
 
4.2. Introduction 
Streptomyces (S.) hygroscopicus have attracted great 
interested due to their well-knowing ability to produce a 
wide variety of antibiotics and other secondary 
metabolites, with some of these compounds showing 
significant importance in the treatment and prevention of 
many diseases [1,2]. One such antibiotic produced by the 
bacterium is ‘geldanamycin’ [Figure 1], a benzoquinone 
ansamycin first described in 1970 [3]. This compound has received much attention over 
the last two decades, mainly due to its potential as a novel antitumor agent [4-7]. The 
antibiotic targets and inhibits the cellular functions of the molecular chaperone 
complex-Heat shock protein 90 (Hsp90), which can be found at abundant and elevated 
levels in cancerous mammalian tissue [7,8]. Geldanamycin combines with high affinity 
to the N-terminal domain ATP binding site of Hsp90, inhibiting its chaperone ability 
 
Figure 1: Molecular structure 
of geldanamycin. 
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towards its client proteins, which subsequently results in tumor destruction by the cells 
natural mechanisms [4]. 
Studies have shown that the antibiotic is produced at relatively low concentrations in 
submerged fermentations [2,3,9,10]. Whilst little is known on the fate and behavior of 
geldanamycin during production [4], in their study Dobson (2008) showed that the 
compound can be sensitive within the culture surroundings, resulting in product 
degradation [2]. 
The sensitivity of bio-products within the production environment can be a serious issue 
for many bioprocessing operations, and can fundamentally lead to very small or 
negligible production titres. This problem has been overcome using methods, such as 
strain improvement [11], or media optimization [12] and have been studied and applied 
for many different bio-products. However, whilst Dobson (2008) showed the capability 
to increase production levels of geldanamycin by up to 500% using a medium 
optimization approach, significant antibiotic degradation still occurred, resulting in poor 
recovery yields [2].  
As discussed by Freeman et al. [13],  Stark and von Stockar [14] and Lye and Woodley 
[15] in their very thorough reviews, the problem caused by product accumulation in a 
culture can be overcome by in-situ product recovery (ISPR). ISPR is a collective term 
used to describe a technique (or combination of techniques), which can be used as a tool 
to improve the overall productivity, recovery and/or final purified yield of the desired 
product in a biotechnological process. It works by continuously removing a produced 
species from the culture environment as soon as it is formed, and transferring into a 
stable environment before significant amounts of degradation takes place. ISPR-
methodologies are used not only to increase production by preventing degradation, but 
can also be used to overcome other limitations characteristic of many biological 
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operations, which can result in low productivities and yields. These include: (1) 
inhibitory or toxic effects of the product on the producing organism. (2) elaborate and 
complex downstream processing (DSP) operations and (3) unfavorable reaction 
equilibrium between the product and substrate. 
Selection of an ISPR-methodology is usually based on the physiochemical properties 
(volatility, size, charge, hydrophobicity and other specific elements) of the product 
being recovered [16]. This enables the chosen technique to exploit the differences in the 
molecular properties of the target product, which differ from the background media, 
hence facilitating removal.  
Recently it was shown in [4] how a new technique (developed within the last decade), 
termed ‘capsular perstraction’, could be used as an ISPR-methodology for the 
successful removal of geldanamycin from a culture medium. This technique uses porous 
particles known as liquid-core microcapsules as extraction aides for the recovery of 
compounds from their associated environments. Liquid-core microcapsules can be 
described as miniature sized spherical structures (ranging in size from nm to mm) and 
consist of a liquid (core) enveloped within a defined membrane [17]. 
In their study, Whelehan and Marison [4] showed how this innovative technology not 
only removed geldanamycin rapidly from the production media, but also demonstrated 
its ability to act as a mechanism to assist DSP. This enabled the purification 
(crystallization) of the drug using a very simple and straightforward procedure and 
resulted in a highly purified product. Stark et al. [18] also used the technique to 
successfully recover 2-phenylethanol from fermentation media. Immediate removal of 
the compound from the vicinity of the producing cells eliminated the inhibitory effect of 
the alcohol on the producing yeast, and resulted in a 50% increase in production 
concentrations.  
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In this study, liquid-core microcapsules consisting of a porous hydrogel membrane of 
alginate and a liquid-core of oleic acid were used as a novel ISPR-approach to recover 
geldanamycin from the fermentation environment. Initially work focused on 
establishing the impetus behind the loss of produced geldanamycin in bacterial cultures. 
Subsequently the work undertaken by Whelehan and Marison [4], was used to 
determine whether liquid-core microcapsules could recover the antibiotic in-situ from 
the culture broth, and thereby stabilize the product. Finally the back-extraction of 
geldanamycin from capsules was examined to determine the capability of coupling the 
extraction process with DSP. 
This study endeavors to show the feasibility and efficiency of using capsular 
perstraction, as a novel ISPR-methodology for the removal and purification of 
geldanamycin from culture environments.  
 
4.3. Materials and methods 
4.3.1. Chemicals 
Geldanamycin microcrystalline powder (> 99% purity) was obtained commercially 
from LC Laboratories (Massachusetts, USA). Water, methanol and acetonitrile were of 
high performance liquid chromatography grade and were all obtained from Sigma-
Aldrich (Dublin, Ireland). Oleic acid, calcium chloride, 3-(N-
Morpholino)propanesulfonic acid (MOPS), Tween 80, N-Z amine A from bovine milk, 
magnesium sulphate heptahydrate and glucose monohydrate (dextrose) were all 
obtained from Sigma-Aldrich (Dublin, Ireland) and were of at least analytical grade. 
Yeast extract, technical agar No. 3, bacteriological peptone and ‘lab-lemco’ beef extract 
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were obtained from Oxoid (Basingstoke, UK). Sodium alginate (Keltone LV) was 
obtained from Inotech Biotechnologies (Basel, Switzerland).  
Due to the reported photolytic nature of geldanamycin, all solutions and experiments 
using the antibiotic were stored and performed in the dark to maintain maximum 
stability. 
When oleic acid was used in its free form i.e. not (non)-encapsulated, all experiments 
were preformed using glass consumables/containers as the fatty acid can react with 
plastics, and therefore interfere with experiments (i.e. purification procedure).  
 
4.3.2. Methods 
4.3.2.1. Strain 
The geldanamycin producing microorganism, S. hygroscopicus var. geldanus strain 
NRRL 3602 was obtained from ARS Patent Culture Collection (Peoria Illinois, USA) 
and was used throughout this study. 
 
4.3.2.2. Spore production 
S. hygroscopicus spores used for cultures were grown on Bennett’s agar consisting of 
the following components:  20 g/l technical agar No. 3, 1 g/l yeast extract, 1 g/l beef 
extract, 2 g/l N-Z amine A and 10 g/l glucose monohydrate, which was autoclaved 
separately from the other components. The agar had a pre-sterilization pH of 7.0. A 
stock solution of 6 x 107 spores/ml was incubated onto the surface of 20 ml of agar in a 
250 ml Erlenmeyer flask (No. 4980, stopper No. 6) at 30 oC for sixty days. This resulted 
in the formation of a mycelia lawn containing aerial spores. The spores were removed 
by washing and re-suspending in a solution containing the following components: 3 g/l 
yeast extract, 5 g/l bacteriological peptone and 1 g/l magnesium sulphate heptahydrate, 
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at 4 oC on an orbital shaker at 100 rpm. Glass beads with a diameter of 5 mm (Sigma-
Aldrich, Dublin, Ireland) were added to help break-up the mycelia. The resulting spore 
suspension was enumerated by placing a diluted spore sample onto Bennett’s agar, and 
incubating at 30 oC for 5-7 days before counting was performed. When not used, spores 
were stored in 20% (v/v) glycerol solution at -80 oC and were employed as the inoculum 
for cultures after defrosting at room temperature. 
 
4.3.2.3. Antibiotic production 
All fermentations were carried out in 250 ml Erlenmeyer flasks containing 100 ml of 
Bennett’s liquid medium, which consisted of the following components: 1 g/l yeast 
extract, 1 g/l beef extract, 2 g/l N-Z amine A and 50 g/l glucose monohydrate, which 
was autoclaved separately from the other medium components. The medium had a pre-
sterilization pH of 7.0. and was inoculated with a spore suspension (1% v/v) containing 
6 x 107 spores/ml. Flasks were subsequently incubated at 30 oC in a temperature-
controlled orbital shaker (model Sheldon SI Series, Medical Supply Company, Dublin, 
Ireland)  at 150 rpm for 20-25 days. The pH was not controlled throughout the 
fermentation. At each defined sampling point, a single flask was removed from the 
shaker, the required analysis performed, and the remainder of the culture was discarded.  
 
4.3.2.4. Quantitative determination of Geldanamycin 
The full details of the high performance liquid chromatography (HPLC) procedure 
employed throughout this study to determine the concentration of geldanamycin in 
different phases can be found in [4]. Standard solutions of geldanamycin for HPLC 
calibrations were prepared in 100% acetonitrile and methanol. 
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4.3.2.5. Geldanamycin extraction from cultures  
To determine the geldanamycin present within control cultures (containing no capsules), 
a homogenous 1 ml samples of medium containing the mycelia and cell by-products 
were removed from the culture, and combined with 4 ml of acetonitrile in a 15 ml 
plastic universal (Sarstedt, Wexford, Ireland). The suspension was agitated for 15 min 
using a vortex, followed by rotating the universal through 3600 about its transverse axis 
for 1 hr at 25 oC. The sample was then centrifuged for 15 min at 4000 rpm and the pellet 
discarded. The supernatant was diluted in the HPLC mobile phase and filtered using a 
0.2 μm nylon filter (Sigma, Dublin, Ireland) and degassed prior to been injected onto 
the HPLC column to quantify the amount of geldanamycin present. This procedure 
extracted > 98% of the antibiotic present in the culture environment.  
 
4.3.2.6. Determination of biomass 
Biomass concentration (dry cell weight) was determined for control (containing no 
capsules) and microcapsule containing cultures using the following procedure (for 
cultures containing capsules, these particles were first removed using a procedure 
described later). Homogenous samples of whole broth (10 ml) were removed and placed 
into 50 ml centrifuge tubes (Sigma, Dublin, Ireland). The samples were subjected to 
three centrifugations at 6000 rpm for 10 min. After the first and second spins the 
samples were re-suspended and washed in distilled water (20 ml). After the final 
centrifugation the sample was transferred to a pre-weighed and pre-dried glass universal 
and incubated at 104 oC for 24 hr. Following evaporation of the water the universals 
were allowed to cool in a desiccator to ensure complete removal of moisture. The 
universal was re-weighed and the dry cell weight of the biomass determined. 
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4.3.2.7. Geldanamycin stability 
Stability studies were carried out in 250 ml Erlenmeyer flasks with a working volume of 
50 ml and performed by examining the breakdown of geldanamycin (fermented and 
commercial) in culture broth. The broth was obtained by filtering whole fermentation 
samples using a 0.22 μm sterile filter membrane system (Steritop, Millipore, Cork, 
Ireland). Experiments were carried-out under sterile conditions to prevent contamination 
of the utilized media or the re-growth of S. hygroscopicus, which may produce more 
geldanamycin and interfere with results. Commercial geldanamycin was added to the 
broth using acetonitrile as a co-solvent, which facilitated the solubilisation of the 
antibiotic [4]. Initially geldanamycin was dissolved in the solvent by agitating on a 
magnetic stirrer and added to broth to make a final acetonitrile concentration of 5% 
(v/v) whilst obtaining the desired concentration of the antibiotic (amount depending on 
experiment being executed). For sampling 0.1 ml was removed from the broth at 
defined intervals, and was analyzed using HPLC analysis to determine the stability of 
the geldanamycin under culture conditions.  
When required, heat treatment of the broth was performed by heating the filtered broth 
in an agitated water bath set at 80 °C ± 1 °C (model SBS40, Stuart, Staffordshire, UK) 
for 90 min. After heating the broth was cooled to 25 °C before use.   
 
4.3.2.8. Preparation and characterization of liquid-core microcapsules  
The full details of the co-extrusion/prilling technique employed to manufacture 
microcapsules used in this study and the procedure used to measure their size has been 
reported previously [17]. All capsules used in this work were manufactured from sterile 
solutions. Alginate stock solutions were prepared by dissolving 25 g/l of alginate 
powder in MOPs buffer [10 mM MOPs, 0.85% (w/v) NaCl pH 7.0]. After solubilisation 
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the alginate solution was filtered using a 0.45 µm cellulose acetate filter membrane 
(Whatman, Dassel, Germany) under a pressure of 2-4 bar to remove most of the 
impurities, which was followed by sterile filtration through a 0.22 µm membrane filter 
system. The gelling (hardening) solution consisted of 32 g/l CaCl2, 10 mM MOPS pH 
7.0 and was filtered sterilized before use. To reduce the surface tension of the hardening 
solution, 0.1-0.2% (v/v) of Tween 80 was added, followed by heating the solution to 55-
60 °C during the capsule production process. Sterile microcapsules were obtained by 
placing the Encapsulator (model IE-50R, Inotech Biotechnologies, Basel, Switzerland) 
within a laminar flow safety cabinet (Model TC-48, Gelaire, Melbourne, Australia). 
After production, capsules were washed extensively with sterile water to remove any 
un-reacted components using a porous mesh (pore size 200-300 μm). The washing step 
was unable to sufficiently remove free oleic acid (occurs due to inadequate break-up of 
the liquid jet, and/or when capsules burst upon enter into the gelling bath, during the 
production process) from around capsules due its very hydrophobic nature. If the fatty 
acid was present in a non-encapsulated form in a batch of capsules, they were discarded. 
Microcapsules were stored under sterile conditions until required. 
 
4.3.2.9. Addition and removal of capsules from cultures 
Capsule-assisted fermentations were inoculated with 20 ml of oleic acid contained 
within the microcapsules. The capsules used in this study had an outer diameter of 
770.86 μm ± 2.3% and an inner diameter, consisting solely of the liquid-core, of 667.2 
μm ± 1.8%. The hydrogel membrane of microcapsules is mainly composed of water (≥ 
97%) and the capsules added to the culture had a total membrane volume of 10.84 ml. 
The dilution affect of this membrane on geldanamycin and biomass levels in the culture, 
was taken into consideration when microcapsules were present. Sterile capsules were 
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added to the fermentation medium five days after inoculation had taken place. The total 
volume of the capsules was measured using graduated tubes. During harvesting the 
buoyant nature of the capsules resulted in them floating to the top of the culture, whilst 
the cells sedimented to the bottom of the flask. The capsules were removed using a 
pipette and washed with water through a mesh filter to remove any media components. 
After removal, capsules were immediately treated to recover the extracted 
geldanamycin. 
 
4.3.2.10. Recovery of geldanamycin from microcapsules 
Geldanamycin extracted into the oleic acid liquid-core of microcapsules during cultures 
was recovered (back-extracted) by one of two methods which have been described 
previously [4]. When complete quantification (and removal) of the extracted antibiotic 
in the microcapsules was required, capsules were contacted and washed in equal 
volumes of methanol and solutions were agitated at 300 rpm for 60 min at 25 °C to 
establish equilibrium. To ensure complete recovery of all the antibiotic additional 
washing steps were performed until no more geldanamycin could be detected. The 
antibiotic required for purification (crystallization) was removed by adding and washing 
capsules with equal volumes (liquid-core volume, 20 ml) of acetonitrile saturated in 
oleic acid. Prior to the addition of this solution, geldanamycin containing capsules were 
placed in an oven overnight at 30 °C to expel the water from the alginate membrane. 
Saturation of acetonitrile with oleic acid was performed by mixing both liquids at 200 
rpm for 24 hr at 25 °C in a temperature-controlled shaker (Innova 43, Brunswick 
Scientific, New Jersey, USA). After agitation, both phases were allowed to settle and 
reach equilibrium for at least 24 hr at 25 °C. Capsules were then added to the back-
extraction solution and agitated at 300 rpm for 60 min at 25 °C to ensure equilibrium 
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had been obtained. After back-extraction capsules were removed from the acetonitrile 
solution by filtration through a porous mesh, and the retained capsules were added to 
fresh back-extraction solution and the washing step repeated. To ensure that the 
majority of the antibiotic was removed, three washing steps were undertaken, after 
which all solutions were pooled and the total quantity recovered determined.  
 
4.3.2.11. Purification and crystallization of geldanamycin recovered from capsules 
The geldanamycin-containing acetonitrile saturated with oleic acid, was purified prior 
crystallization by removing the fatty acid, through the addition of equal volumes of 
water (60 ml) to the solution. This resulted in the displacement (precipitation) of the 
oleic acid. This precipitate was then separated from the suspension by centrifugation at 
4000 rpm for 35 min at 25 °C. Equation 1 was used to calculate the partition ratio 
 for the distribution of geldanamycin between the oleic acid and 
acetonitrile:water phases. 
awoaK /
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where  is the concentration of geldanamycin in the displaced oleic acid at 
equilibrium, and  is the concentration of the antibiotic in the acetonitrile:water 
phase when equilibrium was obtained.  
e
oaC
e
awC
The remaining solution was filtered using hydrophilic 0.22 μm Filtropur membranes 
(Sarstedt, Wexford, Ireland) to remove any unrecovered oleic acid, which remained 
suspended in the aqueous phase. The water addition and filtration steps were repeated 
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twice more, and prior to the final filtration the solution was cooled to 4 °C (to 
precipitate any remaining oleic acid if present). After removal the purified acetonitrile 
and water solution containing geldanamycin was added into a graduated glass beaker 
and placed into a water bath set at 82.5 °C ± 2.5 °C to enable evaporation of the 
acetonitrile. During evaporation, the solution was slowly agitated to facilitate nucleation 
and subsequent crystal growth. When most of the acetonitrile been removed (no visible 
change in the volume of the solution), the temperature was increased to 100 °C ± 2.5 
°C. Evaporation of the remaining solution was continued until < 5% of the original 
volume was left. The solution was immediately cooled to 4 °C to further reduce the 
solubility of the antibiotic in the suspension. Geldanamycin crystals were retrieved by 
filtering the crystal-containing solution through a 0.2 μm nylon filter under vacuum. 
Crystals were dried at 30 °C for at least 48 hr and subsequently placed in a dessicator 
before weighing to determine the amount of antibiotic recovered. The purity of the 
crystals was determined by re-dissolving in acetonitrile and HPLC analysis. These 
results were compared to those generated for commercial geldanamycin solutions 
prepared and analyzed in the same way. 
 
4.4. Results and discussion 
4.4.1. Production of geldanamycin 
The growth of the bacterium S. hygroscopicus followed by the production of 
geldanamycin in submerged fermentation can be seen in Figure 2.  From the results 
antibiotic accumulation appears from the late exponential growth phase (6-7 days after 
inoculation) with the majority formed during a 5 day period (between day 8 and 13). 
During this time the geldanamycin concentration reached a maximum net concentration 
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of 110 mg/l, with a corresponding biomass concentration of 7.2 g/l. Although the 
biomass concentration appeared to remain relatively constant during the stationary 
phase, the concentration of geldanamycin fell rapidly after 15 days, until day 23, where 
no geldanamycin could be detected. 
In previous work Casey [9] and Song et al. [10] had not observed significant reductions 
in geldanamycin titres during the course of batch cultures. However Song et al. (2008) 
used a different Streptomyces subspecies, whilst Casey (2008) inoculated the culture 
with an inoculum containing a smaller concentration of S. hygroscopicus spores. As 
reported in numerous publications [19-22], the inoculum size has the potential to affect 
the morphology of a filamentous organism during growth in shake-flasks, which itself 
may influence product stability [23]. Dobson [2] reported similar results to those 
portrayed in Figure 2 when comparable fermentation conditions were employed. In this 
study it was postulated that the steep decline in geldanamycin concentrations observed 
at day 15 in this study, could be due to enzymatic and/or chemical breakdown in the 
culture [2]. Higher net maximum concentrations of geldanamycin were obtained before 
degradation occurred in Dobson’s work [2], probably due to the addition of extra 
components to the culture medium and cell lysis prior to analysis. This suggests that 
feed-back inhibition was not responsible for the cessation of antibiotic production in 
this work. 
Other limited research studies published on the fate and behavior of geldanamycin in 
cultures have proposed that it may be sensitive to certain elements within the production 
environment [2,3,9]. Indeed, Casey (2006) reported that the use of adsorbent resins 
resulted in a 3-fold increase in overall production concentrations [9].  
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Figure 2: Growth (dry cell weight) of S. hygroscopicus and overall net production of 
geldanamycin in submerged cultures. Legend: dry cell weight (squares) and 
geldanamycin concentration (diamonds).  
 
4.4.2. Geldanamycin stability  
Establishing a successful manufacturing procedure for any bio-product requires a 
stability profile of the molecule in the production environment and this was the goal of 
this part of the study. Initially experiments were conducted to examine the effects of 
different parameters (excluding cells) associated with the culture environment on the 
stability of geldanamycin such as, agitation speed, temperature, media components and 
pH. From this work (results not shown) it was deduced that none of these parameters 
could be responsible for the degradation seen in Figure 2. As a result the stability was 
assessed by addition of known amounts of geldanamycin (commercial and fermented) 
to the culture broth produced by S. hygroscopicus in Bennett’s medium, after the 
bacterial cells had being removed. The following were used: (a) culture broth from Day 
8 of fermentation (Figure 1), which contains geldanamycin (16.95 mg/l) produced by 
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the organism and (b) culture broth (Day 5.7 of fermentation). This solution contained 
geldanamycin at 2.3 mg/l, which was increased to the level in solution a (16.95 mg/l) by 
the addition of commercial geldanamycin. Both samples were incubated under the same 
conditions as those used in the batch culture experiments and the stability of 
geldanamycin determined. 
The results (Figure 3) indicate that at this stage of the fermentation both fermented and 
commercial geldanamycin are relatively stable with only an 8 and 15% loss of product 
occurring respectively over a 15 day period. Such a decrease in geldanamycin does not 
account for the loss in real-time fermentations, and suggests that considerable 
breakdown of geldanamycin is not occurring during the production phase. To further 
understand what maybe responsible for the loss of stability of the antibiotic, two 
additional experiments were performed using: (c) culture broth from day 15 of the 
fermentation, where overall geldanamycin concentration (18.65 mg/l) began to fall 
(‘falloff point’) and (d) culture broth from day 23 of the fermentation, where no 
geldanamycin appeared to be present due to complete degradation. To the latter 
solution, 18.65 mg/l of geldanamycin was added to bring the concentration similar to 
the level in sample (c).  
The stability of geldanamycin in the two solutions was determined under fermentation 
conditions and the results displayed in Figure 3. The results show the geldanamycin 
present in both types of solution is completely degraded after 5-6 days. The increased 
rate of degradation in experiments (c) and (d) compared to that determined in the culture 
(Figure 2) is almost certainly due to the large difference in concentration of the drug in 
each environment. The results suggest that geldanamycin is relatively stable in the 
fermentation environment until a certain critical stage (falloff point) is reached, at which 
 166
Chapter 4: Successful application of capsular perstraction as a novel ISPR technique: 
Removal and purification of geldanamycin from S. hygroscopicus cultures 
 
 
time the degradation of geldanamycin begins due to the presence of a component in the 
broth, which is probably released by the cells. 
Dobson (2008) postulated that enzymatic degradation of the antibiotic might occur to 
replace a limiting substrate, as growth enters a decline or death phase [2]. In a similar 
way Mayer and Decker (1996) speculated that the degradation of clavulanic acid could 
be related to an enzyme [24]. In this case the biocatalyst sets about modifying the 
structure of the antibiotic, enabling the organism to consume it and produce more 
secondary metabolites. It has also been reported that a cell associated enzyme is 
responsible for the breakdown of the secondary metabolite pristinamycin following the 
production phase [25].  
To determine if a cell associated product such as an enzyme, is responsible for 
degradation in the culture broth, both solutions (c) and (d) were heated to 80 °C for 90 
min before again being tested under fermentation conditions. The heating step was 
performed to enable the destruction of any proteins, which may be present in the broth 
and which could be affecting the antibiotic. As reported previously these relatively high 
temperatures have little or no affect on the antibiotic [4], although other reports suggest 
that geldanamycin may be thermo-labile [3,26].  
From Figure 3 it can be seen that both sources of the drug are more stable in the heat-
treated broth compared to the untreated version, in which the antibiotic degrades after 
16 days by 13 and 29% for the commercial and fermented geldanamycin respectively, 
and these values are similar to those obtained for broth samples (a) and (b). On the basis 
of the available experimental data it can be suggested that the greater stability of the 
compound in heat treated broth, is the result of certain components (e.g. enzymes) being 
produced, which are either secreted or released due to cell lysis occurring in the 
stationary phase and subsequently attack the compound. These substances appear to be 
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soluble and remain in the cell-free broth after microfiltration. In the presence of cells the 
rate of breakdown could be greater due to the additional metabolism of geldanamycin 
by the cells themselves. 
 
Figure 3: Stability profile of fermented and commercial geldanamycin in different 
culture solutions. Symbols: solution (a) open diamonds; solution (b) open squares; 
solution (c) closed circles; solution (d) closed triangles; heat treated solution (c) open 
circles and heat treated solution (d) open triangles. 
 
4.4.3. In-situ product recovery using capsular perstraction 
Due to the apparent degradation of geldanamycin in cultures, particularly during the 
stationary phase, it was decided to try to alleviate this problem by removing the 
compound in-situ from the producing environment. An earlier study showed how 
capsular perstraction could be used to extract commercial geldanamycin from Bennett’s 
medium [4]. This work discovered how the main rate-limiting step to the mass transfer 
of the antibiotic into the liquid-core, was the stagnant aqueous layer around the 
capsules. Whilst it was not possible to control this resistance (maximum agitation speed 
 168
Chapter 4: Successful application of capsular perstraction as a novel ISPR technique: 
Removal and purification of geldanamycin from S. hygroscopicus cultures 
 
 
for cultures was at 150 rpm), it was however feasible to control the other resistances 
(size and membrane thickness) during the capsule production process [17], resulting in 
capsules with an outer diameter of 770.86 μm and an inner diameter of 667.2 μm. Such 
capsules enabled rapid removal of geldanamycin (< 60 min, results not shown); the 
membrane thickness also guaranteed mechanical integrity of the particles. The core 
material also ensured that capsules would float to the surface of the culture, thereby 
facilitating their removal for product recovery. In the aforementioned study two 
different solvents (dibutyl sebacate and oleic acid) were examined for the ability to 
extract geldanamycin. In the present work, oleic acid was selected due to its higher 
affinity for the antibiotic with a partition co-efficient of 212 [4]. Additionally, 
geldanamycin could be removed from capsules for detection and purification 
(crystallization), using a back-extraction method which was not detrimental to the 
capsules, thus allowing them to be re-cycled for future work [4]. Previously it had been 
stated that incorporation of an oleic acid liquid-core into an alginate hydrogel membrane 
was technically more challenging compared to incorporation of dibutyl sebacate [4,27]. 
This difficulty was overcome by adding a surfactant and heating the gelling solution, to 
reduce the surface tension of the mixture. This decreased the impact force of capsules at 
the interface between the gelling solution and the surrounding environment, thus 
preventing capsules bursting and liberating the core material, which further interferes 
with the production process, and is also very difficult to remove. A quantity of 
microcapsules containing 20 ml oleic acid was added to the culture on day 5 of growth 
of S. hygroscopicus cells. This volume was chosen as it had displayed the capability to 
recover > 1 g/l of geldanamycin from the culture. Capsules were not added during 
inoculation, since initial germination of the spores resulted in growth of hyphae around 
the microcapsules. This resulted in them becoming entrapped in biomass and this 
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affected sorption capacity. Post-inoculation addition after 5 days, allowed for the 
formation of mycelial pellets which did not adhere to the microcapsules. The low 
density of capsules enabled them to rise to the surface of the medium when agitating 
was reduced, while the pelted cells tend to sediment. This separation of the 
microcapsules and biomass significantly facilitates the recovery of capsules.  
Figure 4 shows the effect of microcapsule addition on the overall net concentration of 
geldanamycin produced and recovered during batch growth of the culture. The results of 
the control fermentation (Figure 2) are also displayed in Figure 4 to simplify the 
comparison of results. From the Figure 4 it can be seen that the microcapsule assisted-
fermentations resulted in a 30% higher maximum net concentration of geldanamycin 
compared to the control fermentation (143 mg/l to 110 mg/l). More important, the 
immediate in-situ extraction of the antibiotic resulted in the recovered material being 
stable in the culture environment over 24 days. It appears that the cell-secreted 
material(s) responsible for the breakdown of geldanamycin, were not extracted into the 
core of the microcapsules, thereby indicating selectivity of the capsules for 
geldanamycin. The addition of microcapsules to the cultures resulted in no great effect 
on the overall cell density obtained.  
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Figure 4: Comparison of the overall net production of geldanamycin and growth of S. 
hygroscopicus between cultures containing oleic acid liquid-core microcapsules (lines) 
and cultures containing no capsules (dashed lines). Symbols: cell dry weight (squares) 
and geldanamycin concentration (diamonds). 
 
4.4.4. Recovery and purification of geldanamycin from microcapsules  
Exiting streams from bioprocessing operations are usually characterized by relatively 
low product concentrations of high value products such as antibiotics, antibodies and 
enzymes, present in large volumes of a complex environment, consisting of medium, 
cell by-products and biomass [28]. Separation and purification of these compounds to 
the desired level often involves long, laborious and complex bio-separation schemes. 
This can severely affect the overall process economics, often accounting for 70-80% of 
total production costs [29-31]. In some cases such problems have slowed down large-
scale manufacture and commercialization of medically important drugs, an example 
being Embrel [32]. In light of this problem, over the last number of decades there has 
been a keen interest and desire in developing efficient, simplified and cost-effective 
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downstream processing techniques, which require little or no change to presently used 
production equipment, whilst still producing highly purified biomolecules [13,14,29,33-
36].  
The aim of this part of the work was to develop a method for the recovery of the 
microcapsules from the fermentation medium, back-extraction of geldanamycin from 
the capsule-core, and purification of the recovered antibiotic in a crystalline state using 
straightforward techniques. Figure 5 shows schematically the proposed bio-separation 
procedure for the purification of geldanamycin used in this work, and is divided into 
five main steps.  
Step 1: Separation of microcapsules from the culture: The incubation of capsules into 
the fermentation resulted in the total recovery (extraction) of 13.4 mg of geldanamycin 
(134 mg/l in the culture), contained within 20 ml of oleic acid, which was entrapped 
within the alginate membrane. Since the buoyancy of microcapsules has been shown to 
be controllable by the parameters used in the production process, it was possible to 
recover them by flotation with an efficiency > 98%. The recovered particles were 
washed with deionized water to remove any media components and cell by-products.   
Step 2: Recovery of geldanamycin from microcapsules: The antibiotic contained within 
the oleic acid liquid-core was recovered by contacting and washing the microcapsules 
with acetonitrile saturated with oleic acid. The higher affinity of the acetonitrile for the 
compound compared to the core material [4] resulted in removal of 75% of the 
antibiotic from the microcapsules after just one wash. A further two washes with fresh 
acetonitrile solution resulted in a further 18 and 4% recovery, of the original 
geldanamycin, without affecting the structure of the microcapsules. The extracts were 
pooled to yield 60 ml of acetonitrile saturated with oleic acid containing > 94% of the 
antibiotic recovered from the culture.  
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Step 3: Recycling of microcapsules: For any downstream processing procedure, 
complete regeneration of the purification material(s) to enable re-use is an important 
consideration in reducing the overall cost of the process. As a result microcapsules from 
step 2, from which > 94% of the geldanamycin had been removed, were washed with 
small amounts of pure acetonitrile. This washing was carried out in ≤ 1 min in order to 
avoid extraction of the oleic acid core [4], while enabling removal of any fatty acid 
adhering to the exterior surface of the microcapsule membrane. Capsules were 
subsequently washed in deionized water to remove acetonitrile and to re-hydrate the 
membrane.  
In order for the microcapsules to be used for future ISPR-cycles, sterilization is 
required. In an earlier study the capsules were heat sterilized at 121 °C for 20 min, 
which caused the shrinkage and weakening of the membrane [18]. To avoid these 
deleterious effects, the particles were sterilized using UV irradiation at 254 nm for 2-3 
hr, before addition to fresh culture medium. This procedure resulted in no 
contamination being detected in the medium, whilst the microcapsules also retained 
their size distribution and mechanical strength (results not shown).  
Step 4: Purification of geldanamycin in back-extraction solution: The geldanamycin 
back-extracting solvent from step 2 is composed of acetonitrile with traces of oleic acid, 
which needs to be removed for successful purification and crystallization of the 
antibiotic [4]. This was achieved by the addition of water to precipitate the oleic acid, 
which formed a separate phase, aided by centrifugation. From the 60 ml of back-
extraction solution, a total of 4.8 ml of oleic acid precipitated. The addition of water to 
the acetonitrile reduced its affinity for the antibiotic. The  value for geldanamycin 
between the acetonitrile:water phase and the oleic acid was calculated to be 148 using 
equation 1. Although the oleic acid has a significantly higher affinity for the antibiotic 
awoaK /
 173
Chapter 4: Successful application of capsular perstraction as a novel ISPR technique: 
Removal and purification of geldanamycin from S. hygroscopicus cultures 
 
 
compared to the acetonitrile:water solution, the majority of the antibiotic (> 81.5%) 
remained in the latter due to the considerably larger volume. Further water addition, 
filtration and cooling, performed to remove any residual oleic acid, caused further loses 
and resulted in 79.46% of the extracted drug being recovered. No effort was made at 
this stage to improve on the recovery, although suitable choice of conditions should 
result in higher recovery yields.  
Step 5: Crystallization of geldanamycin: Low temperature distillation as performed in 
[4], was used in this stage and resulted in the crystallization of 71.3% of the antibiotic 
present after step 4, where < 1% of the antibiotic present at the time was degraded by 
the process. The recovered and weighed crystals were diluted in acetonitrile and HPLC 
analysis confirmed quantity and purity of the produced geldanamycin, with values being 
equivalent to commercially available material. Comparison of weight and concentration 
of crystals with commercial material, indicated that crystals were of a purity > 97%.  
In conclusion, the utilization of this simple DSP methodology resulted in 53.28% (7.14 
mg) of the geldanamycin extracted from the cultures (using capsular perstraction), being 
crystallized at high levels of purity.  
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Addition of liquid-core 
microcapsules to cultures 
Figure 5: Schematic representation of the downstream processing operation used to 
purify geldanamycin recovered from cultures using capsular perstraction. The total 
amount of the antibiotic present after each step is indicated with an asterisk. Symbols: 
GA (geldanamycin). 
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4.5. Conclusions 
Relatively low concentrations in production streams and/or complex and costly 
purification procedures have being a major problem for the production of biomolecules. 
Recent progress in the area of molecular biology and improved cell cultures techniques 
has resulted in production capacity increasing too many grams per liter. Unfortunately 
however, these advances still do not address the problems of product accumulation, 
inhibition and stability in the fermentation, or the requirement for expensive and 
complex purification methodologies. Indeed the recent advances in production 
capacities have somewhat further increased the problems for many DSP procedures, as 
these methods were not designed for the quantities now being manufactured. These 
complications are also amplified further by reluctance within industry to replace long-
established techniques. The outcome is a production bottleneck that is shifting the cost 
further towards an already overly expensive DSP operation.     
Since the first implementation of ISPR-based-methodologies in the early 1980s, it has 
long being anticipated that these techniques would help to overcome the problems of 
low productivities and expensive purification techniques, particularly for the 
manufacture of high valued products such as antibiotics, flavors and fragrances etc. 
However, over the last two-three decades this premature hope has not transpired into 
reality, and is often attributed to the ISPR-procedure, which in order for it to be 
successful can require complex and highly expensive modifications to existing 
production facilities.    
This study demonstrated the feasibility and efficiency of capsular perstraction as a novel 
and innovative approach, to selectively extract large quantities of the high value product 
geldanamycin from cultures of S. hygroscopicus, whilst subsequently providing a stable 
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environment. Incorporation of oleic acid-containing microcapsules improved net 
production by 30% compared to control fermentations. These was achieved by 
removing the antibiotic from its hostile production environment, which was causing 
degradation and severely affecting recovery yields. The ability to subsequently use the 
ISPR-methodology as a DSP mechanism for the purification of the extracted 
geldanamycin using straightforward techniques was also shown and resulted in high 
recoveries (53.28%) of the antibiotic at high levels of purity (≥ 97%).  
Although this work has concentrated on developing the concept at laboratory scale, the 
simplicity of the process and the relatively low cost of the encapsulation, extraction, 
back-extraction1 and purification materials, as well as the low energy requirements, 
should make this process economically feasible for large-scale extraction and 
purification of biomolecules, using scale-up techniques. Nonetheless, further work is 
required to define the process economics. Applying microcapsules should not require 
any major equipment changes and in most cases could significantly reduce the volume 
of DSP equipment required for a successful production process. Addition of capsules to 
cultures will increase the working volumes of bioprocessing vessels, however this can 
be kept to a minimal by using an oil core which has a very high capacity for the 
compound of interest and/or placing the microcapsules in a recycle loop.   
Due to the ease of operation, this procedure should be applicable as an ISPR-
methodology to many similar processes, which are limited due to product degradation 
and/or low recovery yields. This process simply involves identifying a suitable organic 
solvent with a high affinity for the compound requiring extraction; thermodynamic tools 
 
1 Provided the price of acetonitrile continues to fall considerably, from the peak prices occurring in 2009 
to pre-inflated levels of 2008. 
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such as Unifac and Uniquac could be used to facilitate this. This solvent can then be 
encapsulated within a porous membrane of choice, under sterile conditions if required.  
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4.7. Nomenclature 
Table 1: List of abbreviations and symbols, ranked in order in which they appear. 
Abbreviation/Symbol Definition Unit 
ISPR In-situ product recovery - 
S Streptomyces - 
Hsp90 Heat shock protein 90 - 
DSP Downstream processing - 
HPLC High performance liquid chromatography - 
awoaK /  Partition ratio for the distribution of 
geldanamycin between the oleic acid and 
acetonitrile:water phases 
- 
e
oaC  Concentration of geldanamycin in the 
displaced oleic acid at equilibrium 
mg/l 
e
awC  Concentration of the antibiotic in the 
acetonitrile:water phase when equilibrium 
was obtained.  
mg/l 
 178
Chapter 4: Successful application of capsular perstraction as a novel ISPR technique: 
Removal and purification of geldanamycin from S. hygroscopicus cultures 
 
 
GA Geldanamycin - 
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5.1. Vibrating-jet technique 
Spheres/capsules in the micron size range have played a very important role in a vast 
variety of industries such as, pharmaceutical, cosmetics, agricultural etc., since the early 
to mid-twentieth century, with the food industry being one of the biggest benefactors. 
Such has being the success of this employment that in the 1970s scientists set-about in 
implementing the versatile technology to medical and biotechnological fields. 
Originally it was anticipated that similar achievement could be obtained in comparison 
to the aforementioned industries, when it came to developing new products, improving 
existing ones, or in some situations completely re-defining the role of a commodity.  
Unfortunately in this period of time the technology has not reached what many would 
perceive as its full potential when being applied to these areas. This point is exemplified 
by the very few medical and biotechnological products available commercially which 
make use of the science. The problem has being mainly attributed to the slow 
development of methodologies needed to manufacture the particles at a large scale-level 
and bearing the required properties (Section 1.3.1.1.). This has culminated in many 
circumstances whereby a potentially successful product incorporating encapsulation 
technology has being developed, but no method is available to carry out production.  
In recent times mechanical based techniques have been extensively researched on their 
capabilities to produce microspheres/microcapsules for biotechnology and medical 
applications. These procedures enable the production of particles with the desired shape 
and size, under a simple and relatively controllable operation, and do not require the use 
of toxic chemicals. A limit number of these procedures exist and include the following: 
spray-drying, jet cutting, spinning disk, electrostatic extrusion, coaxial air-flow and 
vibrating jet technique. Unfortunately, these methods possess the characteristic 
problems of being unable to produce small (< 100 μm) and homogenous shaped 
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microspheres/microcapsules at a large scale level using highly viscous (up to several 
thousand mPas) materials.  
Of all six techniques discussed in Section 1.3.2., the vibrating jet technique seems the 
most capable of overcoming these obstacles1. The problem of extruding highly viscous 
solutions through the nozzle(s) and ensuring their optimal break-up when subjected to 
vibrational frequencies can be achieved by heating the polymer (using a heating 
nozzle/pulsating-head device as discussed in Section 1.5.4.2.) solutions to temperature ≥ 
60 °C, and can significantly reduce their viscosity. This decrease enables the extrusion 
of the highly viscous solution through the nozzle, subsequently forming a jet, which can 
be broken up into droplets of the desired size.  
Whilst elevated temperatures (≥ 45 °C) can be detrimental to certain animal cells, aroma 
compounds and bioactives, it most be noted that use of these temperatures at the short 
period of time required for the process to be successful, should not affect most 
materials. For heat sensitive encapsulants temperatures of 35-45 °C can be employed. 
This heat should be adequate to reduce the viscosity to the necessary level to obtain 
extrusion and adequate jet breakup, whilst not damaging the encapsulated product.  
Use of the heated nozzle apparatus should provide an optimal method to encapsulate a 
large range of materials within the desired membranes, especially when viscous 
materials like gelatin’s and gums are required.  
As discussed in detail in Section 1.5.4.1., large scale production can be achieved by 
increasing the number of nozzles on the head plate of the encapsulator. For this to be 
successful, each nozzle must obtain identical production conditions, such as frequency, 
amplitude, etc., which can be accomplished in a relatively simple manner. However, 
obtaining similar liquid flow rates is somewhat more problematic. Fortunately this can 
                                                 
1 A very good case could also be made for the jet cutting technique, provided cutting losses are kept to a 
minimal [1].  
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be overcome by employing a concentric split, which enables an equal flow to be 
distributed to all nozzles. Provided that all orifice diameters are identical, the relative 
flow difference between each nozzle should be negligible, if the polymer is pumped 
using a system incorporating air pressure (Section 1.5.2.1.). This delivery mechanism 
also enables large volumes of material to be extruded through the nozzle in any given 
run and reduces or eliminates clogging of the orifice, hence eliminating the need for the 
nozzle to be cleaned when operating.  
It is envisaged that future use of the multi-nozzle system will enable the production of 
required quantities of microspheres/microcapsules for industrial use. 
 
5.2. Removal of pharmaceutically active compounds from water 
Pharmaceuticals are used extensively in the western world for the treatment of human 
and veterinary diseases with EU members alone using over 3000 different types [2]. 
Each year thousands of tons of these drugs are excreted from humans as un-metabolized 
or active forms into sewage water [3], passing onto sewage treatment plants (STPs), 
which are unable to adequately remove them [4,5]. Research performed globally has 
shown that the effluent water from STPs is one of the main point source of entry of 
these pollutants into the environment [4,6-12]. This along with improper disposal of 
medications contributes to the continuous contamination of receiving waters 
downstream from STPs.  
The presence of pharmaceutically active compounds (PhACs) in different 
environmental water spheres is now seen as a real-time problem by many environmental 
scientists and agencies. This is due to the known high level of toxicity possessed by 
some of these compounds [13,14]. Also, continuous release of large quantities of these 
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substances increases the possibility of synergistic effects with other pharmaceuticals 
and/or chemicals released and/or present in the environment [13].  
In chapter 2 a novel extraction methodology termed ‘capsular perstraction’ was 
proposed, and showed its ability to remove seven commonly found PhACs from water, 
by the simultaneous use of dibutyl sebacate and oleic acid liquid-core microcapsules. 
Results indicated that this innovative approach is capable of removing the compounds 
rapidly from water (> 50 min), with a variable efficiency (15-100%), even at relatively 
low agitation speeds.  
The main hindrance to mass transfer was found to be the stagnant organic phase within 
the capsules themselves. Mass transfer coefficients were measured for the diffusion of 
warfarin into different sized capsules (with similar membrane thickness), and it was 
determined that an inversely proportional relationship existed between different capsule 
sizes and the extraction speed for the sizes examined in this work. Fortunately the size 
of capsules can be controlled during the production process (Section 1.5.3.1.), allowing 
the resistance to be managed. Even with this obstruction, the extracting particles are still 
capable of the rapid removal of the tested pharmaceuticals (0.6 x 10-6 – 2.28 x 10-6 m/s).  
Overall this process offers many advantages over conventional treatment methodologies 
like liquid-liquid extraction such as: high interfacial surface area for rapid mass transfer, 
reduction of stable emulsion formation, and most significantly they prevent further 
contamination of water by impeding the direct contact between the organic and aqueous 
phases.  
Future work will involve screening for a solvent(s) which has the capability to recover a 
larger range of compounds at higher quantities in contrast to the solvents used in this 
study. This will reduce the cost of the capsule production process as smaller quantities 
will be required to achieve the desired removal of the pollutant.  
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For large scale implementation it is envisaged that capsules should be applied directly to 
the STPs as a tertiary treatment process, whereby they will remove unwanted pollutants 
from the effluent before release into the receiving waters. When applied, the purpose of 
the tertiary treatment process is to provide a final treatment stage in order to raise the 
effluent quality before being discharged. After primary and secondary treatments the 
water is usually stored in large lagoons containing thousands of cubic liters of water, 
and it is anticipated at this point the capsules can be added to extract the 
pharmaceutically active pollutants. Due to the high mass transfer area offered by the 
capsules; little agitation is required to obtain a suitable mass transfer, which 
significantly reduces the energy demand and cost on the system. After removal the 
pollutant containing particles can easily be recovered by sedimentation or flotation and 
the treated water can be released into the environment.   
 
5.2.1. Future perspectives: Treatment of the extracted pollutants 
Once the pharmaceutical containing microcapsules have being removed from the water 
the scenario arises of how to remove the pollutant(s) completely or to a recommended 
level. Ideally this technique should be a simple and rapid methodology, not damaging to 
the microcapsule structure, which will enable the extractive structure to be used 
repeatedly.  
Wyss at al. (2006a) recovered the carcinogenic pesticide atrazine using liquid-core 
microcapsules. These were then used as a reservoir for the slow and controlled delivery 
of the atrazine as the sole nitrogen source to a Pseudomonas culture, enabling its growth 
by keeping the compound below toxic concentrations to the organism [15]. This 
allowed the Pseudomonas to utilize high quantities of the pollutant; subsequently 
converting (mineralized) it into carbon dioxide and water.  
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Whilst this process was effective it does suffer from some limitations. Significant 
amounts of the pesticide can remain within the capsules after the biodegradation 
process, with the problem being proportional to the initial concentration of the drug 
within the capsules at the start of the fermentation. When the microcapsules are re-used 
the pollutant left inside could affect the sorption capacity of the extractive phase during 
the next course of water treatment. Also disposal steps to discard the biomass produced 
by the Pseudomonas during the degradation process add additional steps (increasing 
complexity) and costs.  
As seen in chapter 3 and 4 it should be possible to back-extract the removed pollutant 
into a solvent possessing a higher affinity for the compound compared to the core 
material. This can also help maintain the structural integrity of the capsules and a 
chemical treatment could be used to completely degrade the pollutant. However this 
approach could be problematic due to large quantities of exhausted waste reaction 
solution which could be left after the breakdown of the pharmaceutical, which must be 
disposed of correctly. This can again increase cost and complexity as well as leading to 
a heavy payload for the environment.  
A possible solution to this disposal problem is to create a reactive capsular perstraction 
system which combines product extraction with simultaneous mineralization of the 
pollutant. This proposition could be achieved by incorporating a photo-catalytic 
mechanism such as titanium dioxide (TiO2) within the capsule structure (Figure 1).   
Photochemical oxidation processes involve using ultraviolet light (UV)-initiated 
oxidation-reduction reactions for the degradation of many different compounds [16]. 
The most widely used photocatalysts is TiO2, mainly due to its desirable properties such 
as: (1) high chemical stability [17], (2) high catalytic activity under UV light [17], (3) 
relatively low cost [17], (4) low biological toxicity [17] and (5) its ability to be 
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implemented in reactions without the need for temperature control [17]. The method is 
based on the generation of a hydroxyl radical (OH-) and other oxidant species at 
concentrations high enough to allow the oxidation of very stable organic compounds 
and pollutants.  
The proposed systems could operate as follows: From Figure 1: liquid-core 
microcapsules containing TiO2 embedded in the membrane could be manufactured 
using the vibrating jet technique and can be subsequently added as a tertiary treatment 
to remove organic pollutants from water as described previously. During extraction the 
capsules could be exposed to a UV light source, which passes through the membrane 
and interacts with the implanted TiO2. This will result in the release of OH- radicals, 
which mineralize the recovered pharmaceutical into non-toxic compounds within the 
core of the capsules.  
It is envisaged that it could be possible to establish a system in such a manner that the 
core extractant has a higher affinity (partition coefficient) for the extracted hydrophobic 
pharmaceutical, but not the non-toxic and harmless degradation product(s), which 
would be released back into the water phase. The continuous breakdown of the 
pharmaceutical within the capsules will allow much high concentrations of the drug to 
be removed (controlled by the partition coefficient of the compound between the two 
phases). It could also enable similar levels of removal using a smaller number of 
extracting particles in comparison to a capsular perstraction process whereby no 
degradation of the pollutant occurs.  
After complete or adequate mineralization, the capsules can be simple recovered from 
the treated wastewater containing the non-toxic mineralization products and safe-levels 
of the original pollutant, which is then released into the aquatic environment. 
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The successful removal of pharmaceutically active compounds (Chapter 2) and 
pesticides/herbicides [18] has being clearly demonstrated. It is envisaged that this 
technique should be capable of removing other persistent organic pollutants from 
effluent and/or environmental waters.  Such pollutants detected regularly in the 
environment include hormones and steroids, such as 17β-Estradiol and 17α-
Ethinylestradiol, as well as industrial dyes (Azo dyes), and the most common pollutants 
of all; synthetic musk fragrances and examples include Tonalide and Galaxolide. These 
compounds are found in personal care products, like cosmetics, perfumes, shampoos, 
detergents etc. The affects of these highly stable compounds on the environment is 
becoming an important matter given the large quantities of this substances that are being 
used2, and because they are generally released directly into the environment without 
undergoing any major structural or chemical changes [19]. 
 Membrane  
containing TiO2 
 Water phase 
 U.V. light 
source 
 Extracting organic phase 
within membrane  Movement of pollutant  
to organic-core 
 Movement of degradation 
products to aqueous phase  Hydroxyl radical  
splitting pollutant 
 
Figure 1: Schematic of the proposed reactive capsular perstraction system. The process 
uses liquid-core microcapsules incorporating TiO2 to simultaneously extract and 
degrade pollutants from water. Symbols: pharmaceutical pollutant (circles) and 
degradation product (squares). 
                                                 
2 In 1998 > 2000 ton were produced in the EU alone [19] . 
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5.3. In-situ product recovery of geldanamycin 
The use of microorganisms to transform biological materials for the production of 
fermented foods has its origins in antiquity. Since then bioprocessing has being 
developed for an enormous range of commercial products; from relatively cheap 
chemicals such as industrial alcohols and organic solvents, to expensive specialty 
materials like antibiotics, therapeutic proteins and vaccines. The process is of 
tremendous economic importance which is evident in the US alone, whereby the 
predicted sales forecast for these products for 2010 is expected to be nearly $50 billion 
[20].  
As discussed in chapter 3 and 4 bioprocessing operations are unfortunately adherent to 
many potential disadvantages during their workings, and is primarily caused by the 
buildup of the produced bio-product in the system [21]. On such example is the 
accumulation of geldanamycin. The polyketide antibiotic is derived from the shikimate 
pathway [22] and is produced by the filamentous organism Streptomyces  hygroscopicus 
var. geldanus in submerged fermentations, where it is subjected to degradation to 
negligible amounts. The aim of this section was to develop and implement an in-situ 
product recovery (ISPR) technique, based on capsular perstraction, to help increase the 
productivity and recovery of the antibiotic from cultures.  
The results of this study showed how capsular perstraction can be executed as an ISPR-
technology for improving the productivity and yield of geldanamycin in fermentations. 
When dissolved in Bennett’s media the sensitive product was removed rapidly (between 
0.88 x 10-6 to 5.66 10-6 m/s), at high quantities (partition coefficient of 212), with a 
good specificity, whilst also been concentrated in the extractive phase at a substantially 
superior degree compared to the fermentation medium (> 1g/l). A similar extraction 
during geldanamycin producing cultures enabled the batch fermentations to be 
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extended, as the geldanamycin was rapidly removed from the vicinity of the producing 
environment which was causing its breakdown. Consequently a 30% increase in 
antibiotic production was achieved. The controllable buoyancy properties of the 
capsules also enabled easy recovery of the extractive particles by flotation, helping to 
improve handling properties of the operation. 
More importantly, the selective removal and concentration of the geldanamycin within 
the capsules enabled the antibiotic to be purified (crystallized) to a very high degree 
using a very simple and effective downstream processing (DSP) operation. Application 
of this innovative procedure enabled the crystallization of > 53% of the antibiotic 
extracted from the fermentation at a purity > 97%, which has the potential to 
significantly reduce the overall manufacturing costs.  
Higher recovery yields from the DSP operation could be achieved by treating the 
geldanamycin contained within the oleic acid after it is displayed from the acetonitrile 
during step 4 of the DSP procedure (Section 4.4.4.). Recently it has been discovered 
that this stage can be simplified even further by removing the water addition, and 
instead replacing it with a cooling step (results not shown). This procedure involves 
reducing the temperature of the oleic acid saturated acetonitrile to 2 °C, causing the 
fatty acid to completely precipitate from the solution. Centrifugation ensures the 
complete separation of this mixture into two distinct phases and enables them to be 
withdrawn independently. This has the following advantages to the existing step 4 and 
is as follows: (1) the absence of water means the acetonitrile solution has a higher 
affinity for the geldanamycin compared to the precipitated oleic acid (as seen in Section 
3.4.9.) and enables higher levels of antibiotic recovery. (2) Oleic acid is denser 
compared to the acetonitrile. This causes the fatty acid to sink to the bottom of the 
holding vessel and allows easier removal of the geldanamycin rich acetonitrile phase, 
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which floats to the top. (3) Replacing the water addition greatly reduces the liquid 
volume to be displaced by evaporation. This significantly reduces the amount of energy 
required for distillation and also lessens the handling requirements.    
 There are several limitations which are blocking the incorporation of ISPR-
methodologies as techniques in improving existing bioprocesses. In many cases the 
successful introduction requires the addition of extra equipment to the operations e.g. 
vacuum pumps, adsorption columns and membrane modules etc. This inclusion can 
very much increase the cost, making the process financial unviable and/or too complex. 
The inherent changes to incorporate the ISPR-technique in the bioreactor can also lead 
to the whole operation been only suitable for the production of one particular type of 
product.  
In this study capsular perstraction has shown the capability to overcome these 
considerable limitations, whilst still transpiring as a simple, relatively cheap and 
effective technology. The procedure itself only requires a small increase in the reactor 
volume (which shouldn’t affect other production operations) for enhanced results and 
this slight volume change could be reduced further by selecting a solvent which has a 
very high capacity for the extracted compound, hence reducing the volume even more. 
A clear role for the application of capsular perstraction as a facile, inexpensive and 
reproducible ISPR-technology for improving the productivity and yield of 
geldanamycin in fermentations has been shown in this work. It should be easily 
implemented at a lab-scale or industrial-level for the in-situ recovery of the antibiotic, 
but more importantly it could be used for the removal of many other compounds, which 
suffer from similar or other production limitations, from the vicinity of their culture 
environments.  
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5.4. Nomenclature 
Table 1: List of abbreviations. 
Abbreviation/Symbol Definition Unit 
STPs Sewage treatment plants - 
PhACs Pharmaceutically active compounds  - 
TiO2 Titanium dioxide  - 
OH- hydroxyl radicals  - 
ISPR In-situ product recovery  - 
DSP Downstream processing  - 
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6.1. Appendix A  
Determination of pharmaceuticals in water using RP-HPLC (Section 2.3.2.2.). 
 
Compounds: Sulfamethoxazole, Metoprolol, Furosemide, Warfarin, Clofibric acid, 
Carbamazepine and Diclofenac. 
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Figure 1: Standard curve for the quantification of sulfamethoxazole. 
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Figure 2: Standard curve for the quantification of metoprolol. 
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Figure 3: Standard curve for the quantification of Furosemide. 
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Figure 4: Standard curve for the quantification of warfarin. 
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Figure 5: Standard curve for the quantification of Clofibric acid. 
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Figure 6: Standard curve for the quantification of carbamazepine.  
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Figure 7: Standard curve for the quantification of diclofenac. 
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6.2. Appendix B  
Determination of geldanamycin in different phases using RP-HPLC (Section 3.3.2.1.) 
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Figure 7: Standard curve for the quantification of geldanamycin in dibutyl sebacate. 
HPLC mobile phase: 80% methanol:20% water (v/v). 
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Figure 8: Standard curve for the quantification of geldanamycin in oleic acid. HPLC 
mobile phase: 80% methanol:20% water (v/v). 
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y = 65027x - 37.04
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Figure 9: Standard curve for the quantification of geldanamycin in Bennett’s medium 
and water. HPLC mobile phase: 50% acetonitrile:50% water (v/v). 
 
